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ABSTRACT
The research presented in this thesis has centred on chemical and 
pharmacological investigations of the phenazine antibiotic clofazimine and certain 
substituted phenazine analogues.
A simple extraction system was developed with dichloromethane and sodium 
hydroxide which quantitatively extracted all o f the agents tested from tissue, faecal and 
blood samples. The extracted drugs could then be quantified using a reversed phase 
HPLC method with a mobile phase o f tetrahydrofuran/acetic acid/hexane sulphonic acid 
and U.V. detection at 285 nm. Purity and chemical structure o f  the agents studied was 
confirmed using NMR, TLC, PDA-HPLC, silica column chromatography and elemental 
analysis.
The tissue distribution of clofazimine (B663) and phenazines B749, B3954, 
B4090 and B4100 was investigated by oral gavaging these agents into mice for 3 weeks 
and measuring drug levels using the HPLC method described. B4100 and especially 
B4090 gave superior tissue levels to clofazimine in all tissues tested except fat. A 
simpler method o f administering phenazines in food was developed for dosing rats. 
B663, B4090, B4100, B4103 and B4154 were incorporated into rat food which was 
given to rats in specially made metabolism cages which allowed the measurement of 
food and water intake and collection o f uncontaminated faeces.
The absorption o f these agents was estimated by giving groups o f rats a single 
dose o f drugged food containing the non-adsorbable dietary marker chromic oxide, with 
subsequent collection and analysis o f faecal drug and chromium levels using HPLC and 
spectrophotometric assays respectively. Absorption levels were found to be different for 
all the agents B4090 giving the poorest absorption at 50.5% and B4103 giving the most 
absorption at 92%. The bio-distribution o f these compounds was measured after 4 
weeks o f administration. Again B4090 gave the highest levels in all tissues excluding
iv
During this study potential toxicity o f these agents was investigated using blood 
enzyme markers, blood cell counts, measurement o f food and water intake, behavioural 
observation, urinary markers and p o s t  m ortem  tissue weights. A newly developed 
method of analysing animal urine by proton-NMR spectroscopy was also used to 
investigate toxicity. None of these tests provided evidence that any o f the compounds 
tested were more toxic than clofazimine.
The absorption and distribution o f complexes of clofazimine with P-cyclodextrin 
(P-CD) and hydroxypropyl-p-cyclodextrin (H-p-CD) were tested. The H-P-CD 
formulation gave a greater absorption o f clofazimine and increased blood and tissue drug 
levels.
Phenazine conjugates to the proteins bovine serum albumin, thyroglobulin and 
keyhole limpet haemocyanin (KLH) were produced using phenazine derivatives with 
amino acid substituents. These conjugates were characterised using TLC, PDA-HPLC 
and spectrophotometric assays. The thyroglobulin and KLH conjugates were used to 
immunise rabbits to produce specific anti-phenazine antibodies which were purified and 
characterised.
v
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1.1. INTRODUCTION
Clofazimine (3-(4-chloroanilino)-10-(4-chlorophenyl)-2,10-dihydro-2-(isopropylimino)- 
phenazine) is an orange-red rimino-phenazine agent which has been used in the treatment of 
mycobacterial diseases including leprosy (Dollery, 1991; British Pharmacopoeia Commission, 
1988; Barry et al., 1957). Clinically it has been shown to be both safe and effective in the 
treatment of these diseases (Hastings et al., 1976; Stenger et al., 1970). This introduction 
describes the pharmacology, metabolism and chemistry of clofazimine, and recent advances in 
our knowledge of this drug, and thus, gives a clearer picture of our present understanding of its 
mode of action.
1.2. HISTORY
Clofazimine (B663 or Lamprcne) emerged as the most active antimycobacterial agent 
of a class of compound, the riminophenazines, synthesised by the laboratories of the Mcdical 
Research Council of Ireland from 1944, as part of a project to find a treatment for tuberculosis.
This programme of compound development initially began with large scale screening 
of several hundred compounds which were available or produced in the chemistry department 
of University College Dublin. These substances included extracted constituents from lichens 
such as usnic acid, roccellic acid and diploicin. Diploicin (Figure 1.1) was the first organic 
chlorinated compound found to occur in nature, and on opening the lactone ring, the sodium salt 
of the resulting carboxylic acid was found to inhibit Mycobacterium tuberculosis in vitro at a 
1/100,000 dilution (Barry, 1969). Diploicin proved to be inactive in animal models and its 
complete substitution prevented increasing activity with further alteration. Attempts to 
chemically imitate the opened diphenyl structure yielded an aminodiphenylamine compound 
which also had anti-bacterial properties. However, on standing, this compound oxidised to give 
a red crystalline precipitate which completely inhibited the growth of the H37Rv strain of M. 
tuberculosis at a dilution of 2 x 10s. Following structural determination, this compound, which 
was termed B283, was shown to be the same as anilinoaposafranine which had been first 
synthesised in 1896 (Barry et al., 1948; Barry et al., 1957; Barry, 1969). In vivo activity against 
leprosy and urinary tuberculosis was demonstrated, but toxicity was also evident (Lane, 1951; 
Allday and Barnes, 1952). Chlorinated derivatives of B283 had far superior activities in rodent 
models of tuberculosis (T.B.), in particular one derivative, B663 or clofazimine (Barry and 
Conalty, 1958; Barry et al., 1959; Barry et al., 1960; Grumbach 1960; Steenken et al., 1960; 
Noufflard and Berteaux, 1961; Barry and Conalty, 1965). Limited clinical trials of B663 in
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Figure 1.1. The chcmical structure of diploicin. This compound was extracted from a 
lichen and was one of the first compounds tested by Barry and colleagues which showed 
significant antitubercular activity.
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human tuberculosis produced poor results (Barry, 1969). When the formulation was changed 
from a coarse crystalline, to an ultrafine micronised preparation, models indicated excellent 
activity against leprosy, and clinical trials vindicated clofazimine’s efficacy as an anti-leprosy 
agent (Browne and Hogerzeil, 1962; Chang, 1962; Lunn and Rees, 1964; Browne, 1965; Chang, 
1966; Chang, 1967; Pettit et al., 1967; Karat et al., 1970). Currently, the major use of 
clofazimine is in the World Health Organisation Multiple Drug Therapy (MDT) for lepromatous 
leprosy (WHO, 1988).
1.3. CHEMISTRY
1.3.1. Properties
Clofazimine, C27H22C12N4, has a molecular weight of 473.14 and a melting point of 210- 
212°C. It has a characteristic deep red to orange colour under normal condition due to its 
complex heterocyclic nature. Chemically it is a phenazine molecule and belongs to a group of 
phenazines with substituents on the N2, N3 and C7 (Figure 1.2) which were termed rimino- 
phenazines by Barry and co-workers who developed these compounds (Barry et al., 1957; Barry, 
1969). Clofazimine is a very hydrophobic molecule as indicated by its log P value Gog of 
organic over aqueous partition) of approximately 7.48(octan-l-ol/water) and will not dissolve in 
non-acidic aqueous solutions (Morrison and Marley, 1976(a,b)). pKa values of 8.35 +/- 0.09 and 
8.37 have been reported although the exact value is a matter of controversy since the 
compound’s aqueous insolubility makes calculation difficult (Morrison and Marley, 1976(a); 
Canavan et al., 1986). Clofazimine is, therefore, a basic drug and must exist in a charged form 
at physiological pH values. In alkaline environments and in organic solvents clofazimine is 
uncharged and has an intense orange-yellow colouration. However, as the pH drops the colour 
becomes more red and the aqueous solubility increases. In strongly acidic solutions this colour 
becomes violet. It is thought that these colour changes reflect the transition from an uncharged 
species (orange) in alkaline conditions, to a mono-protonated form (red) in dilute acid, to a di- 
protonated (violet) form in more concentrated acid to a triply-protonated molecule, which only 
partially exists, in concentrated acid and is colourless (Levy and Randall, 1970). While these 
transitions obviously reflect changes occurring over a very large pH range, clofazimine can also 
accept and donate protons as part of a redox system. The measured redox potential of B663 is -
0.18v at pH 7 (Em7) (Barry et al., 1957; Barry et al., 1960). Although the natural cellular 
environment cannot reach the pH needed to change the colour of clofazimine, it is seen as 
different colours in vivo and this obviously reflects the ability of the body to reduce this 
compound to various extents. The visual colouration represents an absorbance in the range 450-
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Figure 1.2. The chemical structure of the basic phenazine nucleus, with the standard 
system for substituent numbering.
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550 nm and is very dependent on the chemical environment of the molecule, whilst there Is a 
stronger UV absorbance at 284-287 nm in all forms of clofazimine (Barry, 1969; Barry and 
Conalty, 1965; Levy and Randall, 1970; Baneijee et al., 1974).
Clofazimine can also crystallise inside cells, although other rimino-analogues exist which 
have different substituents and do not crystallise in vivo (O’Sullivan et a l, 1992; Van 
Landingham et al., 1993). X-ray studies by Rychlewska et al., (1985) have shed some light on 
the structure of clofazimine. The phenazine plane is almost completely flat, with the N-10 
chlorophenyl ring near perpendicular to this plane, and the phenyl ring on the anilino moiety 
inclined at 34° to the phenazine plane (Eggleston et al., 1984; Humprey-Broom et al., 1984; 
Rychlewska et al., 1984; Rychlewska et al., 1985).
1.3.2. Synthesis
Early methods of producing rimino-phenazines were quite difficult, involving the 
oxidation of derivatives of o-phenylenediamine with ferric chloride or p-benzoquinone with 
subsequent catalytic hydrogenation of the imidazophenazine produced (Barry et al., 1958(a,b,c); 
Barry et al., 1970). The same rimino-phenazines can now be prepared by the reduction of 
substituted anilinoaposafranines in the presence of a suitable ketone (O’Sullivan, 1984).
1.4. PHARMACOKINETICS
1.4.1. Absorption
The absorption of clofazimine is very variable, both between patients and with different 
pharmaceutical preparations (Barry, 1969; Vischer 1969; Baneijee et al., 1974; Yawalker and 
Vischer, 1979). Initially clofazimine was produced as a crystalline preparation until studies 
indicated that only approximately 20% of an oral dose was absorbed. In a microcrystalline 
suspension of oil-wax, after a fat-rich meal, approximately 70% is absorbed (Yawalker and 
Vischer, 1979). Schaad-Lanyi et al., (1987) have shown that the peak plasma concentration 
(Cmax.) was 0.41 mg/1 eight hours after a single 200 mg dose. Others have shown that, in 
patients on long duration therapy, the peak time (t^.) lies between one and six hours (Baneijee 
et al., 1974). It has also been shown that the absorption was increased by 30-60%, and the t^ . 
decreased from twelve to eight hours, when clofazimine is administered after food. With a 50 
mg daily dose, it was estimated that 70 days would be needed to reach a steady-state plasma
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concentration, which correlates with the long duration needed for the clinical effects of the drug 
to be evident in vivo (Baneijee et al., 1974; Venkatesan, 1989).
Absorption also varies between species, being good in mice, rats, and monkeys, poorer 
in rabbits and guinea pigs, and negligible in dogs. This may reflect some species specificity in 
the absorption mechanism of the drug (Barry and Conalty, 1958 and 1965; Barry et al., 1960; 
Banerjee et al., 1974).
Absorption after intra-muscular injection is very slow, probably due to the aqueous 
insolubility of the drug, and, hence, only the oral route has been used. The exact mechanism 
of absorption of clofazimine is uncertain (Barry et al., 1948; Barry et al., 1959; Vischer, 1969).
After an initial dose the drug can be seen to slowly build-up in the plasma and then 
starts to appear mainly in the cells of the reticulo-endothelial system and adipose tissue (Vischer 
, 1969; Conalty and Jackson, 1962; Conalty, 1966; Conalty et al., 1971). Four explanations for 
the accumulation of the drug in these tissues were originally suggested by Barry et al., (1959) 
1) that B663 is present in the plasma attached to a carrier which transports the drug across the 
membrane of target cells. 2) B663 may be free in the plasma and accumulate via an active 
transport mechanism in the target cell. 3) B663 may be free in the plasma and diffuse passively 
into the target cell where it is bound and crystallises. 4) the drug may enter by phagocytosis 
or pinocytosis. The partition coefficient value of 7.48 mentioned in the previous section 
indicates that the molecule should be so lipophilic as to limit its capacity to traverse the cell 
membrane, since it would tend to stay in the lipophilic layer of the membrane (Morrison and 
Marley, 1976(a,b)). This observation precludes the idea of clofazimine being transported by any 
form of passive mechanism. Very little clofazimine seems to reach the excretory portions of the 
kidney since excretion in the urine is very slow, indicating that little or none of the plasma 
clofazimine is in free solution. A certain amount of B663 in the plasma is in solution in 
chylomicra which have reached the blood via the intestinal lymph (Barry, 1959). Conalty and 
Jina (1971) demonstrated that clofazimine is not taken up by macrophages in particulate form 
but rather enters in solution linked to some form of carrier (Conalty, 1966; Conalty etal., 1971).
In an unpublished report, Barry and co-workers quoted results by Dr. L. H. Schmidt 
from monkeys treated with a twice daily dose of lOOmg/kg for 7 days. Schmidt was able to 
measure serum levels of drug in the range of 2.3 -6.7 pg/ml but this level dropped to .07 ug/ml 
after the serum had been ultracentrifuged. Other results with human, mouse and guinea-pig 
serum showed that clofazimine bound appreciably to the a- and p- lipoproteins in serum,
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particularly the (3- lipoproteins, and that this binding was very firm but was saturated at 
approximately lOug/ml. Binding to y-globulin and albumin was negligible.
Unfortunately, no other work was performed to further identify the lipoprotein 
responsible for clofazimine transport in blood. It also appears likely that a specific carrier 
mechanism is responsible for the uptake of the clofazimine-lipoprotein complex which then 
yields free clofazimine within the cell by enzymatic cleavage of the complex within the 
lysosome. This intracellular clofazimine is often seen as crystal inclusions around osmiophilic 
rods (Conalty and Jackson, 1962; Conalty, 1966; Conalty and Jina, 1971; Conalty et al., 1971; 
McDougall, 1974).
1.4.2. Distribution
The distribution of clofazimine throughout the body is slower than absorption and is very 
heterogenous (Vischer, 1969). Hence, the volume of distribution has never been calculated and 
would probably have no clinical relevance. Clofazimine has two main target areas consisting 
of certain cellular groups of the reticulo-endothelial system and fat cells in the adipose tissues, 
where it is avidly taken up (Conalty and Jackson, 1962; Vischer, 1969). This means that any 
intra-cellular effect of the drug cannot be correlated to plasma levels. Clofazimine has been 
detected (often as crystals), or measured, in other regions of the body including bone, muscle, 
skin, heart, eye, gallbladder and nervous tissue. The drug has also been found in urine, bile, 
sweat, milk, sebum, tears, and sputum. The highest levels of clofazimine are found in the 
spleen, liver, lung, adipose tissue, and mesentery (Vischer, 1969; Mansfield, 1974; Desikan et 
al., 1975; Desikan and Balakrishnan, 1976; Kumar et al., 1987). The lowest levels of drug are 
found in the brain. Mansfield, (1974) found levels below the limit of determination (<0.1mg/g) 
in the brains of humans at autopsy and coupled with the cerebral drug level measurements in 
pharmacology chapter (see section 5.8.1.) and that of Barry et al., (1960), which showed 
measurable levels in the brains of rats and mice, indicates, that contrary to established belief, 
clofazimine can cross the blood-brain-barrier, although in very small amounts. In many tissues 
clofazimine is mainly found in crystalline form (up to 99%) and it is believed that in this way 
the drug can remain in the body for years after cessation of the dosage regime (Baneijee et al., 
1974).
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1.4.3. Metabolism and Elimination.
A two compartment pharmacodynamic model has been suggested based on experimental 
models (Banerjee et al., 1974; Levy, 1974; Hastings et al., 1976). The first compartment is 
evident with short-term low dosages and has an elimination half-life of approximately 1 week, 
whereas with higher doses and/or longer duration therapy a second elimination half-life of 70 
days or greater is seen. However, this slow elimination does not appear to be dependent on the 
presence of the drug in crystal form in the body (Baneijee et a l., 1974). Small amounts of 
clofazimine are eliminated in the sebum and sweat (Vischer, 1969). Urinary excretion of un­
metabolised clofazimine has been shown to be in the range of 0.03 to 0.41% of a dose, daily 
(Levy, 1974). Three metabolites of clofazimine have been identified in patients urine (Feng et 
a l., 1981 and 1982). The proposed structures and routes of production of these compounds are 
shown in Figure 1.3. Metabolite I arises from hydrolytic dehalogenation, metabolite II by 
hydrolytic deamination followed by glucuronidation of the resultant hydroxyl group, and 
metabolite III by hydration at C4, followed by glucuronidation of the resultant hydroxyl group. 
Besides the actual structures of these compounds, very little else is known about them, i.e. there 
is precedent to assume that they are the product of hepatic metabolic pathways, but no hard 
evidence, and their therapeutic value, if any, is unknown. Like clofazimine, these compounds 
are found in very small concentrations in urine, representing 0.20%, 0.25% and 0.2% of a daily 
dose, respectively, for metabolites I, II and III assuming a 70% absorbance value of a 300 
mg/day dose.
Studies to measure faecal or biliary metabolites have not been performed, and although 
faecal levels have been followed in volunteers for 3 days, these values only give an estimate of 
absorption rather than faecal elimination (Levy, 1974; Mathur et a l., 1985).
How clofazimine is able to remain largely un-metabolised is uncertain, but perhaps its 
necessity for a carrier to cross cellular membranes, as suggested earlier, infers that very little can 
enter the mitochondria of metabolically competent cells.
1.5. PHARMACOLOGY
1.5.1. Mechanism of action
Until recently there have been several different theories about how clofazimine works, 
with a limited amount of experimental observation to back up these findings. However, none of
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Figure 1.3. The chemical structures and proposed metabolic routes of the three 
clofazimine metabolites which have been isolated and identified in human urine. (After 
Feng et al., 1981 and 1982)
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these ideas fully accounted for the broad range of effects seen with clofazimine in vivo and in 
vitro.
The first observation suggesting a mode of action was that clofazimine bound tightly to 
DNA (Morrison, 1972; Morrison and Marley, 1976(a,b) and 1977). At the high concentrations 
of drug used, Morrison et al., showed that clofazimine selectively binds to runs of guanine and 
deoxyguanine, DNA with dG + dC bases and purified yeast tRNA. Mycobacteria have a high 
G + C content (67-69%), whereas human cells have a much lower G + C content. It was, 
therefore, suggested that clofazimine has a selective effect on mycobacteria due to differences 
in base pair content which allowed clofazimine to inhibit the template function of DNA in 
mycobacteria. With other analogues of clofazimine it was shown that DNA binding was 
increased with increasing chlorine substitution, which correlates with the increases in activity 
seen in vitro with these compounds. These experiments showed an interaction between 
clofazimine and isolated and synthetic strands of ribo- and deoxyribonucleic acids, where 
clofazimine had to be dissolved in 10% DMF or DMSO at concentrations in excess of its 
aqueous solubility. The implications of results so abstracted from the in vivo situation must 
therefore be very questionable, without further evidence, for example, the demonstration of in 
vivo binding of clofazimine to DNA.
It has also been suggested that clofazimine acts by inhibiting the respiratory chain of 
certain cells, since phenazine compounds are auto-oxidisable and it has been suggested they 
could act as artificial electron acceptors. Clofazimine is taken up (2 mg/g dry weight) and 
decolourised by living mycobacterial cells under anaerobic conditions but readily re-oxidised 
when re-exposed to air (Barry et al., 1957; Rhodes and Wilkie, 1973; Delhanty et al., 1974). 
Rhodes and Wilkie, (1973) reported that clofazimine was absorbing some of the terminal 
hydrogen transfer capability in yeast (Saccharomyces cerevisiae), fibroblast cells and rat liver 
mitochondria, i.e. the respiratory system was oxidising clofazimine instead of normal cellular 
substrates, such as NADH, causing a reduction in the amount of ATP available for all cellular 
processes. Interestingly, these authors were able to isolate mutant yeast strains resistant to the 
effects of clofazimine. The resistance appeared to be of two distinct types, the first involving 
a change in permeability to clofazimine since these organisms remained unstained by the drug. 
The second type had some form of intracellular change, probably an alteration in a mitochondrial 
element involved in drug reactivity, since the cells of yeast mutants in this group were stained 
by clofazimine. Clofazimine-resistant organisms were also cross-resistant to a number of anti- 
mitochondrial agents.
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It has been shown in catalase-negative mycobacteria, that when the reduced forrrt of 
clofazimine is re-oxidised, as with other redox compounds, hydrogen peroxide is produced 
(Barry et al., 1957). This would be one explanation for the increased clofazimine sensitivity of 
isoniazid-resistant catalase-negative strains of Mycobacterium tuberculosis, and the observation 
that normal M. tuberculosis, which grows readily in an aerobic environment grows only 
anaerobically in the presence of inhibitory concentrations of clofazimine (Barry et al., 1957).
While these authors have demonstrated that clofazimine can inhibit the growth of 
prokaryotic and eukaryotic cells by interfering with hydrogen transfer, it is not known how 
important this is clinically. If clofazimine interacts significantly with mitochondria in vivo, it 
should cause very serious side effects, especially in bone marrow cells where it can be found in 
high concentration (Desikan and Balakrishnan, 1976). However, these expected effects have 
never been seen, even at very high doses. Resistant prokaryotic and eukaryotic cells have been 
produced in vitro by continuous culture in a clofazimine-containing medium (Rhodes and Wilkie, 
1973; O’Sullivan et al., 1988). Although there are two questionably reliable reports of 
clofazimine resistance in patients (Wamdorff-vanDiepen, 1982; Kar et al., 1986), this has never 
emerged as a problem in clinical use.
1.5.2. Selective effects on the immune system
Clofazimine has been demonstrated to have several different effects on different aspects 
of the immune system. These include an increase in the number and size of lysosomes and 
phagolysosomes in isolated macrophages (Conalty et al., 1971), an increase in the lysosomal 
level of cultured macrophages (Saracent and Finlay, 1982), an inhibition of complement- 
mediated solubilisation of immune complexes (Kashyap et al., 1992), a dose-dependent inhibition 
of neutrophil motility and lymphocyte transformation (Gatner, et al., 1982) and an enhancement 
of reactive oxidant production (Anderson et al., 1986 and 1988a,b; Sahu et al., 1991 and 1992). 
Based on a compilation of these observations, there is significant evidence to show that 
clofazimine has a potent effect on specific elements of the functioning of the immune system.
Several recent papers have suggested an explanation for the wide variety of effects 
caused by the interaction of clofazimine with the immune system and perhaps also its direct 
effects on bacteria (Anderson et al., 1986 and 1988(a,b); Sahu et al., 1991 and 1992; Van 
Rensburg et al., 1992 and 1993). It has been shown by these authors that clofazimine, at 
concentrations within the therapeutic range (0.01-5 pg), stimulates reactive oxidant (specifically 
lysophospholipid) production in human polymorphonuclear leucocytes (PMNL) and gram-
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positive bacteria. These substances are the products, or result from the products of, a selective 
stimulation of phospholipasc A2, since the activities of clofazimine could be blocked with the 
selective phospholipase A2 inhibitors . One of the major targets of these products in 
lymphocytes is the enzyme Na+, K+-ATPase, whose inhibition causes a repression of lymphocyte 
proliferation (Anderson and Smit, 1993).
Combining this recent information, with established observations allows us to formulate 
a more comprehensive picture of the pharmacology of clofazimine. Early work has shown that 
clofazimine is transported by a lipoprotein carrier ([3-lipoprotein now known as Low Density 
Lipoprotein LDL) through the body. LDLs are primarily concerned with the transport of 
cholesterol, and certain cells, particularly adipose and reticulo-endothelial cells, have specific 
receptors to transport LDL-cholesterol across the membrane with a subsequent lysosomal 
cleavage and recycling of the LDL to provide cholesterol in a suitable form within the cell 
(Goldstein and Brown, 1977; Goldstein et al., 1979). This also allows for the selective entry 
of clofazimine into particular cells. In adipose cells, the level of clofazimine rises to 
macroscopic levels, where colour can be seen visually, but does not appear to have any other 
significant clinical effect; in reticulo-endothelial cells clofazimine also builds up, but by 
interacting with Phospholipase A2, it causes several changes in the normal function of the 
immune system a whole. These stimulatory effects on Phospholipase A2, coupled with a direct 
anti-bacterial action, and a selective concentration in one of the main targets of mycobacterial 
infection (phagocytic cells), explain how clofazimine produces its anti-mycobacterial effect.
1.5.3. Diseases where clofazimine has been used
As mentioned in the introduction, clofazimine is mainly used as part of the WHO 
recommended Multi-Drug Therapy (MDT) regime to treat lepromatous leprosy (WHO, 1982). 
Clofazimine is also used to control some of the acute reactionary phases which can occur with 
leprosy , especially erythema nodosum leprosum, and to reduce the dose of corticosteroids 
necessary to manage these episodes (Pettit, 1967; Morgan, 1970; Helmy et al., 1972; Imkamp, 
1981). Although largely inactive against tuberculosis, clofazimine is used to treat other rarer 
mycobacterial diseases, e.g. Beruli ulcer (Lunn and Rees, 1964; Oluwasani et al., 1975). 
Clofazimine has been successfully used to control the mycobacteraemia common as an 
opportunist in Acquired Immune Deficiency Syndrome (AIDS), alone, and in combination with 
other agents, reversing the weight loss, night sweats and lethargy associated with these infections 
(Nunn and McAdam, 1988; Young, 1988; Polis and Masur, 1989; Garrelts, 1991; Goldschmidt 
and Dong, 1991). Bums and non-specific skin lesions (human and veterinary) have been
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successfully treated by a topical cream formulation of clofazimine (Ellis, 1973; Knottenbelt et 
al., 1989; Venkateswarlu et al., 1992); in addition, as outlined in Tabic 1.1, clofazimine 
hasshown in vitro and/or in vivo activity in a number of other unrelated diseases and disease 
models. A patent has been registered for the use of a clofazimine derivative, B669, in the 
treatments for cancer and tissue rejection by the University of Pretoria, and the riminophenazines 
have also shown some potential in reversing multi-drug resistance in cancer cells (Anderson and 
Smit, 1993).
1.5.4. Structure-activity relationships
To date, several hundred rimino-phenazine agents have been synthesised, and certain 
relationships have been shown to exist between chemical substituents and biological and 
chemical properties, based on in vitro and some in vivo experiments with these compounds. 
These compounds can be grouped on the basis of substitutions of the phenazine ring, as shown 
in Figure 1.2.
1.5.4a. R, substitution
In general, substitution in this position with a chlorine, methoxy or ethoxy group, causes 
an increase in activated superoxide and arachidonate generation by neutrophils, gives increased 
anti-bacterial activity in vitro, and lipophilicity. Other substituents in this position have little or 
no effect (Barry, 1969; Barry et al., 1970; Zeis and Anderson, 1986; Zeis et al., 1987 and 1990; 
Savage et al., 1989; Van Landingham et al., 1993).
1.5.4b. R2 substitution
Here, chlorination (to give dichloro-analogues) again increases anti-bacterial activity, 
although, the resultant elevation in lipophilicity is a major factor in fat retention as is well 
documented for clofazimine. The increases in activity associated with R2 substitution appears 
to be due to the molecular size of the substituent, rather than its electronegativity. Bromine, 
ethoxy, and methoxy substitution ail give increased activity, whereas hydrogen, or fluorine 
substituents produce compounds with reduced activity. Combined meta- or para- substitution 
with chlorine (tetrachlorinated compounds), have an even greater activity than their equivalent 
dichloro- compounds. Chlorinated compounds also have superior anti-tubercular activities. 
Unfortunately chlorination is linked to crystal formation in compounds not possessing a tertiary 
nitrogen in the R3 position. It is this crystal formation which may be involved in some gastro-
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Table 1.1: A list of various diseases, or disease models where clofazimine has been shown to 
possess some activity.
Disease where activity seen Reference
Leishmaniasis
Malaria
Scleroma
Fistulous withers (horses)
Pyoderma gangrenosum
Annular elastolytic giant cell granuloma 
Discoid lupus erythematosus 
Pustular psoriasis
Regressive ulcerative histiocytosis 
Vitiligo
Nodulocystic acne
Oedematous complications of acne vulgaris 
Cutaneous malacoplakia 
Erythema dyschromicum perstans 
Necrobiosis lipodica 
Granulatomatous macrochelitis
Crohn’s disease
Evans et al., (1989).
Sheagren, (1968).
Shehata et al., (1989).
Knottenbelt et al., (1989).
Michaelson et al., (1976); Stone, (1990); 
Merret et al., (1990); Kaplan et al., (1992). 
Vehring et al., (1991).
Mackey, (1973 & 1976); Zeis et al., (1989). 
Chuaprapaisiep and Piamphongsant, (1978); 
Nair and Shereef, (1991).
Horiguchi et a i, (1989).
Kumar et al., (1987).
Mascaro et al., (1991).
Helander and Aho, (1987).
Herrero et al., (1990).
Picquero-Martin, (1989).
Mensing, (1989).
Friedrich, (1989); Gali et al., (1989); Cusano et 
al., (1991).
Afdhal et al., (1972); Pines et al., (1993).
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intestinal side-effects associated with clofazimine (Barry and Conalty, 1958; Barry, 1969; Barry 
etal., 1970; Zeis et al., 1987 and 1990; Franzblau and O’Sullivan, 1988; Franzblau et al., 1989; 
Van Landingham et al., 1993).
/ ,5.4c. R3 substitution
This is the major substituent varied in studies to further develop this class of drugs. A 
substituted imino group is essential for activity . Imino alkyl substituents have various activities, 
but are generally quite active, as exemplified by clofazimine which has an isopropyl amine 
substituent in this position. Compounds with a basic nitrogen substitution in the group on the 
imino-nitrogen are active against organisms engineered to be resistant to clofazimine. Primary 
and secondary nitrogens in this class are poorly absorbed, with the exception of the 
tetramethylpipcridine group of substituents, whereas tertiary nitrogen-containing compounds are 
generally well absorbed. The compounds with nitrogen in the imino side chain also have reduced 
body fat solubility and do not crystallise in the cells of the body. Activity generally requires that 
the basic nitrogen be spaced at least three carbons from the imino- nitrogen, whether this basic 
nitrogen is primary, secondary or tertiary (Barry and Conalty, 1958; Barry, 1969; Barry et al., 
1970; Zeis et al., 1987 and 1990; Franzblau and O’Sullivan, 1988; Franzblau et al., 1989; 
O’Sullivan et al., 1992; Van Landingham et al., 1993).
1.5.5. Toxicity and side effects
1.5.5a. Common side effects
Clofazimine is generally a well tolerated and very safe drug. Nevertheless, like all 
drugs, there are some drawbacks and side effects associated with its use. The side effects seen 
are normally mild, dose related, and reversible (Yawalker and Vischer, 1979; Garrelts, 1991).
The most common side effect seen is a red-brown discolouration of the skin, which 
becomes visible 2-4 weeks after commencing treatment, and is evident in almost all patients on 
high doses (300 mg/day) (Browne et al., 1981; Moore, 1983). This pigmentation is especially 
evident on the trunk and face, but other regions may be affected, particularly the conjunctiva, 
and discolouration has also been noted in sweat, hair, sputum, urine, faeces, tears, and the inner 
organs, with the exception of the central nervous system (Browne and Hogerzeil, 1962; Desikan 
and Balakrishnan, 1976; Desikan et al., 1975; Kumar et al., 1987; Kumar, 1991). Certain 
cultures, particularly some Asian races, find the associated colouration stigmatising and
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unacceptable, and this is the major cause of non-compliance in treatment regimes (Pettit, et al., 
1967; Warren, 1968; Moore, 1983). Lepromatous lesions can tend to become hyperpigmented, 
becoming a dark brown-black colour (Browne and Hogerzeil, 1962). Whilst the initial 
pigmentation is obviously due to the strong colour of the drug itself deposited in the skin, the 
later appearance of a deep tan colour appears to be due to hypermelanosis associated with the 
chemical structure of clofazimine, similar to an effect seen with high/prolonged doses of 
chlorpromazine, an anti-psychotic agent with a similar heterocyclic nucleus (Satanove, 1965; 
Levy and Randall, 1970). Differences in the oxidation state of clofazimine in different areas of 
the skin may explain the tendency to colour uncovered regions of the body (Browne and 
Hogerzeil, 1962). The pigmentation may also be associated with a general dryness of the skin, 
xerosis, in approximately 30% of patients, which can progress to ichthyotic changes (scaly 
patches) (Moore, 1983; Kumar, 1991). The skin may also become pruritic (itchy) with a burning 
sensation which can extend to the eyes. There appears to be little correlation between these 
symptoms and dose. Other effects reported include phototoxicity, non-specific rashes, and, 
controversially, dimness of vision (Hastings and Trautman, 1968; Yawalker and Vischer, 1979; 
Moore, 1983; Kumar et al., 1987).
Abdominal pain and transient digestive disturbances are also common side-effects, 
reported normally with high-dose therapies, but not usually severe (Yawalker and Vischer, 1979; 
Moore, 1983; Kumar et al., 1987; Dollery, 1991; Garrelts, 1991). However, a more serious 
gastro-intestinal syndrome associated with very high-dose long-duration therapy, termed the Late 
Syndrome, has been reported. Symptoms of this syndrome include persistent diarrhoea, severe 
abdominal pain, nausea and weight loss (Jagadesan et al., 1975; Mason et al., 1977; Yawalker 
and Vischer, 1979; Venencie et al., 1986; Hassan et al., 1987). This syndrome appears to be 
more common in Indian patients, and, although occasionally fatal, can generally be reversed by 
removal of the drug, and may not recur with re-administration. It is currently thought that these 
symptoms reflect the deposition of large amounts of B663 in the cells of the intestinal mucosa. 
These crystals may cause irritation, leading to intestinal disturbances.
Various forms of clofazimine enteritis have been reported, and in some cases, although 
apparently initially triggered by clofazimine therapy, other causes e.g. gluten sensitivity appear 
to maintain the disease state (Jost et al., 1986). Prostaglandins may play a role in these states, 
since clofazimine stimulates prostaglandin production, especially PGE2 synthesis (Zeis and 
Anderson, 1986), which, in the gut, increases permeability, smooth muscle contraction and can 
cause diarrhoea (Bennet et al., 1968 and 1981; Hawkey and Rampton 1985). Supporting this
17
idea is the observation that anti-spasmolytics have been used with some success in treating 
uncomplicated B663-induced diarrhoea (Kumar et al., 1987).
There has been no evidence to date to suggest that clofazimine is carcinogenic, 
teratogenic or mutagenic in humans (Peters et al., 1983) despite limited evidence of 
clastogenicity in mice (Das and Roy, 1990; Dash et al., 1990; Roy and Das, 1990).
1.5.5b. Biochemical and haematological side effects
A study by Hastings et al., (1976) on patients receiving long-term B663 treatment 
reported no statistically significant changes in the following haematological parameters; SGOT 
(serum glutamine oxaloacetic transaminase), thymol turbidity, serum globulins, uric acid, alkaline 
phosphatase, white blood cell count, haematocrit, haemoglobin, BUN (blood urea nitrogen), 
serum creatinine, serum cholesterol, serum albumin, serum potassium and calcium and routine 
urinalysis. Significant, but clinically asymptomatic changes were seen in fasting blood sugar and 
total bilirubin. In addition, Bulak et al., (1983), have shown that 12 months of clofazimine 
therapy caused a reversal of the liver dysfunction common in leprosy.
1.5.6. Drug Interactions
Mehta et al., (1986) have shown an absence of any significant difference in various 
pharmacokinetic parameters of dapsone, when co-administered with clofazimine. With 
rifampicin, clofazimine delayed the time to reach its peak plasma concentration, and increased 
the half life 0%) marginally. However, this had no effect on the area under curve (AUC) or peak 
plasma concentration (Cmax) values. Hence, the relevance of these findings is unclear. One study 
has shown that isoniazid increased the serum concentration and urinary excretion of clofazimine, 
by as yet uncertain mechanisms (Venkatesan et al., 1980).
In addition, there is evidence of clofazimine interacting with endogenous substances. 
Duncan et al., (1983) reported a diminished oestrogen excretion in pregnant women receiving 
300 mg clofazimine per week, with an uncertain clinical relevance. Bharadwaj et al., (1982) 
have shown reduced skin and plasma levels of vitamin A in leprosy patients, and a more 
pronounced reduction of these levels in leprosy patients on clofazimine therapy.
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1.6. SUMMARY
Although much still remains to be understood about the chemical and pharmacological 
properties of clofazimine and other phenazine agents, recent advances have provided a dearer 
picture of how and why these agents work. They aiso provide strong evidence that more useful 
compounds in this class can be produced, and that existing agents may be more broadly useful 
in a variety of disease states than was initially anticipated.
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1.7. THESIS OUTLINE
The preceding sections have outlined much of the general information known about 
clofazimine and phenazine agents in general. The aim of this project was to provide further 
basic knowledge on selected properties of these agents. For clarity, the research undertaken has 
been divided into three chapters, with a separate chapter (chapter 2) for the materials and 
methods which were used.
Chapter 3 describes the investigations into some of the chemical properties of the rimino- 
phenazines which were selected for testing. The development and validation of a new method
for quantification of phenazines in biological matrices is also described.
Chapter 4 reports the production and characterisation of phenazine-protein conjugates, 
their use in the production of polyclonal antisera and attempts to develop a quantitative assay 
system based on the antibody produced.
Chapter 5 describes the studies of some of the pharmacokinetic properties of the chosen 
agents which were undertaken using the methods discussed in chapter 3.
20
CHAPTER 2
MATERIALS AND METHODS
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MATERIALS
2.1. SOURCE OF PHENAZINE COMPOUNDS
All phenazine compounds used in this study, except the pharmaceutical grade 
clofazimine, were synthesised by Dr. Sean O’Sullivan in the Chemistry Department of University 
College Dublin, Dublin 4. Pharmaceutical grade clofazimine was supplied by Geigy 
pharmaceuticals, Horsham, West Sussex, England.
2.2. REAGENTS AND CHEMICALS
All reagents, unless specified otherwise were, purchased from the Sigma Chemical Co., 
Poole, Dorset, England. Chromium, cyclodextrins and deuterated solvents were bought from The 
Aldrich Chemical Co., The Old Brickyard, New Road Gillingham, Dorset, SP8 4JL, England. 
Silica and silica TLC plates and other listed reagents were supplied by Riedel-de Haen, 
Wunstorfer Straße 40, P.O. Box, D-3016 Seelze 1, Germany. Alumina was supplied by 
Macherey-Nagel GmbH & Co. KG, P.O. Box 101352, D-5160 Düren, Germany. Hexane 
sulfonic acid was purchased from Romil Chemicals Ltd., 63 Ashby road, Shepshed, 
Loughborough, Leicestershire, England. All organic solvents used were of HPLC grade and 
were supplied by LabScan,unit T26, Stillorgan Industrial Park, Co. Dublin. The water used in 
HPLC mobile phases was Ultrapure grade (1018 Q resistivity) produced by a still supplied by 
Millipore, 80 Ashby Rd., Bedford, MA 01730, USA. Sephadex and the BIAcore equipment and 
reagents were supplied by Pharmacia, Bjorkgaten 30, S-75182, Uppsala Sweden. KLH was 
purchased from Calbiochem, Behring Diagnostics, La Jolla, CA 92037, USA. All animal food 
was provided by W.M. Connolly and Sons Ltd., Redmills, Goresbridge, Co. Kilkenny.
2.3. CONSUMABLE LABWARE
BM-test-8 urine test strips were supplied by Boehringer Mannheim UK Ltd., Bell Lane, 
GB-Lewes, East Sussex, England. Maxisorb ELISA plates were supplied by NUNC, Postbox 
280 - Kamstrup DK, Roskilde, Denmark. Amine Binding ELISA plates were purchased from 
COSTAR, 1 Alewife Ctr., Cambridge, MA 02140, USA. Emphase and BCA reagents were 
purchased from Pierce and Warringer (UK) Ltd., 44 Upper Northgate Street, Chester, Cheshire, 
England. Centricon SR3 and Centriplus centrifugal concentrators were purchased from Amicon 
Ltd., Upper Mill, Stonehouse, Gloucestershire, England. Bondclone C18 and Biosep SEC-4000 
HPLC columns were purchased from Phenomenex, Melville House, Queens Avenue, Hurdsfield
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Ind. Est., Macclesfield, Cheshire SK 10 2BN, England. 10 ml glass blood tubes were purchased 
l'rom Medlabs Ltd., Unit 1C, Stillorgan Industrial Park, Stillorgan, Co. Dublin. 1.1 ml glass 
autosampler vials and 8 mm PTFE septae were supplied by Chromachol, P.O. Box. 293, 
Trumbull, CT 06611, U.S.A. 2500 um polyethylene mesh was produced by E.C. Stewart 
Filtration, 128 Botanic Avenue, Dublin 9, Ireland.
2.4. EQUIPMENT
All pH measurements were performed on a 3015 pH meter from Jenway Ltd., Gransmore 
Green, Felsted Dunmow, Essex CM6 3LB, England. I.R. analysis was performed on a Nicolet
I.R. spectrometer supplied by The Nicolet Instrument Corp., 5225-1 Verona rd., Madison, WI 
53711, USA. Electrophoresis was performed using gels supplied by the Atto Corp., 2 -3  Hongo 
7- chome, Bunkyo-Kui, Tokyo 113, Japan. NMR analyses were performed on a 400 MHz AC- 
400 NMR spectrometer from Brucker, Banner Lane, Coventry CV4 9GH, England. Samples 
were analysed in 5 mm glass NMR tubes supplied by the Wilmad Glass Co., Route 40, 1 Oak 
Road, Buena, N.J. 08310, U.S.A. Freeze drying was performed using Hetosicc, Hetofrig and 
Hetovac apparatus from Heto Lab Equipment A/S, Gydevang 17 - 19, DK 3450, Allerod, 
Denmark. The complete System Gold HPLC system, consisting of a 507 autosampler, 126 
pump, 166 U.V. detector, 168 PDA detector and version 8 software were supplied by Beckman 
Instruments Inc., Bioindustrial Business Unit, Fullerton, CA 92634-3100, U.S.A. The 
photodiode HPLC system used for protein conjugate analysis was supplied by the Waters Corp., 
34 Maple St., Milford, MA 01757, U.S.A. All spectrophotometric measurements were made on 
a U.V.-160A spectrophotometer from the Shimatzu Corporation, 1 Nishinokyo-Kuwabaracho, 
Nakagyo-ku, Kyoto 604, Japan. Centrifugation was performed on the specified Heraeus 
centrifuges supplied by Heraeus Instruments Inc., 111-A Corporate Blvd., South Plainfield, N.J. 
07080, U.S.A. The absorbances in ELISA and BCA assays was measured using a Titertek 
Mulitscan plate reader produced by Flow Labs. Ltd., Woodcock Hill, Harefield Rd., 
Richmansworth, Hertfordshire WD3 1PQ, England. Faecal samples were oxidised in a high 
temperature oven supplied by Lenton Thermal Designs Ltd., Unit C2 Valley Way, Welland 
Industrial Estate, Market Harborough, Leicestershire LEI 7PS, England.
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2.5. LICENSING
All of the experiments involving animals were thoroughly vetted before initiation. Each 
investigation was performed with the appropriate licences and exemptions from the Department 
of Health. In every cases, all appropriate efforts were made to minimise distress and discomfort 
to the animals used.
2.6. DISTRIBUTION STUDIES IN MICE
Selected phenazine agents were administered to female Schofield mice housed in groups 
of six by oral gavage. Suspensions of each agent, at a concentration of 1.28 mg/ml, were made 
in 1 % (w/v) Carboxymethyl Cellulose 1 % (v/v) Tween 20 (Riedel-de Haen) and 0.4 ml 
administered using a modified spinal needle to each animal every day for 21 days. On day 22 
the animals were sacrificed and organs and blood removed. The samples were stored at -18 °C 
and thawed just before analysis of drug levels measured by DCM extraction and HPLC as 
described in sections 2.9.1 - .4. and 2.10., respectively.
2.6. RAT EXPERIMENTS
2.6.1. Metabolism cage construction
For absorption, distribution and toxicity studies female Wistar rats were maintained in 
purpose built metabolism cages in groups of 3 animals. Each animal was identified by a series 
of rings or lines indelibly marked on its tail. Figure 2.1 (a) shows a side view of this cage. The 
cages consisted of standard polypropylene rat cages (41 x 24 x 13 x 20 cm) with "high type" 
stainless steel mesh lids and the bottom cut out. A stainless steel grid (39.5 x 23.5 cm) with a 
mesh of 4.75 x 0.8 cm provided the living surface at the bottom of the cage through which food, 
faeces, urine and water could freely fall. Faeces were directed by a 2.5 cm polyethylene mesh 
(E.C. Stewart) (see Figure 2.1 (b)), suspended at a 45° angle under the cage, to a detachable bag 
made from the same mesh. Urine was collected by a polythene plastic sheet (see Figure 2.2 (a)) 
suspended under the mesh at a similar angle. A 50 ml universal tube at the lowest angle of the 
bag was used to collect this urine.
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Figure 2.1. A cut away, side view of the metabolism cage used for the absorption and 
distribution studies of phenazines in rats. The cage dimensions are outlined in the text. 
The dimensions of the mesh used for faecal collection are shown in part (b).
Figure 2.1 (a)
High type lid
Polypropylene rat box 
Stainless steel mesh
Polythene bag for urine collection 
Polyethylene mesh for faecal
Perspex food 
guides
Waste food 
collection tray
Figure 2.1 (b)
<—
58 cm
56 cm
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Weighed amounts of food were given into the feeding compartment of the high sided 
lop which had a rectangle of perspex allowing the rats access to the food only from the side. 
Waste food was collected by a perspex box (24 x 8 x 2 cm) suspended underneath the food area 
using steel springs. Sheets of perspex either side of this food area bolted to the bottom mesh 
of the cage prevented food from falling anywhere but into this box (see Figure 2.2 (b)). Water 
was administered in a standard 250 ml water bottle in the water slot of the cage.
2.6.2. General method for absorption studies in the rat
Rats were maintained in the metabolism cages on normal rat food for one week before 
each study to allow the animals to acclimatise to their environment and allow baseline 
measurements of all parameters investigated. All food was removed from the cages 15 hrs. 
before the scheduled beginning of the study but animals still had free access to water. A known 
weight of drug-doped food was added to the cage to begin the experiment. All faeces were 
collected at this time to provide blank measurements. After 4 hrs. any remaining food and waste 
food were removed and weighed and the animals returned to their normal diet. Faecal samples 
were collected at intervals for 105 hrs.
2.6.3. Drug doping of food for absorption studies
Drug doped food was prepared by hydrating 20 g of rat pellets (W.M. Connolly and 
Sons Ltd.) in 40 ml of distilled water. 0.12 g of chromium (III) oxide powder (Aldrich), with 
a particle size less than 53 pm, and 7 mg of test phenazine dissolved in ethanol, or in the case 
of cyclodextrin complexes, 0.121 g of powdered complex, were thoroughly mixed into the food. 
The food was then fully dried overnight in an oven at 80 °C.
2.6.4. General method for distribution studies in rat
The animals were given a two week "washout" period after the absorption study, being 
maintained in the metabolism cages on normal rat pellets. Drugged food was prepared by 
hydrating 1.8 kg of rat pellets with 3.6 L of distilled water. 0.63 g of test phenazine dissolved 
in excess ethanol was thoroughly mixed in. As a control a batch of food was prepared in the 
same way except no phenazine was added. This food was given to one group to control for any 
anomalies caused by the hydration and heating processes. In the case of cyclodextrin complexes, 
10.9 g of the powdered complex was mixed in. The food was dehydrated on oven trays in an 
oven at 80 °C for 24 hrs.
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Figure 2.2. (a) The dimensions of the polythene sheet suspended beneath the metabolism 
cage to collect urine produced by the animal in the cage, (b) Shows a cut away, side view 
of the waste food collection apparatus in the metabolism cage. As shown in this diagram 
waste food can only fall into the collection box, allowing easy quantification.
Figure 2.2 (a)
. 38 cm .
< >
76 cm
Figure 2.2 (b)
27
The treated food was given for 5 days of the week with normal untreated food being 
administered for the other two days of each week, to insure against possible nutritional 
deficiency due to the food treatment process, and allow measurement of normal feeding habits 
throughout the course of the experiment. This continued for 4 weeks with no period of normal 
food in the final week (ie 26 days total) as represented in the Figure 2.3.
The animals were killed by exsanguination on day 27 and drug levels were measured 
by the DCM extraction and HPLC methods as described in sections 2.9.1 - .4. and 2.10. 
respectively.
2.6.5. Toxicity assessment
During the absorption/distribution studies indicators of toxicity were measured for selected 
phenazines. After the initial settling in period, blood and clean urine samples were taken. The 
food and water consumption, behavioral characteristics, urinary parameters and individual animal 
weights were recorded regularly during the experiment. Post mortem tissue weights were also 
measured and compared between the groups.
2.6.5a. Haematological monitoring
1 ml blood samples were taken from the rats by tail bleeding, initially, and by cardiac 
puncture at termination, and clotting prevented by collection in potassium EDTA-coated tubes. 
Samples were immediately sent to Dr. Hugh Larkin in the Veterinary College of University 
College Dublin for routine analysis for the following parameters:- packed cell volume (PCV), 
haemoglobin concentration (HB), red blood cell count (RBC), mean corpuscular haemoglobin 
concentration (MCHC), mean corpuscular volume (MCV), white blood cell count (WBC), 
protein content, neutrophil count, eosinophil count, lymphocyte count, monocyte count. Samples 
were also analysed for the enzymes Sorbitol Dehydrogenase (SDH), Alanine Aminotransferase 
(ALT) and Aspartate Aminotransferase (AST) using clinical chemistry kits (Sigma Diagnostics).
2.6.5b. Urinary monitoring
Urinary samples were pooled and analysed with a combination test strip (Boehringer 
Mannheim) for the following indicators :- Nitrite, pH, protein, glucose, ketones, urobilinogen, 
bilirubin and blood (erythrocytes and haemoglobin).
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Figure 2.3. A diagrammatic representation of the drugged food administration schedule for 
the rats on distribution studies.
5 days on treated food
2 days on 
normal
untreated food
26 days
2.7. PROTON-NMR ANALYSIS OF URINE
Urine samples taken before and after the drug distribution experiment, and from New 
Zealand rabbits being used to produce antibodies, were analysed for indicators of toxicity. This 
analysis was performed on a Brucker AC-400 Mhz NMR spectrometer with the help of Dr. 
Paraic James and Mr. Michael Burke in the dept, of Chemisty, D.C.U. Freshly collected urine 
samples were centrifuged at 13000 rpm on a Heraeus Biofuge 13 for 10 minutes and frozen, 
after which, 800pl aliquots were freeze dried in an eppendorf tube centrifuge connected to a 
freeze drier. These samples were reconstituted in 800pl of deuterated water (D20) (Aldrich) and 
the pH adjusted to 7.0 with HCl/NaOH. The samples were analysed in the NMR machine using 
the presat water suppression programme to remove the strong 'H20  peak. As a positive toxic 
control urine was taken from a rat injected subcutaneously with 1 ml of carbon tetrachloride. 
Urinary results were compared with positive and negative controls to indicate areas of difference. 
Important peaks were identified by analysis of the purified compound in D20  under the same 
conditions as the samples, and by comparison with published chemical shifts for urinary 
metabolites.
2.8. TREATMENT OF MURINE MALARIA WITH PHENAZINES
Selected phenazines were incorporated into mouse pellets at a concentration of 120 mg 
of drug per 1.2 kg (initial weight of food), with a food control prepared also, as described in 
section 2.6.4. for preparation of doped rat food. CD1 mice were housed in groups of six 
animals and given ad libitum access to drugged food and water for two weeks. A positive 
therapy group of mice given ad libitum access to the anti-malarial agent sulfasalazine, at a 
concentration of 30 mg/1 in their drinking water, was concurrently dosed. On day 14 each 
animal was infected intraperitoneally with 250pl of mice blood with a 10 % Plasmodium berghii
29
parasitaemia (64 x 107 parasites/ml). Animals continued to receive their dosage regime until 
they became ill, when they were sacrificed, or, in the case of the sulfasalazine group, for a week 
longer, when the drug was removed, and the animals became susceptible to the infection.
2.9. DRUG EXTRACTION
2.9.1. Tissue samples
0.1 g of tissue was homogenised in a 2 ml mortar, with a motor-driven revolving teflon 
pestle (AGB), in 1 ml of ultrapure (U.P.) water (Millipore). The homogenate was poured into 
a 10 ml glass blood tube (AGB) previously coated with 2pg of an appropriate phenazine internal 
standard (I.S.). Remaining homogenate was washed from the homogeniser tube with 1 ml of 
5 M sodium hydroxide (NaOH). 2 ml of dichloromethane (DCM) was added and each tube was 
mixed for 20 mins. on a blood tube mixer. Tubes were further mixed in a sonicating bath 
(Elma) for 5 mins. The tubes were centrifuged (Heraeus, Labofuge GL) at 4000 rpm for 15 
mins. resulting in the bottom organic layer being covered by a solid disc of tissue debris in the 
aqueous layer. 1.1 ml of the organic layer was carefully removed to a glass autosampler vial 
(Chromachol) and allowed to evaporate off over 2 hrs. by heating at 40°C on a heating block.
For spiked standards blank tissue was homogenised and the extraction tube was coated 
with I.S. and spiked amounts of drug.
2.9.2. Faecal samples
Faecal samples were collected from the metabolism cages in plastic scintillation tubes 
(Beckman) and dried overnight under vacuum. Each dried sample was powdered and mixed 
using a mortar and pestle. 0.1 g of powdered sample was then extracted as described above.
2.9.3. Fat tissue
0.1 g of sample was homogenised as per the tissue method (section 2.9.1.). After 
centrifugation, the aqueous layer was aspirated off and 1.5 ml of alcoholic sodium hydroxide (10 
% (w/v) NaOH in ethanol) added to the DCM layer. The tubes were then heated in a heating 
block at 80 °C until bubbling stopped indicating complete evaporation of the DCM. 6 mis of 
cold U.P. water and 2 mis of DCM were then added. The tubes were mixed for 5 mins on the 
blood tube mixer and then centrifuged at 3,500 rpm for 10 mins. The aqueous soapy layer was
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aspirated off and the DCM layer was washed twice more in the same manner. 1.1 mis of the 
DCM layer was removed and evaporated off in autosampler vials as described above.
2.9.4. Serum samples
1 ml of serum sample was added with 1 ml of NaOH and 2 ml of DCM to internal 
standard (I.S.)-coated blood tubes. Extraction was carried out as per the tissue extraction method 
(section 2.9.1.).
2.9.4a. Estimation o f bound clofazimine fraction in serum.
1 ml of fresh serum sample was placed in centricon SR-3 centrifugal filters with a M.W. 
cut-off of 3,000 Da. The tubes were centrifuged in a Sorval SS-34 head at 7000 rpm for 2.5 hrs. 
The lOOpl retained in the top (high m.w. fraction) and bottom 900jil (low m.w.) were placed in
I.S.-coated blood tubes and the volumes brought up to 1 ml with U.P. water. Drug 
concentrations were measured using the extraction and HPLC method in section 2.9.4. and 2.10. 
respectively.
2.10. HPLC QUANTIFICATION OF PHENAZINES
After extraction, samples were reconstituted in 60pl of acidified tetrahydrofuran (THF) 
(60pl of acetic acid in 10 ml of THF). Fat samples were reconstituted in 120pl of acidic THF. 
Measurement was performed using a Beckman System Gold HPLC system comprising 507 
autosampler, 126 pump, 166 U.V. detector, with data collected and analysed by computer using 
version 8 of the Gold software. The peak height ratio of analyte to I.S was used to quantify 
drug concentrations from spiked standards. The mobile phase consisted of 594 ml of U.P. water, 
6 ml of acetic acid, 400 ml of HPLC grade THF and 0.471 g of hexane sulfonic acid (Romil 
chemicals). This was mixed and degassed in a sonicating bath for 5 mins. The system operated 
by pumping the mobile phase through the column at 1.5 ml per min. at ambient lab. temperature 
(18-21 °C) with the column eluent recycling into the mobile phase reservoir as part of a sealed 
recycling circuit of mobile phase flow. Separation occurred on a Phenomenex Bondclone C18 
reversed phase column with dimensions of 300 x 3.9 mm and a particle diameter of 10 um with 
a C18 pBondapak cartridge precolumn. Absorbance of the column eluent was monitored at 285 
nm. This wavelength was chosen because it was an average of the wavelengths at which all the 
agents gave their strongest absorbance.
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To determine the intra-day precision and accuracy, blank tissue, fat and serum samples 
were spiked with B663 and I.S. (B4100) across the linear range. Five sets of samples spiked 
with identical concentrations of drug were prepared using a single group of standards and 
quantified using calibration standards. The inter-day precision and accuracy for these samples 
was determined by preparing and analysing spiked standards prepared on five different days. 
Inter- and intra-day variability was also measured in the same way for B4090 using B663 as the
I.S.
2.10.1. PDA-HPLC analysis of phenazines
The same method of analysis was employed as described above, except a 168 System 
Gold PDA detector module was substituted for the U.V. detector.
2.11 CHROMIUM MEASUREMENT IN FAECES
2.00 g of the freeze-dried and powdered faecal samples from the absorption studies were 
completely oxidised at 600 °C in a high temperature oven overnight in ceramic crucibles. The 
ashed samples were then reweighed and transferred 10 ml blood tubes. The chromium content 
of the samples was then measured spectrophotometrically by a modification of the method of 
Czubayko et al., (1977) 2 ml of conc. ortho-phosphoric acid and 3.5 ml of 4.5 % (w/v) aqueous 
solution of potassium bromate were added to each tube and standards of faecal ash and known 
masses of chromium (III) oxide powder. The tubes were heated to boiling in a heating mantle 
until no more bromine gas was being evolved (paper in vapour remained white) indicating 
complete oxidation of the sample to chromium (IV). The tubes were then centrifuged at 3,500 
rpm for 10 mins to precipitate ash. Suitable dilutions of each supernatant were made in distilled 
water and the absorbance of all tubes was measured in quartz cuvettes at 346 nm in a 
spectrophotometer (Shimatzu).
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2.12. CONJUGATE PRODUCTION
2.12.1 Glutaraldehyde conjugations
2.12.1a.One step conjugation
B3976 (phenylalanine derivative) (0.5 mg/ml) was mixed with solutions of BSA (20 
mg/ml) or THYR (2.5 mg/ml) in various molar ratios in U.P. water at 4 °C. 0 - 1 ml of 1 % 
(v/v) aqueous glutaraldehyde was added to the mixtures and the solutions were reacted for 60 
mins. Conjugates were dialysed overnight against U.P. water to remove unconjugated 
compound.
2.12.1b.Two step conjugation
10 ml of BSA solution (10 mg/ml) or THYR (2.5 mg/ml) were dialysed against 200 ml 
of 0.2 % (v/v) aqueous glutaraldehyde for 16 hrs at 4 °C. The activated carrier proteins were 
dialysed against U.P. water to remove free glutaraldehyde. The activated proteins were dialysed 
against 100 ml of 0.2 mg/ml aqueous B3976 for 16 hrs at 4 °C. 0.1 ml of 0.2 M lysine was 
added to each bag and incubated for 2 hrs. The bags were dialysed against U.P. water to 
remove free drug and lysine.
2.12.1c.Preservation and storage of glutaraldehyde conjugates
The dialysed samples were frozen to the side of a round bottomed flask using a freezer 
bath (Heto) and -80 °C freezer. Samples were then freeze dried on a Heto freeze drier overnight. 
Samples were kept frozen until use.
2.13. CARBODHMIDE CONJUGATION
100 mg of Keyhole Limpet Haemocyanin (Calbiochem) solution (1.46 ml) was dialysed 
overnight against 50 mM phosphate buffer to remove the glycerol preservative. This solution 
was removed and made up to 4 ml with phosphate buffer. 9.77 mg of B3955 (glycine 
derivative), 3.33 mg of l-ethyl-3(3-dimethylaminopropyl)-carbodiimide (EDC) and 6.67 mg of 
N-hydroxysuccinimide (NHS) were mixed together in 2 ml of dimethyl formamide (DMF) for 
a few seconds before the KLH solution was added. The reaction was mixed at 25 °C for 7 hrs 
followed by overnight dialysis against P.B.S., (0.15 M), pH 7.4, with 1 mg/ml lysine added. The
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conjugate was concentrated by reverse dialysis against 6 KDa molecular weight polyethylene 
glycol (PEG). This conjugate was freeze dried and kept frozen until used as described in section 
2.12.1c.
2.14. CHARACTERISATION OF GLUTARALDEHYDE CONJUGATES
2.14.1. SDS-PAGE analysis of conjugates
The freshly prepared samples were adjusted to a concentration of 1 mg/ml and diluted 
1 : 1 with sample buffer (2 % (w/v) SDS; 0.08 M Tris/HCl, pH 6.8; 10 % (w/v) Coomassie 
Brilliant Blue). The samples were boiled for two minutes and 25pl aliquots applied to the wells 
of a 5 - 20 % polyacrylamide gel (Atto). The gels were run at a constant current of 20 mA per 
gel for approximately 2 hours. The electrode buffer for electrophoresis consisted of 0.025 M 
Tris, 0.192 M glycine and 0.1 % (w/v) SDS at a pH of 8.3. The gels were stained for 30 mins 
in 0.5 % (w/v) Coomassie Brilliant Blue in acetic acid ; water methanol (1:10:8, v/v/v) and 
destained overnight in the same solvent to visualise the protein bands.
2.14.2. TLC analysis of conjugates
Conjugate samples and controls were applied to silica TLC plates with a capillary tube 
and the spots developed with an 80 : 20 (v/v) methanol: water solvent. When the drug spot had 
migrated 2/3 of the plate length, the plates were removed and the protein present was stained 
in an iodine chamber.
2.14.3. HPLC analysis of conjugates
Protein conjugate samples were characterised using the Beckman system Gold HPLC 
system pump and detector as described in section 2.10. The proteins were separated using a 
Protein Pak (Millipore) SW 300 column with a particle diameter of 10 pm. The mobile phase 
was 0.1 M phosphate buffer, pH 7.0, at a flow rate of 0.5 ml/min with U.V. detection at 280 nm. 
20 pi of sample was manually injected into the system.
2.14.4. PDA-HPLC analysis of conjugates
BSA, THYR and conjugates were analysed with the same column and mobile phase as 
described in the previous section. Peak characterisation was carried out using a Waters 990
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pump, 990 PDA detector, 990 plotter and 990 30 chromatogram measure APC 3 computer:
2.14.5. Size exclusion chromatography of conjugates
Sephadex G-25 was swollen overnight in U.P. water. A 200pl sample of the conjugate 
was applied and washed through with water at a flow rate of 1 ml/min. A coloured fraction 
eluted in the void volume fraction and the amount of B3955 was estimated using a standard 
curve of dilutions of the drug in water. The concentration of protein present in this fraction was 
measured using the micro B.C.A. protein assay (section 2.17.3.) with standards of BSA. 
Calculation of the molar masses of protein and drug present gave an approximation of the 
conjugation ratio.
2.15. CHARACTERISATION OF EDC CONJUGATE
Sephadex G-100 (Pharmacia) powder was swollen overnight in P.B.S., (0.15 M), pH 7.4. 
The gel was poured into a 10 ml column and allowed to settle. A 200pl fraction of the P.B.S.- 
dialysed KLH conjugate was applied to the column and fractions collected with absorbance 
monitored at 488 nm. A coloured fraction eluted in the 10 - 12.5 ml fraction and the amount 
of B3955 was estimated using a standard curve of dilutions of the drug in P.B.S., (0.15 M), pH
7.4. The concentration of KLH present in this fraction was measured using the micro B.C.A. 
protein assay (section 2.17.3.) with standards of KLH. Calculation of the molar masses of 
protein and drug present gave an approximation of the conjugation ratio.
2.16. PRODUCTION OF ANTI-PHENAZINE ANTIBODY
2.16.1 Immunisation protocol
A 0.5 mg/ml solution of B3976-THYR conjugate was made by homogenising 1.5 mg 
of conjugate in 1.5 ml of P.B.S., (0.15 M), pH 7.4, and 1.5 ml of Freunds adjuvant in a mortar 
and pestle type homogeniscr. 1 ml of this suspension was subcutaneously injected at several 
sites along the back of two female New Zealand rabbits. Control sera was taken before 
immunisation. The first immunisation was made with complete adjuvant and all subsequent 
immunisations were using incomplete adjuvant. Animals were boosted on day 28 and bled 11 
days later from the marginal vein in the ear. This cycle was repeated until the antibody titre was 
sufficient.
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2.16.2. Screening for antibody production
2.16.2a.Direct assay using one step glutaraldehyde immobilisation
Scrum from immunised animals was screened for the presence of antibodies by enzyme- 
linked immunosorbent assay (ELISA). 25p.l of 2 % (w/v) BSA in P.B.S. (0.15 M), pH 7.4, and 
25|jl of a 0.1 % (v/v) solution of gultaraldehyde in P.B.S. (0.15 M), pH 7.4, was added to each 
well of an Maxisorb ELISA plate (NUNC). The plate was incubated overnight at 37 °C. 50pl 
of 0.25 mg/ml B3955 was added and allowed to react for 2 hrs. at 37 °C. The plate was washed 
with U.P. water and blocked with 2 % (w/v) BSA for 1.5 hrs. After 4 washes with 0.15 M PBS, 
pH 7.4, containing 0.05 % (v/v) Tween-20, 50pl dilutions of test serum 2 % (w/v) BSA PBS 
were added for 1.5 hrs at 37 °C. After 3 washes with PBS-Tween and one PBS wash, 50pl of 
a 1 in 15,000 dilution of horseradish-peroxidase (HRP)-conjugated goat anti-rabbit 
immunoglobulin in blocking solution was added for 1 hr at 37 °C. The plate was washed 4 
times in PBS-Tween. 50pl of peroxidase substrate (10 mg of o-phenylenediamine (OPD) 
dissolved in 25 ml of 0.15 M citrate buffer, pH 5.0, and 5pl of 30 % (v/v) H20 2) was added to 
each well and incubated at room temperature (R.T.) until colour developed. 50pl of 1 M H2S04 
was added to stop the reaction and the absorbance of each well was measured at 492 nm using 
a TiterTek Twinreader plus plate reader.
2.16.2b.Two step glutaraldehyde immobilisation
25pl of 2 % (w/v) BSA and 25pl of 0.2 % (v/v) glutaraldehyde was added to the ELISA 
wells and incubated overnight at 4 °C. The wells were washed and 50pl of phenazine added. 
The plate was incubated at 37 °C for 2 hrs. The plate was washed and antibody binding 
measured as described in the previous section.
2.16.2c.Competitive assay
The plate was coated with 250pl of 1 % (w/v) BSA for 5 hrs at 37 °C. Excess BSA was 
removed and aspirated out. lOOpl of 0.2 % (v/v) glutaraldehyde was added and the plate 
incubated for 2 hrs at 37 °C. The plate was washed with water, lOOpl of B3976 added and the 
plate was incubated at RT overnight. The plate was washed four times and lOOpl of 1 % (w/v) 
lysine added for 1 hr. at 37 °C. The lysine was removed by aspiration and the plate blocked 
with lOOpl of 1 % (w/v) BSA. The plate was washed four times and 50pl of a two times B3976 
concentration added. 50pl of two times rabbit antibody concentration diluted in P.B.S. (0.15 M),
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pH 7.4, was added and the plate incubated at 37 °C for 1 hr. The plate was washed and 
antibody binding measured as described in section 2.16.2a.
2.16.3. Measurement of amount of bovine serum albumin bound to ELISA plate
50pl, 25pl of 2 % (w/v) BSA in P.B.S. (0.15 M), pH 7.4, 25ul of 2 % (w/v) BSA and 
0.2 % (v/v) of glutaraldehyde or 25pl of 0.25pg/ml glycine were added to the ELISA plate wells 
and the plate was incubated overnight at 4 °C. The plate was washed as described above and 
dried for 1 hr. at 60 °C. lOpl of water was added to each dry well and the amount of protein 
present determined using the micro BCA protein assay (section 2.17.3.).
2.16.4. Experiments using Amine binding plate
lOOpl aliquots of B3955 and B3976 in the range 0 - 1  mg/ml in water were added to 
wells of a Costar amine binding plate and left overnight at 4 °C. Concentrations of B3832 were 
made by diluting a stock concentration of 1 mg/ml B3832 in DMF with water and only 
concentrations of 0.2 mg/ml or less could be used due to the effect of DMF on the plastic. The 
wells were washed 4 times and blocked with 2 % (w/v) BSA for 1 hr. The blocking solution 
was washed out with four washes of P.B.S.-Tween and a 1 in 2000 dilution of rabbit serum 
added to the wells. After a one hour incubation the plate was washed and the antibody binding 
quantified (section 2.16.2a.).
2.16.5. EDC/NHS immobilisation of phenazine to ELISA plate
50pl of 2 % (w/v) BSA was added to the wells of a maxisorb ELISA plate and incubated 
overnight at 4 °C. The wells were washed and lOpl of 0.1 mg/ml of B3955 in U.P. water, lOpl 
of 0.5 mg/ml glycine, 35pl of 5 mg/ml NHS, 35pl of 5 mg/ml EDC and lOpl of 4.5pg/ml 
Na2HP04 were added. The plate was incubated overnight at 4 °C and washed. lOOpl of 0.5 
mg/ml glycine was added to each well to cap any free reactive groups and the plate was 
incubated for an hour at 37 °C. The plate was then blocked with 200pl of 2 % (w/v) BSA for 
a further hour. The plate was washed and lOOpl of the test anti-serum, diluted in 1 % (w/v) 
BSA in 0.02 % (v/v) P.B.S.-Tween added. For competitive assays 75pl of antibody dilution and 
25pl of B3955 in P.B.S.-Tween was added. After an overnight incubation at 4 °C, the amount 
of antibody binding was assessed as per section 2.16.2a.
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2.16.6. Experiments using Nunc covalink plate
50pl of a 1 mg/ml aqueous solution of bis(sulfosuccinimidyl) suberatc (BS3) was added 
to the wells of a Nunc Covalink ELISA plate. After incubation at R.T. for four hours, the plate 
was washed with water and 50pl of drug dilution was added. The plate was incubated at 4 °C 
overnight, washed and blocked with 2 % (w/v) BSA. Dilutions of antibody were added and 
binding assessed as described in section 2.16.2a.
2.16.7. Experiments using silica coated plate
30(jl of 0.05 % (w/v) polyisobutylmethacrylate in cyclohexane was added to the wells 
of a maxisorb plate. Each well was filled with silica powder and the cyclohexane evaporated 
off at 56 °C. The excess silica was washed out with water and concentrations of rimino- 
phenazines from 0.002 to 1 mg/ml added in water or methanol as appropriate. Direct and 
competitive assays were performed in the conventional manner (sections 2.16.2a and 2.16.2c.).
2.17. ANTIBODY PURIFICATION
Frozen rabbit serum was thawed and filtered using 100 KDa molecular weight cut-off 
Centriplus centrifugal filtration tubes (Amicon) at 4000 r.p.m for 3 hrs. The retentate was 
washed twice by adding 5 ml of P.B.S. (0.15 M), pH 7.4, to it and centrifuging at the same 
speed for one hour.
2.17.1 Affinity chromatography of antibody
327 mg of B3832 was dissolved in 10 ml of DMF with 100 mg of biotinyl-e- 
aminocaproic acid N-hydroxysuccinimide ester (Biotin-NHS) and 3 ml of 0.1 M borate buffer, 
pH 8.2, added. The reaction was mixed overnight at R.T. and characterised using T.L.C. and 
PDA-HPLC. Several solvent mixes were employed for separation of the resultant compounds 
including an 8 : 1 DCM/methanol mix and a mixture of butanol/acetic acid/water (93 : 5 : 5 
(v/v/v)). However, even when coupled with a biotin visualisation agent, D.A.C.A, the results 
were not clear due to the similarity in colour between the phenazine and biotin-D. A.C.A product. 
Biotinilated compounds were visualised by the method of McCormick and Roth, (1980) using
0.2 % (w/v) p-dimethylaminocinnamaldchyde (D.A.C.A) in 2 % (v/v) sulfuric acid - ethanol 
sprayed onto the plates to produce a pink product indicating the presence of the biotin group. 
Samples were also analysed by PDA-HPLC using the method described for phenazine analysis
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(section 2.10.1.).
35 mg of avidin was dissolved in 17.5 ml of a mix of 0.2 M carbonate buffer and 0.6 
sodium citrate (1.68 g of sodium bicarbonate and 17.65 g of sodium citrate dissolved in 100 ml 
of water with pH adjusted to 9.0 with NaOH). This was added to 1.25 g of Emphase Biosupport 
Medium AB 1 (Pierce) with 7.5 ml of buffer used to wash out all the remaining protein. The 
protein and beads were mixed overnight. The B3832-Biotin-NHS reaction was then added to 
the swelled beads and allowed to mix for 2 hrs. The mixture was poured into a 10 ml column 
and unbound compounds removed by washing with water and DMF. Free reactive groups were 
quenched using a 1% (w/v) lysine solution. The column was stored in a 0.05 % (w/v) aqueous 
azide solution.
Before use the column was blocked with 2 % (w/v) BSA in P.B.S. (0.15 M), pH 7.4,. 
This was washed out with P.B.S. (0.15 M), pH 7.4, and the partly purified antibody solution was 
applied. The antibody solution was washed into the matrix with 4 ml of PBS and allowed to 
equilibrate and bind for 10 mins. Non-specific protein was eluted at 1 ml/min with PBS until 
the 280 nm absorbance of the eluent returned to baseline. 4 ml of 0.1 M glycine, pH 2.5, with 
10 % (v/v) dioxane was added to the column for 15 mins. Eluted 2 ml fractions were then 
collected in tubes containing llOpl of 1 M 2-amino-2-(hydroxymethyl) 1,3-propanediol (Tris), 
pH 10.9, to return the pH of the fractions to approximately neutral. Fractions from all stages 
of purification were collected and assayed for protein content using the BCA assay (section
2.17.3.). The samples were also analysed by HPLC using a Biosep SEC-4000 column and the 
same equipment and conditions described in section 2.14.3.
2.17.2. BIAeore™ analysis of antibody
Antibody samples were analysed using BIAeore technology. The machine and the 
immobilisation chemicals were supplied by Pharmacia. B3955 was immobilised to a sensor chip 
surface by the following procedure. 35pl of a 1 : 1 mix of 75 mg/ml EDC and 11.5 mg/ml NHS 
was applied to the chip surface at a flow rate of 5pl/min. 40pl of B3955 in 0.01 M sodium 
acetate, pH 4.5, was applied at 2pl/min and remaining reactive groups on the chip capped by 
35pl of 1 M ethanolamine at 5pl/min. 20yl of antibody dilution at 0.2 mg/ml was added to the 
B3955 surface at 1 Oul/min.
2.17.3. Bicinchoninic acid (B.C.A.) protein assay
This assay is based on the reduction of Cu++ to Cu+ by proteins under alkaline
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conditions, the Cu+ produced being quantitated by complexation with BCA which results in a 
coloured product. The BCA reagents (Pierce) were added together 1 part reagent B to 50 parts 
reagent A. 200pl of this solution was added to lOpl of sample or standard solutions in microtitre 
wells. The colour was developed at 37 °C for 30 mins. with absorbance being quantified at 562 
nm using a plate reader . The protein concentration of samples was determined from standard 
curves plotted from the absorbance of concurrently run standards of the same protein.
2.18. CHEMICAL CHARACTERISATION OF PHENAZINES
2.18.1. Analysis by I.R. spectroscopy
Phenazine samples were mixed with desiccated potassium bromide (KBr) with a mortar 
and pestle. Part of this homogenous powder was transferred to a disc press. After 5 mins at 10 
tons pressure, the resultant glass disc was carefully removed and placed in the slot of a Nicolet
I.R. spectrometer which had been appropriately blanked. Spectral peaks were identified by 
comparison with reference spectra (Socrates, 1980; Pouchert, 1981; Kin-Vien, 1991).
2.18.2. Analysis by N.M.R. spectroscopy
N.M.R. analysis was performed on a Brucker 400 MHz N.M.R. spectrometer by Dr. 
Paraic James and Mr. Michael Burke in the Chemistry Dept, of D.C.U. Samples were dissolved 
deuterated chloroform or DMSO to saturation and transferred to glass N.M.R. tubes (Wilmad). 
After a sufficient number of scans the resulting spectra were recorded and analysed by 
comparison with reference spectra (Pouchert and Campbell, 1974).
2.18.3. Purification by Silica and alumina chromatography
Kieselgel S Silica (0.032-0.063 mm particle size) and neutral alumina (Brockmann 
Activity 1) columns were prepared by mixing the powders with the mobile phase used for the 
particular chromatographic separation. This slurry was transferred to a 20 cm glass column and 
allowed to drain until the liquid level was just above the gel level. Compounds to be separated 
were dissolved in the mobile phase and slowly applied to the top of the gel using a long glass 
pasteur pipette. Columns were eluted at atmospheric pressure and fractions were collected. 
Initially fractions were analysed by T.L.C. Fractions of interest were pooled and the solvent 
extracted on a rotary evaporator. Selected samples were further analysed by HPLC (section
2.10.) and N.M.R. (section 2.18.2.).
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2.18.4. Analysis by thin layer chromatography (T.L.C.)
Samples to be tested were applied to silica coated aluminium plates in a line 10 mm 
from the end using capillary tubes. The plates were placed in mobile phase to a depth of 5 mm 
(below the sample line). The solvent was allowed to migrate to 4/5 of the length of the plate 
where they were removed and allowed to dry. Phenazines were visualised by eye and the 
retention factor (Rf) was measured.
2.19. PRODUCTION OF CYCLODEXTRIN-CLOFAZIMINE COMPLEXES
Clofazimine-cyclodextrin complexes were prepared by Ms. Bemie Brady in the 
Chemistry Dept, of University College Dublin. 5.5 g of clofazimine was dissolved in sufficient 
acetone to allow mixing with an aqueous solution of cyclodextrin, 89.67 g of P-cyclodextrin or
90.00 g of hydroxypropyl-p-cyclodextrin (Aldrich). The mixtures were stirred for 48 hrs. with 
acetone being removed by vacuum. The mixture was then freeze-dried and powdered.
2.19.1. Intravenous (I.V.) administration of clofazimine-cyclodextrin complex
The central ear artery of a New Zealand White rabbit was cannulated and a 3 ml control 
blood sample taken. The I.V. dose was prepared by adding 1 g of hydroxypropyl-P-cyclodextrin 
complex to 10 ml of 0.9 % (w/v) saline and mixing. The animal was given a bolus I.V. dose 
into the ear vein of 5 ml of the solution, which was filtered with a 0.22 pm filter fitted between 
the syringe and the infusion needle. A 1 ml sample of the filtered solution was also removed 
for measurement of the clofazimine content by HPLC. 3 ml blood samples were taken 
immediately and after time periods of 5, 15 and 30 mins, and 1, 2, 4, and 8 hours. Two further 
samples were taken at 24 and 48 hrs after the dose. These samples were then analysed for the 
presence of clofazimine using the extraction and HPLC method (section 2.9.4. and 2.10.).
A 15 ml bolus dose of saturated clofazimine-hydroxypropyl-P-cyclodextrin was 
administered I.V. to the same rabbit to test if the complex was being sequestered within tissues 
in the body. The animal was sacrificed and tissue samples were taken for analysis by the 
extraction and HPLC method (section 2.9.1. and 2.10.).
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C H A P T E R  3
CHEMICAL STUDIES ON RIMINO-PHENAZINES
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3.1. INTRODUCTION
This chapter is concerned with investigations undertaken to study the purity, some of the 
chemical properties and the development of an accurate and precise method for the quantification 
of phenazine agents used in this project. A new liquid extraction method and an improved 
HPLC measurement procedure were developed and validated for these compounds. The HPLC 
method, coupled with TLC, IR and NMR spectroscopy, was also used to investigate the purity 
of selected phenazines.
3.2. NEED FOR SUBSTITUTED PHENAZINES AND METHODS FOR THEIR
ANALYSIS
The anti-leprosy agent, clofazimine, was produced as a result of a directed structure- 
activity investigation to produce a more active anti-mycobacterial agent from a non-substituted 
phenazine (B283). B283 was the first phenazine to show signs of anti-mycobacterial activity, 
as outlined in section 1.2. of the introduction. Initially only a limited number of substituted 
phenazines were tested as part of the development programme. Clofazimine (B663) was the 
most effective anti-tubercular (in vitro) and anti-leprosy (in vitro and in vivo) agent of this 
chemical series (Barry, 1957) and became an established drug for the treatment of leprosy. 
Although efficacious and generally clinically safe (Vischer, 1969; Stenger, 1970; Hastings, 
1976; Bulakh, 1983; Peters, 1983), use of clofazimine has a number of shortcomings (Hastings, 
1976; Moore, 1983) (see section 1.5.5. in introduction), which can be generalised as failings in 
activity and pharmacokinetics. To try and overcome these problems, many phenazines with 
various different substituents have been synthesised by Dr. Sean O’Sullivan in the Chemistry 
Dept, of University College Dublin (O’Sullivan et al., 1988, 1990 and 1992). Examination of 
the properties of the various substituted derivatives synthesised has produced the outline for an 
approximate structure activity relationship. The activity of these agents in vitro has been 
established elsewhere (Franzblau and O’Sullivan, 1988; O’Sullivan et al., 1988 and 1992; Byrne 
et al., 1989; Franzblau, 1989; Savage and O’Sullivan, 1989; Zeis et al., 1990), but measuring 
these agents in biological samples for pharmacokinetic evaluation has been problematic due to 
endogenous interfering compounds and the physico-chemical properties of phenazines.
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3.3. EXISTING PHENAZINE EXTRACTION METHODS
3.3.1. Extraction difficulties
To allow accurate quantification by methods such HPLC or spectroscopy, one must 
isolate phenazines from the interfering substances present in the body. Extraction of phenazines 
poses particular difficulties due to their inherent physicochemical characteristics.
3.3.2. Properties relevant to extraction
The phenazine ring is inherently hydrophobic due to its aromatic carbon backbone. 
The various substituent groups present also contribute to the strong organic solubility of all these 
agents. These include groups such as the phenyl, anilino, or chlorphenyl and chloroanilino 
groups, present on all the agents produced in this programme, and also many of the various 
carbon chain rimino- substituents. For example, clofazimine, is a very hydrophobic molecule 
with a calculated log P value of approximately 7.48(octan-l-ol/water) (Morrison and Marley, 
1976). As a result, rimino-phenazines without any hydrophilic substituents have extremely low 
aqueous solubilites. The presence of ionisable atoms especially nitrogen in all of the rimino- 
phenazines introduces the added complication of the net charge on the phenazine molecule being 
dependent on the pH of the environment. These nitrogen atoms are generally alkaline. A pKa 
value of 8.35 +/- 0.09 has been reported for clofazimine (Morrison and Marley, 1976), although 
the exact value is a matter of controversy since the compound’s aqueous insolubility makes 
calculation difficult. Hence, in neutral pH environments, rimino-phenazines are both strongly 
hydrophobic and polarised. As the pH decreases the nitrogens in the phenazine heterocycle can 
become ionised increasing the aqueous solubility until, in strong acid solutions, all phenazines 
become fully soluble. In compounds such as B3955, B3954 and B3976 the aqueous insolubility 
at neutral pH is partly overcome by rimino- substitution with water soluble amino acids which 
greatly increase net water solubility of the whole molecule.
As a result of the polarised hydrophobic properties of rimino-phenazines at physiological 
pH, these agents are found tightly bound to lipids and proteins or in many cases, crystallised 
within cells. Therefore, any extraction system must be able to remove rimino-phenazines from 
these pockets into free solution. Treatment with strong acid will solubilise all phenazines, but 
is not applicable to the whole range of compounds due to the acid lability of certain derivatives 
in light (Barry et al., 1960). Consequently, acid solubilisation is not suitable as a general 
method for extracting phenazines.
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3.3.3. Existing liquid extraction methods
Most of the phenazines developed initially were not significantly acid labile and hence 
acidic and organic solvents could be used to extract these agents. Barry et al., (1960) extracted 
rimino-phenazines from biological matrices using benzene. Although tissue samples were 
homogenised to allow complete equilibration with benzene, 25 % acetic acid was also needed 
to quantitatively extract these agents from proteins present. The benzene layer was removed and 
phenazines re-extracted, using 10 M hydrochloric acid, for spectrophotometric quantification. 
This method was modified by others (Byrne et al., 1989; O’Sullivan et al., 1990) who used 
chloroform (as the organic solvent) and 50 % phosphoric acid. Extraction via this method 
suffers from a number of drawbacks including the need for large volumes of a toxic chemical, 
benzene or chloroform, in the extraction, co-extraction of interfering contaminants, suspected to 
be porphyrins, variability in the final drug estimates, time consumption, due to the need for 
several transfers of extraction liquor, and variability due to the light-sensitivity of certain of the 
tested phenazines in acidic solution (Barry, 1960). The neutralisation of acetic acid in the 
mother homogenate liquor with 40 % (w/v) sodium hydroxide was also necessary for the more 
basic phenazines due their insolubility in benzene - acetic acid mixes. In addition, this method 
is also only suitable for later quantification by spectroscopy, since the drug is dissolved in strong 
acid, and hence restricts the limit of quantification.
Other liquid-based extraction methods have been developed for extraction of clofazimine 
from plasma. Gidoh and Tsutumi, (1981) redissolved clofazimine from evaporates of serum 
using ammonium sulfate and a mix of chloroform/DMF. Peters et al., (1982) extracted 
clofazimine from plasma by mixing it with phosphate-citrate buffer, pH 6.0, and chloroform - 
methanol (4:1, v/v). The clofazimine present was further extracted by removing the organic 
layer, evaporating it under nitrogen, and extracting the resulting solution by mixing in 0.0425 
M phosphoric acid in 81 % (v/v) methanol and hexane. Hence the clofazimine extracted into 
the methanol - phosphoric acid. Dill et al., (1970) developed a method which could extract 
clofazimine from plasma and tissue homogenate. The sample was mixed with a degradative 
enzyme, "maxatase" (Pfizer) in 2 % (w/v) borax and incubated for 30 mins. This was extracted 
with n-heptane followed by extraction of the heptane with 1 M citric acid for quantification by 
further treatment to produce a fluorescent derivative.
45
3.3.4. Solid phase extraction
Liquid extraction of hydrophobic compounds involves using large volumes of organic 
solvents. However, new extraction systems have been developed which have a solid organic 
phase, which reduces this problem. A method of extracting clofazimine from plasma samples 
into such a solid phase was developed by Krishnan and Abraham, (1992). For the first time this 
allowed the inclusion of an internal standard (I.S.) for more accurate and precise analysis. The 
cyano solid phase extraction (SPE) columns used were conditioned by treating sequentially with 
methanol, water, and 0.1 M phosphate buffer, pH 6.0. Plasma samples, diluted in 0.1 M 
phosphate buffer, were applied and allowed to percolate through the columns. After drying and 
addition of I.S., both compounds were eluted with a solution of THF, acetonitrile and methanol 
in the ratios 2:2:1 (v/v/v) containing 2.5 mM hexane sulfonic acid. The eluent was evaporated 
to dryness under a stream of nitrogen gas and reconstituted for HPLC analysis.
3.3.5. Shortcomings of existing methods
All existing extraction methods have a number of drawbacks which limit their use in the 
analysis of phenazines. In short, many methods use large volumes of toxic solvents, are limited 
in the range of rimino-phenazine they can extract, are only suitable for small numbers of samples 
and are not readily automated for routine analysis. The use of large volumes of organic solvents 
also tends to magnify errors in compound measurement.
3.4. METHODS FOR THE QUANTIFICATION OF PHENAZINES
3.4.1. Spectrophotometric quantification
Once extracted, the strong U.V. and visible absorbances of phenazines can be readily 
used to quantify these compounds spectrophotometrically (see Figure 3.1. for a typical spectrum). 
The spectrum of rimino-phenazines is dependent both on the chemical environment (Levy and 
Randall, (1970) especially pH, and the exact type and position of chemical substituents, but, in 
general there is a strong extinction coefficient at about 285 nm with a lesser absorbance around 
490 nm (very variable) giving rise to the visual colouration of these agents. This visible 
absorbance was used by Barry et al., (1960) to quantify phenazines from 5 to 0.2 pg/ml. This 
method was also used by Mansfield et al., (1974) and in practice gave a maximum limit of 
detection of 100 pg/g of tissue.
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Figure 3.1. The spectrum of clofazimine (p) in the HPLC mobile phase. The HPLC 
conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % 
(v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml /min. 
The spectrum was taken using a PDA detector. Absorbance maxima are seen at 290 and 
492 nm with an absorbance ratio of 1.97 between the UV and visible peak.
Wavelength (nm)
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3.4.2. Fluorescent quantification
Dill et al., (1970) used a fluorometric method to quantify clofazimine with a similar 
limit of detection. This method converted clofazimine to a fluorescent product by adding 3 % 
(w/v) titanous chloride and 6 N sulfuric acid to a citric acid extract of the drug with heating to 
100 °C for 10 mins. The resulting product was extracted with 2-ethyl hexanol and the 
fluorescent emission measured at 366 nm.
3.5. HPLC AND TLC METHODS OF QUANTIFICATION
The extracted solvent generally contains interfering impurities from the biological 
sample. Therefore, measurement systems need to separate these substances from rimino- 
phenazines to give more accurate and sensitive results. To date, this has been accomplished 
using thin layer chromatography (TLC) and high performance liquid chromatography (HPLC).
3.5.1. Principle of reversed-phase HPLC
Normal-phase HPLC consists of a high-pressure pump capable of accurately pumping 
volumes of organic solvent at high pressure. The mobile phase is pumped through an injection 
system which introduces the sample to be analysed into the flow stream without interrupting the 
flow. The sample is then separated over a polar column generally consisting of silica or alumina 
with some form of detector system to quantify the sample components as they elute from the 
column. The mobile phase typically consists of a non-polar organic solvent with polarity and 
solubility modifiers flowing over a stationary phase of a polar matrix, usually silica. The 
separation of the sample components is a result of the different polarities of each component in 
the mixture. However, in reverse phase (RP) HPLC the situation is reversed (hence the name) 
and the stationary phase is hydrophobic, due to chemical derivatisation of the silica typically 
with an 18 carbon hydrophobic chain. The mobile phase is polar and generally water based with 
an organic modifier to fully solvate the stationary phase. Compounds added to the column elute 
on the basis of their net hydrophobicity. Poorly lipophilic, polar compounds elute first due to 
their small affinity for the stationary phase, whereas more hydrophobic agents take longer to 
elute.
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3.5.2. Principle of TLC
Basic TLC methodology involves depositing a small spot of the sample of interest onto 
a plate of glass or aluminium coated with an adsorbent, usually consisting of silica or alumina. 
The spot is placed at a point so that when the plate is placed into a tank of a solvent it is just 
above the solvent level. As the solvent travels up the adsorbent it separates out the various 
components present in the sample which can be visualised, usually visually or under U.V. light, 
as discrete spots. This methodology is quick, simple and cheap as a guide to purity or the 
progress of a reaction, and can give useful information for column chromatography or HPLC.
Compounds separate as they travel with the solvent front on the basis of their polarity 
and their relative affinity for the solvent or adsorbent. Adsorbents are generally polar (although 
non-polar adsorbents exist) and silica is most commonly used. If a compound is not particularly 
polar it will be moved up the silica by a relatively non-polar solvent such as hexane due to a low 
affinity for the adsorbent. More polar substances will tend to remain at the point of application 
and will need a more polar solvent such as methanol to overcome the charge attraction and move 
up the plate with the solvent front. A mixture of solvents is normally employed which optimally 
separate the spots of interest from each other.
3.5.3.HPLC and TLC based methods for quantitation of clofazimine
Lanyi and Dubois, (1982) developed a sensitive TLC method with quantitation of serum 
clofazimine by densitometry. Serum clofazimine was extracted into toluene and applied to 
HPTLC silica gel 60 plates predeveloped in 1:1 chloroform - methanol. The plates were 
developed with a 50:50:4 toluene - acetic acid - water mix. Densitometric scanning with 
absorption at 545 nm allowed quantitation down to a limit of 5 ng/ml.
Three other methods based on HPLC have also been reported for the analysis of serum 
or plasma levels of clofazimine, all based on reversed-phase C18 columns. Peters et al., (1982) 
used an ultrasphere-octyl column at 40 °C with a mobile phase of 0.0425 M phosphoric acid in 
81 % methanol, pH 2.4, flowing at 1.5 ml/min, to analyse plasma clofazimine extracted into the 
same solvent mix as the mobile phase. Clofazimine was quantified by integration of the peak 
area produced by monitoring the column eluent at 285 nm. Gidoh and Tsutsumi, (1981) 
developed another HPLC method for quantitation of serum clofazimine levels as part of an 
investigation to measure serum levels of all anti-leprosy agents and their metabolites. They used 
two different methods with a pBondapak C18 column at ambient temperature and monitoring at
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287 nm to measure clofazimine levels. The first method used a 40:60 mix of THF - 0.5 % (V/v) 
acetic acid flowing at 1.5 ml/min. The authors also modified this mobile phase to a mix of 
50:50 THF - water containing PIC B-5 (pentane sulfonic acid in acetic acid), the exact levels 
of reagents being a commercial secret. Using the second system they reported a practical 
minimum measurable quantity of clofazimine of approximately 5 ng/ml. The final and most 
recently reported HPLC method was developed by Krishnan and Abraham, (1992). These 
workers measured plasma clofazimine levels extracted using SPE columns into a solvent mix of 
2:2:1 THF - acetonitrile -methanol containing, 0.7 mM hexane sulfonic acid. The samples were 
analysed on a pBondapak C18 column at room temperature monitoring at 280 nm, with a mobile 
phase 8:11:1 THF - 0.5 % (v/v) acetic acid - methanol containing 2.5 mM hexane sulfonic acid. 
This method had a reported limit of detection of 3 ng/ml and, as mentioned in section 3.3.4., for 
the first time included an internal standard for more accurate and precise measurement.
3.6. LIMITATIONS OF ESTABLISHED QUANTITATION METHODS
With the exception of the method employed by Barry et a l„ (1960), all of the methods 
mentioned in the preceding sections have been developed for the analysis of clofazimine, and 
their use in biological measurements of other phenazines, was never investigated. Sensitivity 
has been increased by 10 to 20 fold compared to the original quantitation methods, allowing the 
measurement of typical blood levels of clofazimine, but the extraction and measurement methods 
are laborious and relatively time consuming, with limiting sample volumes and throughput. All 
of the methods outlined involve the use of volatile organic solvents, and with the exception of 
the method of Krishnan and Abraham, (1992) do not employ an internal standard. Therefore, 
they are prone to the inaccuracies inherent in the use of such solvents. In short, investigation 
of biological levels of several phenazines necessitated the development of a new measurement 
system.
3.7. INTRODUCTION TO CHEMICAL STUDIES ON RIMINO-PHENAZINES.
All the rimino-phenazines investigated were synthesised by Dr. Sean O’Sullivan in the 
Chemistry Dept, of U.C.D. When synthesised these agents were purified by recrystallisation and 
analysed by elemental analysis to confirm the correct ratio of atoms, indicating a largely pure 
substance. When many of these agents were analysed by TLC, at the outset of this project, a 
major spot was noted in all cases, but minor spots with different retention factor (rf) values were 
also evident. To quantify and further investigate the purity of these compounds samples were
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analysed by HPLC. Column chromatography of B4100 was used to investigate if further 
purification was possible by this method. TLC, HPLC and proton NMR spectroscopy were used 
to investigate this process. To further confirm the basic chemical structure and since many of 
these agents were new, IR scans were also taken.
3.9. HPLC AND TLC ANALYSIS OF PURITY
The principles of these two methods have been described in sections 3.5.1 and 3.5.2. 
TLC gives a lot of qualitative information on the purity of test compounds. Impurity, and 
conversely, purity, is indicated by the number of spots and their relative intensity. This gives 
a good visual estimate of purity but quantification is difficult due to variation in the absorption 
spectrum between the different components present. The variety of spot sizes present on a plate 
also prevents accurate quantification, even when scanned with a densitometer, since this scans 
at one wavelength along a narrow lane. HPLC can also be used to investigate the purity of a 
compound. The number of peaks present in a chromatogram give a good indication of purity. 
Using a photo-diode detector allows the complete spectrum of the impurities present to be 
investigated. If these impurities have similar absorption spectra, then the purity can be measured 
by integration of the chromatographic peaks at the maximum absorption wavelength. Careful 
investigation of the spectra can also provide information as to the likely structure of any 
contaminant present.
If these methods provide evidence of the presence of impurities, these will normally have 
to be removed, since the pharmacological assessment of a drug will be hampered if other agents 
are present. Many different methods are available for compound purification but one of the 
more common is column chromatography.
3.10. PRINCIPLE OF COLUMN CHROMATOGRAPHY
Column chromatography involves the separation of compounds as they are carried 
through a glass column filled with a solvated polar adsorbent (generally silica or alumina) by 
an organic solvent mix, and is the forerunner of HPLC. The compounds emerge with the 
solvent and are collected as separate fractions. Generally these fractions are initially checked 
for purity by TLC and compounds of interest are separated from the solvent on a rotary 
evaporator. The principle of compound separation is the same as that for TLC separation. Since 
there is a much larger volume of silica to travel through and equilibration between solvated 
compound and adsorbent is complete, a more polar solvent mix is necessary to develop the
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plates in  a reasonable tim e .
The purity information from HPLC and TLC is all based on the UV-visible absorbance 
of compounds and is, therefore, limited. To completely verify the purity and chemical structure 
of a drug necessitates the use of NMR and IR spectroscopy. These methods provide analysis 
on the basis of the atoms present in a molecule and thus describe the chemical structure present 
as well as indicating if any contaminating organic molecules are present.
3.11.1. Principle of proton NMR analysis
Nuclear magnetic resonance (NMR) is a sensitive technique for the measurement and 
identification of atoms with a magnetic moment, particularly hydrogen (H1) and carbon (C13). 
In chemical analysis proton NMR is routinely used for the identification of chemical compounds 
and can also indicate the presence of impurities. Samples are generally dissolved in a deuterated 
organic solvent, i.e. one in which all the hydrogen atoms present have been exchanged for non­
magnetic deuterium (H2), since the presence of H1 in the solvent generally swamps the 
compound absorbances. The samples are placed in a narrow glass tube and spun in a very 
strong varying magnetic field which causes alignment of the magnetic atomic nuclei present 
(protons in hydrogen since neutrons are absent from the hydrogen nucleus). As the field varies 
the molecular motions of the nuclei can resonate and at specific frequencies they absorb energy 
in the radio frequency band due to movement from one magnetic alignment to another. This 
absorption is detected by a sensitive radio frequency detector. The energy absorbed is 
proportional to the mass of protons present and its exact frequency is dependent on the local 
electromagnetic environment of the constituent protons, thereby giving information both on the 
relative concentrations of protons and the nature of atoms in their immediate vicinity.
3.11.2. Principle of IR spectroscopic analysis
The constituent atoms in a molecule are joined together by bonds which generally allow 
the atoms to move relative to each other as opposed to the common perception of atomic bonds 
as fixed and inflexible. In this way these bonds can be visualised as having properties similar 
to a spring allowing movements like stretching, bending and twisting. Each type of movement, 
known as a vibrational mode, has its own frequency of oscillation and distinct frequencies of 
electromagnetic energy in the infra red (IR) region of the spectrum can interact and cause these
3.11. METHODS OF VERIFYING DRUG PURITY
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modes to resonate if the vibration produces an oscillating dipole moment that can interact with 
the electric field of the radiation. This interaction with the vibrational modes causes compounds 
to absorb IR radiation at characteristic frequencies dependent on the available vibrational modes 
of constituent bonds and the electric field associated with other elements of the whole molecule. 
The IR absorbance spectrum, therefore, gives information on the presence of particular chemical 
groups in a compound and can be used as a quick and simple method to confirm chcmical 
structure.
In practice, powdered samples such as drugs, are analysed by IR spectroscopy generally 
in the form of mulls (pastes), or, more readily, as glass discs formed by compressing a ground 
mixture of the compound and KBr powder in a press at several tons of pressure. The disc 
becomes transparent under this pressure and when placed in the light path of the spectrometer 
only absorbances due to the compound present are evident. The frequency of absorbance is 
generally expressed in terms of wavenumbers (cm1) which are the reciprocal of the wavelength 
(1A) and therefore proportional to the frequency.
3.12. CHEMICAL ANALYSES OF PHENAZINES
The methods outlined in the previous sections were all combined in this project to give 
a broad picture of the purity and chemical properties of selected phenazines. The methods 
outlined are those which are used in the initial chemical investigations of a new pharmaceutical 
agent. When compared to the mass of information needed for the acceptance of a drug 
developed in the present age, very little background information is available on clofazimine and, 
especially, the other phenazines. While the extent of their application, as described in the results 
and discussion sections, was limited, this work provides the outline for the further studies which 
would be necessary for the pharmaceutical and pharmacological investigation of new phenazine 
agents.
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RESULTS
3.13.1. Percentage recovery and reproducibility of extraction
Comparison of the chromatographic peak height ratios of extracted standards with those 
of paired unextracted standards in Tables 3.1.-3.3.shows that the recovery of clofazimine was 
100 % across the linear quantification range 50 - 0.01 pg/ml (pg/g) for serum and tissue samples 
and 100 - 0.02 pg/g for fat samples. 100 % recovery was seen with B4090 in the linear range 
50 -0.02 pg/ml (pg/g). Complete recovery for the other phenazines tested was also observed. 
However, this was not investigated with a large scale recovery and reproducibility study on 
every agent.
3.13.2. Difficulties with phenazine extraction
Extraction of phenazines from fat and faecal samples proved particularly difficult. For 
fat extractions this was largely overcome by heating the extract in alcoholic sodium hydroxide. 
This reduced the interference from co-extracting lipids. With faecal extractions a mixture of 
contaminants were found, which could not be selectively removed. The spectrum of this extract 
(Figure 3.2.(i)) indicated that an extracted mixture probably consisted of faecal porphyrins and 
bile salts (Fasman, 1976). As shown in the chromatogram in Figure 3.2.(ii), these compounds 
interfered with the analysis of low faecal phenazine levels by eluting around the same time as 
several of the phenazines. Photo-diode array (PDA) analysis of these peaks also indicated that 
a heterogenous mixture of substances was present (Figure 3.2.(ii).(b)).
3.13.3. Effect of component variations of the mobile phase
Several mobile phase variables were modified to try to optimise the chromatography and 
Figure 3.3. and Table 3.4. show the effect of these alterations on peak parameters. As shown, 
a 40 % (v/v) THF content in the mobile phase gave a compromised optimum between rt and 
peak width, and the acid content was also critical. Increasing the strength of the acetic acid from 
0.5 to 1 % (v/v) also increased the speed of elution without causing damage to the stationary 
support. Increasing the acetic acid content might further reduce the retention time. However, 
the associated drop in pH might also be expected to hydrolyse the silanol-C18 bond.
3.13. HPLC ANALYSIS OF PHENAZINES IN BIOLOGICAL SAMPLES
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Table 3.1.
The percentage recoveries of B663 and B4090 from serum determined across the linear range 
(n=5). Recovery was determined by dividing the peak height ratio of the extracted spiked serum 
samples by the ratio obtained by injecting equivalent amounts of unextracted standards. The 
ratio was determined five times on a single day from samples prepared from the same standards.
DRUG Cone, added 
(pg/ml)
% Recovery
(± SD)
RSD
(%)
B663 0.01 102.8 ± 24.7 24.0
0.02 95.2 ± 6.9 7.2
0.05 87.1 ± 9.4 10.6
0.2 94.4 ± 5.8 6.1
0.5 80.2 ± 8.2 10.3
2 96.3 ± 9.6 9.9
5 101.7 ± 2.8 2.8
20 104.2 ± 4.3 4.1
50 99.1 ± 1.4 1.4
B4090 0.02 95.4 ± 5.9 6.2
0.05 99.1 ± 6.1 6.2
0.2 103.2 ± 7.6 7.4
0.5 100.1 ± 3.2 3.2
2 96.9 ± 6.8 7.0
5 101.7 ± 3.9 3.8
20 102.5 ± 4.4 4.3
50 99. ± 1.3 1.4
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Table 3.2
The percentage recoveries of B663 and B4090 from liver determined across the linear range 
(n=5). Recovery was determined by dividing the peak height ratio of the extracted spiked liver 
samples by the ratio obtained by injecting equivalent amounts of unextracted standards. The 
ratio was determined five times on a single day from samples prepared from the same standards.
DRUG Cone, added 
(jig/ml)
% Recovery
(± SD)
RSD
(%)
B663 0.01 97.6 ± 9.2 9.4
0.02 137.6 ± 28.7 20.8
0.05 103.6 ± 14.0 13.6
0.2 100.8 ± 2.2 2.2
0.5 89.4 ± 12.4 13.9
2 98.4 ± 1.3 1.3
5 99.2 ± 5.4 5.4
20 100.1 ± 3.7 3.7
50 102.2 ± 5.0 4.9
B4090 0.02 95.2 ± 10.3 10.8
0.05 118.6 ± 12.4 10.5
0.2 106.2 ± 7.9 7.4
0.5 98.4 ± 1.3 1.3
2 97.9 ± 2.7 2.7
5 100.7 ± 1.7 1.6
20 99.6 ±4.1 4.1
50 99.2 ± 3.2 3.3
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Table 3.3.
The percentage recoveries of B663 and B4090 from fat determined across the linear range (n=5). 
Recovery was determined by dividing the peak height ratio of the extracted spiked fat samples 
by the ratio obtained by injecting equivalent amounts of unextracted standards. The ratio was 
determined five times on a single day from samples prepared from the same standards.
DRUG Cone, added 
(pg/ml)
% Recovery
(± SD)
RSD
(%)
B663 0 . 0 2 100.3 ± 5.5 5.5
0.05 1 0 1 .8  ± 1 0 .2 1 0 .1
0 . 2 102.0 ± 5.3 5.2
0.5 99.5 ± 9.0 9.0
2 96.8 ± 5.6 5.8
5 99.9 ± 4.0 4.0
2 0 97.2 ± 6.9 7.1
50 95.3 ± 5.17 5.4
1 0 0 1 0 0 . 0  ± 1 .0 1 .0
B4090 0 . 0 2 96.2 ± 10.8 1 1 .2
0.05 90.0 ± 3.2 3.6
0 . 2 93.7 ± 4.9 5.2
0.5 98.5 ± 10.5 10.7
2 99.3 ± 1.5 1.5
5 101.0 ± 9.5 9.4
2 0 98.1 ± 2.9 3.0
50 115.0 ± 15.0 13.0
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Figure 3.2.(i) A spectrum of a DCM extract from blank faecal material. The visible and 
UV absorption indicate that this spcctrum is most likely the result of extraction of a 
mixture of porphorins and bile salts. The chromatogram of this extract is shown in Figure
3.2.(ii).
oo
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Figure 3.2.(ii) (a) The HPLC chromatogram of an extract from blank faeces. The HPLC 
conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % 
(v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml /min. 
The presence of a number of compounds is indicated by the peaks shown. These peaks 
interfer with phenazine peaks resulting in a reduced limit of quantification. The spectra 
of four of these peaks is shown in part (b). These spectra were taken using a PDA 
detector in the HPLC system.
Time (mins.)
59
Figure 3.3. The effect of varying the water content of the HPLC mobile phase on peak 
width, retention time and peak height. The HPLC conditions were a Bondclone Clg 
column, with the amount of concentrated acetic acid at 6  ml/L and the hexane sulfonic 
acid concentration at 2.5 mM, kept constant in the mobile phase. The flow rate was 1.5 
ml/min. The effect of the variation of the mobile phase on peak width is shown in (a), 
retention time, in (b), and, peak height, in (c). A 60 % (v/v) water content (40 % (v/v) 
THF) can be seen to be optimal for all three parameters.
(b)
Retention
time
% W ater in  m ob ile  phase
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Table 3.4.
The effect of mobile phase pH on retention time, peak width and peak height of a standard 
clofazimine peak. The HPLC conditions were a Bondclone C18 column, with a mobile phase of 
40 % (v/v) THF, 60 % (v/v) water and 2.5 mM hexane sulfonic acid, at a flow rate of 1.5 
ml/min, with detection at 285 nm. The pH represents the pH of the aqueous solution, adjusted 
with different concentrations of acetic acid, before addition of THF. Peaks with a retention time 
greater than 30 mins. could not be quantified. Decreasing the pH leads to improved 
chromatographic parameters.
Aqueous pH Retention time 
(mins.)
Peak width 
(mins.)
Peak height 
(abs. units)
2.8 6.14 2 0.124
3.4 18.52 5 0.045
3.9 > 30 - -
5.1 > 30 - -
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Although retention times became more reliable, drifting was still noted in the retention 
time of phenazines over several hours and was variable between batches of mobile phase. 
Ultimately this problem was traced to the evaporation of THF from the mobile phase. Figure
3.4. demonstrates this evaporation by showing the reduction in mass of 1 g of mobile phase in 
an open container over time. By sealing the eluent tubing into the mobile phase reservoir, a 
closed liquid flow circuit was produced where the free reservoir head space was rapidly saturated 
with THF and no further evaporation could take place. A 1.5 ml/min mobile phase flow rate 
was chosen as this gave a fast resolution of all phenazines whilst maintaining a back pressure 
(around 2,800 P.S.I.) within tolerances for maximum column lifetime.
The pBondapak Clg column was also changed for a Bondclone Clg produced by 
Phenomenex which gave almost identical chromatography.
This system proved to be successful because all the synthetic phenazines dissolved in 
high concentration in the mobile phase, each phenazine gave a well resolved peak clear from 
contaminant peaks and eluted rapidly from the column, giving a rapid analysis. Figures 3.5.(i) - 
(iii) shows typical chromatograms for the phenazines analysed. The retention times of these 
compounds are shown in Table 3.5. The individuality of retention times also meant that 
mixtures of phenazines could be chromatographed. This allowed phenazines to be used as 
internal standards for one another, increasing the accuracy and precision of the analysis. Figure
3.6. shows chromatograms of 5 pg of clofazimine with I.S., extracted from serum, liver and fat. 
These chromatograms show that the I.S. produces a separate and distinct peak for all samples.
3.13.4. Limits of detection and quantification
Samples containing 10 ng/ml produced peaks readily resolved from the background noise 
of the U.V. detector giving reproducible results for quantification and this value was taken as 
the limit of quantification for the analyses. The peaks produced by concentrations down to 5 
ng/ml were also resolved from baseline noise. However, the underlying noise produced a peak 
height variability which made accurate quantification difficult. Injection of samples from 
standards containing 70 pg/ml or more in 60 pi produced peaks which were poorly resolved due 
to broader peak width and peak tailing. This form of peak abberation is consistent with column 
saturation. The peak broadening and tailing causes the analyte peak to no longer be proportional 
to its concentration. As a result, standards of 50 pg/ml were taken as the maximum limit of 
quantification, implying column saturation above approximately 9 pg of phenazine on the
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Figure 3.4. The mass of a 1 ml sample of HPLC mobile phase in an open vessel, at room 
temperature, over 30 mins. This sample consists of 40 % (v/v) THF, 60 % (v/v) of 1 % 
(v/v) acetic acid and 2.5 mM hexane sulfonic acid. The mass steadily decreases over time 
due to evaporation of the THF component.
0 10 20 30
Tim e (m ins.)
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Figure 3.5.(i). HPLC chromatograms of the rimino-phenazines investigated in this project. 
The HPLC conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) 
THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 
ml/min, with absorbance monitored at 285 nm. The spectra are of: (a) clofazimine (p), (b) 
clofazimine (s), (c) B749 and (d) B4154. The retention time of each compound is shown 
in table 3.5.
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Figure 3.5.(ii). HPLC chromatograms of the rimino-phenazines investigated in this 
project. The HPLC conditions were a Bondclone C18 column, with a mobile phase of 40 
% (v/v) THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, 
flowing at 1.5 ml/min, with absorbance monitored at 285 nm. The spectra are of: (a) 
B3640, (b) B3954, (c) B3955 and (d) B3976. The retention time of each compound is 
shown in table 3.5.
(a) (b) :
(c) (d)
V a .  „t.
Time (mins.)
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Figure 3.5.(iii). HPLC chromatograms of the rimino-phenazines investigated in this 
project. The HPLC conditions were a Bondclone C18 column, with a mobile phase of 40 
% (v/v) THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, 
flowing at 1.5 ml/min, with absorbance monitored at 285 nm. The spectra are of: (a) 
B 4090, (b) B4100 and (c) B4103. The retention time of each compound is shown in 
table 3.5.
(a) (b)
(c)
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Table 3.5.
The chromatographic retention time of the rimino-phenazine compounds analysed. The HPLC 
conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % (v/v) 
of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml/min, with 
absorbance monitored at 285 nm. The chromatograms of each compound are shown in Figure
3.5.(i). - (iii).
Compound Retention time 
(mins.)
Compound Retention time 
(mins.)
clofazimine 5.6 B3955 2 . 6
B749 3.4 B3976 3.2
B4154 4.1 B4090 4.4
B3640 2.7 B4100 3.9
B3954 9.0 B4103 3.7
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Figure 3.6. Representative HPLC chromatograms of clofazimine and internal standard
(I.S.) extracted from; (a) serum, (b) liver and (c) fat samples. The HPLC conditions were 
a Bondclone Clg column, with a mobile phase of 40 % (v/v) THF, 60 % (v/v) of 1 % (v/v) 
acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml/min, with absorbance 
monitored at 285 nm. In each case the I.S. gives a sharp peak well resolved from the 
analyte peak.
(a) (b)
*
(c)
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column. The high levels of clofazimine found in fat were often in excess of this concentration. 
This problem was overcome by reconstituting samples and standards in 120 pi of THF - acetic 
acid, thereby diluting the amount loaded on to the column. This dilution increases the maximum 
measurable concentration but doubles the limit of quantification to 2 0  ng/ml.
The compound B4090 had a higher limit of quantification of 20 ng/ml due to a reduced 
extinction coefficient. As Figure 3.7. shows the spectrum of this agent is very similar in shape 
to that of other phenazines, however comparison with the spectrum of an equal concentration 
of B4100 which is the most similar rimino-phenazine shows the reduced absorption across the 
whole spectrum. Besides additional chlorination on the phenyl and anilino rings, the only 
difference between these compounds is that B4090 is chlorinated in the 7-position. It would, 
therefore, seem likely that this chlorine atom significantly affects the electron flow in the 
phenazine backbone responsible for its U.V.-visible absorption spectrum. Comparison of the 
spectra and spectral derivatives of B3954, B3955 and B3976 with that of the parent B3640 
showed that although the retention times of these agents were different, the spectra were exactly 
identical. This indicates that substitutions distant from the phenazine ring had no effect on its 
spectrum (see Figure 3.8.).
3.13.5. Accuracy and precision of the HPLC method
To determine the intra-day accuracy and precision of the combined extraction and HPLC 
quantification method, blank liver, serum and fat samples were spiked with clofazimine standards 
using an I.S. of 2 pg of B4100, or B4090 standards using an I.S. of 2 pg of B663 (clofazimine). 
Five sets of standards were prepared using the same stock concentrations. These standards were 
analysed with a set of calibration standards overnight in a single chromatographic run. The 
concentrations of the standards were determined from the log plot of PHR to concentration of 
the calibration set. Tables 3.6. - 3.8. show the mean, standard deviation and % relative standard 
deviation (RSD) of these spiked standards for both compounds in the serum, liver and fat during 
the intra-day analysis.
The inter-day accuracy and precision of this method were also determined for B4090 and 
B663 in the same samples. A set of spiked standards were prepared daily on 5 different days 
from freshly prepared stock concentrations and the drug concentrations determined from the log 
plot of PHR vs. concentration of a calibration set. Tables 3.9. - 3.11. shows the inter-day mean, 
standard deviation and % RSD of the spiked standard values for these analyses.
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Figure 3.7. An overlaid comparison of the spectra of 20 ug/ml B4090 and B4100 under 
HPLC conditions. These conditions were a Bondclone C18 column, with a mobile phase 
of 40 % (v/v) THF, 60 % (v/v) of 1 % (v/v) acelic acid and 2.5 mM hexane sulfonic acid, 
flowing at 1.5 ml/min, with PDA detection. The spectrum of B4090 is enlarged on the 
absorbance axis since it has a lower extinction coefficient than B4100. The comparison 
shows that the spectrum of B4090 is slightly different from that of B4100. This is due to 
chlorination of the phenazine ring in B4090.
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Figure 3.8. An overlaid comparison of the spectra of 20 ug/ml B3654, B3955, B3976 
with the parent compound B3640 under HPLC conditions. These conditions were a 
Bondclone C18 column, with a mobile phase of 40 % v/v THF, 60 % v/v of 1 % (v/v) 
acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml/min, with PDA detection. 
Although the compounds have individual chromatographic retention times, the spectra are 
identical with the same nodal points when derivatised and a correlation coefficient of 
0.998. This indicates that substituents distant from the phenazine ring have no effect on 
the phenazine spectrum.
Wavelength (nm)
71
Table 3.6.
Intra-day precision and accuracy for spiked serum samples extracted across the linear range 
(n=5). Precision and accuracy were determined by spiking blank serum samples with B663 and 
2pg of B4100 as IS, or B4090 with 2pg of B663 as IS as appropriate. The concentration was 
determined five times on a single day from samples prepared from the same standards and 
quantified by log vs. log plots of peak height ratio (PHR) vs. concentration prepared from a 
calibration set.
DRUG Cone, added 
(jig/ml)
Mean conc. measured 
(fig/ml ± SD)
RSD of mean
(%)
B663 0 .0 1 0.013 ± 0.003 27.6
0 . 0 2 0 .0 2 1  ± 0 .0 0 1 8 .0
0.05 0.051 ± 0.005 11.3
0 . 2 0 . 2 1  ± 0 .0 1 6 .2
0.5 0.58 ± 0.06 10.3
2 1.9 ± 0.1 5.7
5 4.9 ± 0.1 3.1
2 0 22.0 ± 0.9 4.2
50 49.1 ± 0.7 1.4
B4090 0 . 0 2 0.019 ± 0.003 19.2
0.05 0.051 ± 0.004 9.4
0 . 2 0 . 2 0  ± 0 .0 1 7.7
0.5 0.51 ± 0 .0 1 2.3
2 2 . 0  ± 0 .1 7.0
5 5.0 ± 0.1 3.6
2 0 2 0 . 0  ± 1 .0 5.4
50 50.1 ± 0.3 0.7
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Table 3.7.
Intra-day precision and accuracy for spiked liver samples extracted across the linear range (n=5). 
Precision and accuracy were determined by spiking blank liver samples with B663 and 2pg of 
B4100 as IS, or B4090 with 2pg of B663 as IS as appropriate. The concentration was 
determined five times on a single day from samples prepared from the same standards and 
quantified by log vs. log plots of peak height ratio (PHR) vs. concentration prepared from a 
calibration set.
DRUG Cone, added 
(jig/ml)
Mean conc. measured 
(fig/ml ± SD)
RSD of mean
(%)
B663 0 .0 1 0.009 ± 0.003 34.6
0 . 0 2 0.027 ± 0.005 2 1 . 2
0.05 0.041 ± 0.012 31.2
0 . 2 0 . 2 0  ± 0 .0 1 3.7
0.5 0.47 ± 0.06 13.5
2 1.9 ± 0.1 1.9
5 4.9 ± 0.3 6 .8
2 0 23.0 ± 1.4 6 .1
50 48.2 ± 6.1 1 2 .8
B4090 0 . 0 2 0.019 ± 0.003 16.0
0.05 0.052 ± 0.005 10.3
0 . 2 0 . 2 0  ± 0 .0 1 6.5
0.5 0.49 ± 0.02 4.2
2 1.9 ± 0.1 2 . 2
5 4.9 ± 0.1 1.5
2 0 19.8 ± 0.7 3.5
50 49.4 ± 1.4 2 . 8
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Table 3.8.
Intra-day precision and accuracy for spiked fat samples extracted across the linear range (n=5). 
Precision and accuracy were determined by spiking fat samples with B663 and 2pg of B4100 
as IS, or B4090 with 2pg of B663 as IS as appropriate. The concentration was determined five 
times on a single day from samples prepared from the same standards and quantified by log vs. 
log plots of peak height ratio (PHR) vs. concentration prepared from a calibration set.
DRUG Cone, added 
(Mg/ml)
Mean conc. measured 
(pg/ml ± SD)
RSD of mean
(%)
B663 0 . 0 2 0.017 ± 0.002 13.2
0.05 0.053 ± 0.007 14.7
0 . 2 0.19 ± 0.01 5.8
0.5 0.46 ± 0.04 1 0 .6
2 1.9 ± 0.1 6 . 6
5 4.9 ± 0.2 4.1
2 0 20.0 ± 1.4 7.1
50 50.2 ± 2.8 5.5
1 0 0 99.3 ± 1.0 1 .0
B4090 0 . 0 2 0 . 0 2 0  ± 0 . 0 0 1 9.5
0.05 0.051 ± 0.003 6.5
0 . 2 0 . 2 1  ± 0 .0 1 2 .8
0.5 0.50 ± 0.01 2 . 0
2 1.9 ±0.1 4.1
5 5.0 ± 0.1 2.5
2 0 21.0 ± 0 .7 3.5
50 50.3 ± 1.1 2 . 2
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Table 3.9.
Inter-day precision and accuracy for spiked serum samples extracted across the linear range 
(n=5). Precision and accuracy were determined by spiking blank serum samples with B663 and 
2ug of B4100 as IS, or B4090 with 2pg of B663 as IS as appropriate. The concentration was 
determined five times on five different days from samples prepared from the same standards and 
quantified by log vs. log plots of peak height ratio (PHR) vs. concentration prepared from a 
calibration set.
DRUG Cone, added 
(jig/ml)
Mean cone, measured 
(jig/ml ± SD)
RSD of mean
(%)
B663 0.01 0.0097 ± 0.000 6.3
0.02 0.019 ± 0.006 35.1
0.05 0.054 ± 0.009 17.1
0.2 0.20 ± 0.01 7.7
0.5 0.52 ± 0.01 2.6
2 1.9 ± 0.1 8.4
5 4.7 ± 0.1 3.5
20 20.6 ± 1.1 5.4
50 49.7 ± 0.6 1.3
B4090 0.02 0.021 ± 0.002 11.6
0.05 0.046 ± 0.009 19.7
0.2 0.20 ± 0.01 3.2
0.5 0.49 ± 0.02 5.7
2 2.0 ± 0.1 6.0
5 4.9 ± 0.1 1.5
20 23.0 ± 1.6 7.3
50 48.6 ± 3.4 7.1
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Table 3.10.
Inter-day precision and accuracy for spiked liver samples extracted across the linear range (n=5). 
Precision and accuracy were determined by spiking liver serum samples with B663 and 2pg of 
B4100 as IS, or B4090 with 2pg of B663 as IS as appropriate. The concentration was 
determined five times on five different days from samples prepared from the same standards and 
quantified by log vs. log plots of peak height ratio (PHR) vs. concentration prepared from a 
calibration set.
DRUG Cone, added 
(pg/ml)
Mean cone, measured 
(fjg/ml ± SD)
RSD of mean
(%)
B663 0 .0 1 0.013 ± 0.002 19.4
0 . 0 2 0.019 ± 0.003 15.6
0.05 0.051 ± 0.014 27.4
0 . 2 0.19 ± 0.01 5.3
0.5 0.49 ± 0.01 2 . 8
2 2 . 0  ± 0 .1 4.9
5 5.2 ± 0.1 2.7
2 0 21.5 ± 0.6 2 .8
50 50.3 ± 0.6 1.3
B4090 0 . 0 2 0.018 ± 0.004 2 2 . 0
0.05 0.049 ± 0.001 2.7
0 . 2 0 . 2  ± 0 .0 1 3.4
0.5 0.49 ± 0.01 3.8
2 2 . 0  ± 0 .1 2 .8
5 4.9 ± 0.1 1.7
2 0 19.9 ± 0.7 3.7
50 49.2 ± 1.4 2.9
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Table 3.11.
Inter-day precision and accuracy for spiked fat samples extracted across the linear range (n=5). 
Precision and accuracy were determined by spiking fat samples with B663 and 2jjg of B4100 
as IS, or B4090 with 2jig of B663 as IS as appropriate. The concentration was determined five 
times on five different days from samples prepared from the same standards and quantified by 
log vs. log plots of peak height ratio (PHR) vs. concentration prepared from a calibration set.
DRUG Cone, added 
(pg/ml)
Mean cone, measured 
(pg/ml ± SD)
RSD of mean
(%)
B663 0.02 0.019 ± 0.001 5.8
0.05 0.053 ± 0.004 9.1
0.2 0.20 ± 0.02 10.1
0.5 0.48 ± 0.02 6.0
2 1.9 ± 0.1 9.1
5 4.9 ± 0.3 7.8
20 21.1 ± 3.3 15.9
50 52.5 ± 4.4 8.5
100 98.4 ± 6.1 6.2
B4090 0.02 0.020 ± 0.001 5.0
0.05 0.051 ± 0.005 9.9
0.2 0.20 ± 0.01 6.0
0.5 0.50 ± 0.01 2.0
2 1.9 ± 0.1 5.2
5 5.0 ± 0.1 2.0
20 20.8 ± 0.9 4.6
50 52.5 ± 4.1 7.8
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Although a graph of the PHR vs. concentration gave apparently straight lines with very 
good linear regression (r > 0.995 for all agents) use of the resultant equation with the ratios from 
lowest concentrations produced apparently anomalous results. This was due to the inherent bias 
of linear regression for larger values (i.e. the points with higher concentration-PHR values have 
a greater effect on the linear regression than lower value points). The quantification range was 
very broad (5000 fold difference between smallest and largest concentrations) so results were 
quantified using a plot of the log of PHR to the log of the concentration. By this method all 
points are given approximately equal bias in the linear regression allowing the use of a single 
equation to quantify phenazines across the whole range. Figure 3.9.(i) illustrates the errors 
involved with a conventional plot and Figure 3.9.(ii), how this is overcome using logarithmic 
plots.
3.13.6. Linearity of quantification for all rimino-phenazines
The DCM extraction and HPLC quantification method was also used for the analysis of 
all the other rimino-phenazine compounds tested in animals. Although a large scale investigation 
of inter- and intra-day variability was not undertaken for these compounds, standard log plots 
were prepared for all these agents as shown in Figures 3.10.(i). and 3.10.(ii). In all cases the 
resultant lines had regression coefficients of 0.997 or greater.
3.13.7. Compatibility with other anti-leprosy drugs
To investigate if other anti-leprosy drugs would interfere with this HPLC analysis 
system, dapsone (DDS) and rifampicin, two of the most used anti-leprosy agents, were extracted 
in a tube with clofazimine. All three compounds produced peaks in a PDA chromatogram.
Figure 3.11. shows the chromatogram of an extracted mixture of DDS, rifampicin and 
clofazimine with spectra of each peak included. By comparing the spectra produced with 
reference absorbances (Budavari, 1989; British Pharmacopoeia, 1980) and with analysed standard 
controls, each peak was identified. The first peak at 2.9 mins. is due to dapsone as indicated 
by strong absorbances at 262 and 300 nm. The small peak at 3.43 mins. appears to be a 
derivative of rifampicin due to its very similar spectrum and presence in the chromatogram of 
rifampicin on its own. Rifampicin appears at 4.03 mins. and its presence is confimied by its 
spectrum and since the extinction ratio at 334 to 475 nm, 1.75, is the same as the quoted value 
(Budavari, 1989). Clofazimine appears at 5.49 mins. As shown in this figure, there is no 
interference between the peaks of rifampicin and clofazimine. However, since rifampicin
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Figure 3.9.(i) (a) A plot of the peak height ratio versus drug concentration for
clofazimine. Although all points appear to be very close to the linear regression line, 
enlargment of the region around the points of lowest value (b), shows that the regression 
line is very distant from these points. (See figure 3.9.(ii) for the log plot of this data.)
(a)
Peak height 
ratio
B663 Concentration Qig/ml)
(b )
Peak height 
ratio
B663 Concentration (pg/ml)
79
Figure 3.9.(ii) A log plot of the peak height ratio versus concentration data for 
clofazimine used in figure 3.9.(i). Since the log value is used, the resulting linear 
regression is not biased towards the larger values as was the case in figure 3.9.(i)(b). 
Therefore this regression line can be used across the full concentration range.
Log B663 concentration 
(log units)
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Figure 3.10.(ii) Log plots of PHR vs. drug concentration for; (a) B4100, (b) B4103 and
(c) B4154. The linearity across the whole range is indicated in each case by the proximity
of each regression factor (r) to a value of 1
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Figure 3.11. (a) The HPLC chromatogram of an extracted mixture of dapsone, rifampicin 
and clofazimine. The HPLC conditions were a Bondclone Clg column, with a mobile 
phase of 40 % (v/v) THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic 
acid, flowing at 1.5 ml /min, with PDA detection. The peaks and their retention times are 
shown on the chromatogram. The spectra of the 4 major peaks are also included (b).
(a)
Oo
I
i
(b)
Wavelength (ran)
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appears as a broad peak at 4.03 mins. and has a spectrum quite similar to phenazines (see Figure 
3.12.) under the chromatographic conditions, the IS used in this analysis would be unsuitable.
3.14. RESULTS FROM CHEMICAL ANALYSES OF PHENAZINES
3.14.1. TLC analysis of rimino-phenazines
Initially, compounds were spotted onto silica plates and various mixtures of non-polar 
and polar organic solvents were employed for development. A mix of DCM with methanol (7:1 
v/v) was found to be optimal and Figure 3.13. shows some typical results seen with phenazines 
on silica plates. The rf values for these compounds are shown in Tables 3.12(i) - (iii). The 
silica plate used are coated with a fluorescent dye to aid visualisation. However, no clear 
additional spots were visible under a short- or long-wave U.V. lamp.
Pharmaceutical grade clofazimine (clofazimine (p)), supplied by Ciba Geigy, and purified 
B4100 gave single spots on these plates but all other rimino-phenazines tested gave a major spot 
with several minor spots, indicating the presence of unknown impurities in these compounds. 
Certain compounds can be unstable on silica potentially producing additional spots so samples 
were also spotted onto alumina plates. Alumina is less polar than silica and so a mix of DCM - 
methanol 32:2 (v/v) was found to give good resolution for separation. Figure 3.14. shows 
typical TLC results with alumina plates, with the rf values for the compounds analysed shown 
in Table 3.13. In general similar patterns of resolved spots were seen with silica and alumina 
plates giving no evidence for silica instability of these compounds. Additional alumina spots 
seen with some compounds may reflect differences in the amount of compound spotted onto the 
plates.
3.14.2. Determination of purity by HPLC
TLC gives a lot of qualitative purity information, but these results are generally difficult 
to quantify. The HPLC method developed was employed to give additional quantitative 
information on purity. Analysis of the rimino-phenazines with the PDA detector showed that 
impurities had similar spectra to that of typical phenazines, indicating that these were likely other 
forms of phenazine derivatives produced as side reactions in the original synthesis (see Figure
3.15.). Since all the compounds had a maximal absorbance around 285 nm, the relative 
percentage of each present could be quantified by integrating the absorption area of each peak 
at 285 nm. Figure 3.16. shows a chromatogram of B4100 with the main peak off scale to show
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Figure 3.12. A comparison of the spectra of rifampicin and clofazimine under HPLC 
conditions. The HPLC conditions were a Bondclone Clg column, with a mobile phase of 
40 % (v/v) THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, 
flowing at 1.5 ml /min. The comparison shows how both compounds have absorbances 
in similar regions of the UV and visible spectrum.
Wavelength (nm)
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Figure 3.13. A picture of silica TLC plates used to indicate the presence or absence of 
impurities in the rimino-phenazine compounds. Compounds were spotted onto the baseline 
of a silica TLC plate and developed with a mixture of 12 % (v/v) methanol and 8 8  % (v/v)
DCM. The outlined areas indicate the presence of spots visible when the plate is wet with
solvent.
From left to right each plate shows the following compounds separated.
Plate (i) shows B749, B3832, clofazimine (s), clofazimine (p), and B628.
Plate (ii) shows B4090, B4103, B4154 and B4100.
Plate (iii) shows B3955, B3976, B3954, and B3640.
Plate (iv) shows multiple spots of purified B4100, impure B4100, purified, impure and 
purified B4100 with a solvent of 90 % DCM to better resolve each spot.
Plate (v) shows B3955, B3976, B3954, and B3640 with a solvent of twice the original 
methanol concentration to migrate the baseline spots further.
The rf values of each spot are reported in table 3.12 (i) - (iii).
Plate (i) Plate (ii) Plate (iii)
I
I
Plate (iv) Plate (v)
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Table 3.12.(i).
The rf values of spots resolved under silica TLC. Samples were spotted onto the baseline of a 
silica TLC plate and developed with a solvent mix of 12 % (v/v) methanol and 8 8  % (v/v) 
DCM. Purity is indicated by the presence of a single spot. The actual TLC plates are shown 
in Figure 3.13 (plates i-iii).
Compound Main spot Other spots
B749 0.60 0.23, 0.81, 0.93, 0.95.
B3832 0.80 0.16, 0.54, 0.59, 0.64, 0.90, 0.95.
clofazimine (s) 0.70 0.91, 0.95.
clofazimine (p) 0.70 (only single spot)
B628 0.58 0.91, 0.94.
B4090 0.60 0.55, 0.71, 0.89, 0.93.
B4103 0.57 0.48, 0.64, 0.69, 0.92.
B4154 0.92 0.49, 0.60, 0.77. (
B4100 0.61 0.70, 0.94.
B3955 0.23 0.00, 0.64, 0.84, 0.94, 0.97.
B3976 0.51 0.13, 0.70, 0.97.
B3954 0.81 0.00, 0.16, 0.52, 0.91, 0.97.
B3640 0.16 0.55, 0.93, 0.97.
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Table 3.12.(ii).
The rf values of spots resolved under silica TLC. Samples were spotted onto the baseline of a 
silica TLC plate and developed with a solvent mix of 10 % (v/v) methanol and 90 % (v/v) 
DCM. This mixture was different from that described in Table 3.12.(i). to improve spot 
resolution. Purity is indicated by the presence of a single spot. The actual TLC plates are 
shown in Figure 3.13 (plate (iv)).
Compound Main spot Other spots
B4100 0.43 0.51, 0.94.
Purified B4100 0.43 (only single spot)
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Table 3.12.(iii).
The rf values of spots resolved under silica TLC. Samples were spotted onto the baseline of a 
silica TLC plate and developed with a solvent mix of 24 % (v/v) methanol and 76 % (v/v) 
DCM. This mixture was different to that described in Table 3.12.(i). to improve spot resolution. 
Purity is indicated by the presence of a single spot. The actual TLC plates are shown in Figure 
3.13 (plate (v)).
Compound Main spot Other spots
B3955 0.62 0.66, 0.92, 0.96, 0.97.
B3976 0.79 0.93, 0.97.
B3954 0.58 0.92, 0.96.
B3640 0.58 0.92, 0.96.
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Figure 3.14. A picture of alumina TLC plates used to indicate the presence or absence 
of impurities in the rimino-phenazinc compounds. Compounds were spotted onto ihc 
baseline of an alumina TLC plate and developed with a mixture of 6  % (v/v) methanol and 
94 % (v/v) DCM. The outlined areas indicate the presence of spots visible when the plate 
is wcl with solvent.
From left to right each plate shows ihc following compounds separated.
Plate (i) shows B749, B3832, clofazimine (s), clofazimine (p), and B628.
Plate (ii) shows B3955, B3976, B3954, and B3640.
Plate (iii) shows B4154, B4103, B4100, and B4090.
Plate (iv) shows multiple spots of purified B4100, impure B4100, purified and impure 
B4100.
Plate (v) shows multiple spots of pure, impure, pure and impure clofazimine.
The rr values of each spot arc reported in lablc 3.13.
Plate (i) Plate (ii) Plate (iii)
«9
1
I
| l
• . |
Plate (iv) Plate (v)
•  «
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Table 3.13.
The rf values of spots resolved under alumina TLC. Samples were spotted onto the baseline of 
an alumina TLC plate and developed with a solvent mix of 6  % (v/v) methanol and 94 % (v/v) 
DCM. Purity is indicated by the presence of a single spot. The actual TLC plates are shown 
in Figure 3.14 (plates (i) - (v)).
Compound Main spot Other spots
B749 0.87 0.63, 0.69, 0.92.
B3832 0.28 10.19, 0.63, 0.79, 0.86, 0.91, 0.94.
clofazimine (s) 0.92 0.85, 0.95.
clofazimine (p) 0.92 (only single spot)
B628 0.69 0.87, 0.94, 0.96.
B3955 0.28 0.00, 0.69, 0.87, 0.91.
B3976 0.71 0.93.
B3954 0.93 0.00, 0.21, 0.26, 0.60, 0.85.
B3640 0.28 0.62, 0.85, 0.94.
B4154 0.91 0.10, 0.41, 0.56.
B4103 0.62 0.22, 0.93.
B4100 0.69 0.93.
B4090 0.71 0.93.
B4100 0.56 0.23, 0.80, 0.89.
Purified B4100 0.56 (only single spot)
clofazimine (p) 0.92 (only single spot)
clofazimine (s) 0.92 0.82.
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Figure 3.15. Spectra of the impurity peaks in a B4100 chromatogram. The HPLC 
conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % 
(v/v) of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml /min, 
with PDA detection. This figure illustrates that the impurities have a typical phenazine 
absorption spectrum. (See figure 3.16 for the chromatogram of these compounds and 
B4100).
Wavelength (nm)
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Figure 3.16. The HPLC chromatogram of B4100 with an expanded view of the baseline 
absorbance showing impurity peaks. The HPLC conditions were a Bondclone C!g column, 
with a mobile phase of 40 % (v/v) THF, 60 % (v/v) of 1 % (v/v) acetic acid and 2.5 mM 
hexane sulfonic acid, flowing at 1.5 ml /min, with absorbance monitored at 285 nm. (See 
figure 3.15 for the spectra of each peak.)
Time (mins.)
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the impure peaks. Table 3.14. shows the purity determinations of these compounds derived by 
monitoring absorption at 285 nm. With the exceptions of B4154 (64 % pure) and B749 (46 % 
pure), which are particularly impure, all the compounds used in animal studies were relatively 
pure (greater than 80 %). Comparison of the PDA chromatograms of B3954, B3955, and B3976 
with B3640 indicated that the principal contaminant in these amino acid derivatives was the 
parent compound B3640.
This method was also used to compare extracted and unextracted samples of each agent 
to confirm their stability under the NaOH/DCM extraction procedure. Comparison of the 
chromatograms and spectra for each agent showed no differences for any of the compounds 
indicating their stability in the extraction process, (see Figure 3.17.)
Attempts were made to develop a method of purifying these compounds since absolute 
purity is a prerequisite for most pharmaceutical agents. Purification of rimino-phenazines by 
HPLC was unsuccessful due to the low saturation concentration of the reverse phase column. 
Addition of greater than 10 pg of drug to a semi-preparative column produced peak broadening 
which prevented resolution of the impurities present. It was then decided to develop a 
purification method based on conventional column chromatography.
3.14.3. Column chromatography of B4100 as a model for other rimino-phenazines
B4100 was used to develop a general method for purification since it was already 
relatively pure and represented the substitution class most likely to supersede clofazimine. Initial 
attempts to increase the polarity of the solvent mix on the column to elute pure B4100 were 
unsuccessful due to the limited solubility of B4100 in more polar solvents such as methanol and, 
particularly, ethyl acetate. This problem was overcome by adding 5 ml of 5 M NaOH to a 40:60 
(v/v) mix of methanol and DCM, which reduced the charge on the phenazine and hence, made 
elution faster and easier. The eluted pure compound was removed from the solvent on a rotary 
evaporator. TLC and HPLC analysis indicated that this method purified B4100 (99.5% by 
HPLC) and this was further verified by NMR spectroscopy (see section 3.144.). A 20 cm silica 
column was capable of purifying approximately 600 mg of B4100 at a time.
Purification using an alumina column was also investigated. Initially mixes of 50 to 90 
% (v/v) ethyl acetate in DCM were investigated since alumina is partially soluble in methanol. 
This proved unsuccessful because increasing the solvent polarity with ethyl acetate also reduced 
the solvent’s capacity to dissolve B4100. Addition of 20 ml of methanol to the head of the
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Table 3.14.
A comparison of the purity of the rimino-phenazine compounds used in this investigation as 
assessed by measuring the peak areas of the peaks produced by HPLC analysis. The HPLC 
conditions were a Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % (v/v) 
of 1 % (v/v) acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml/min, with 
absorbance monitored at 285 nm. The peaks were integrated by the HPLC software to give the 
peak area value. Purity varies among the synthesised derivatives from 99.0 % with B3976 to 
46 % with B749.
Rimino-phenazine % Purity
clofazimine (p) 99.8
clofazimine (s) 98.1
B4090 88.9
B4100 93.1
B4103 82.4
B4154 64.1
B3640 97.7
B3954 84.5
B3955 98.4
B3976 99.0
B749 46.0
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Figure 3.17. (a) A comparison of the chromatograms and (b) spectra of an identical 
concentration of extracted and unextracted clofazimine. The HPLC conditions were a 
Bondclone C18 column, with a mobile phase of 40 % (v/v) THF, 60 % (vAO of 1 % (v/v) 
acetic acid and 2.5 mM hexane sulfonic acid, flowing at 1.5 ml /min, with PDA detection. 
The chromatogram and spectrum of the extracted sample have been moved slightly to 
make them visible. The identical nature of spectrum and chromatogram indicate the 
stability of B663 under the extraction process. =
Wavelength (nm)
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alumina column eluted the retained pure B4100 band. The added methanol caused the eluted 
B4100 to be contaminated with dissolved alumina. This was removed by mixing the column 
eluent with a mix of water, NaOH, Methanol and DCM (200:2:200:600 respective volumes) in 
a separating funnel, the purified B4100 extracting into the DCM layer which was removed and 
evaporated. Although capable of purifying B4100, this method was more laborious than using 
a silica column.
3.14.4. NMR spectra of rimino-phenazines
Representative spectra for rimino-phenazines could not be found in the chemical 
literature so pure clofazimine (p) was initially analysed on a 400 MHz spectrometer and the 
spectra interpreted with the help of Dr. Paraic James and by comparison with spectra of 
constituent groups found in the literature (Pochert, 1974). Spectra of B4090 and B4100 were 
interpreted by comparison with the clofazimine spectrum. All spectra were consistent with the 
chemical structures of each agent. Figure 3.18. shows the spectra obtained for B663 (p) and 
B4090. The spectrum of the initial B4100 and silica purified B4100 as shown in Figure 3.19. 
are very similar as might be expected. However, the purified B4100 spectrum was better 
resolved and the small doublet at 2.9 ppm caused by an unidentified impurity was removed.
3.14.5. IR spectra of rimino-phenazines
The spectra of the synthesised clofazimine (s) and pharmaceutical grade clofazimine (p) 
were initially compared with the reference spectrum in the British Pharmacopoeia, (1980). As 
would be expected, the spectrum of clofazimine (p) was exactly identical. The clofazimine 
supplied by Dr. O’Sullivan, clofazimine (s), was also identical except for an additional peak at 
1680 cm'1, further confirming the presence of impurity (probably the C=N bond of the parent 
compound B628). The spectra produced by rimino-phenazine compounds is complex due to the 
number of atoms present and is therefore difficult to assign on an atomic basis. Impurity peaks 
are also difficult to pick out, and may be totally invisible due interferences from the main 
compound, as was the case with B4100 and its purified form. Figures 3.20.(i) - (iv). show the 
spectra of several of the compounds analysed. Certain features are evident in each which are 
consistent with their assigned molecular structures.
A broad band is evident in all spectra centred around 3500 cm'1 due to N-H stretches. 
A stronger band in this region is associated with the piperidine substituted compounds. This
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Figure 3.18. 400 MHz spectra of (a) clofazimine (p), and, (b) B4090. The peak at 0.0 
ppm in the B4090 spectrum is due to a calibrating standard of T.M.S. The peaks from 6 - 
8 ppm are due to aromatic hydrogens on the phenazine and phenolic rings. The peak at 
5.2 ppm is due to the anilino N-H, with a second peak appearing at this chemical shift in 
the B4090 spectrum due to the pyridine N-H. The peaks 3.7 and 2.9 ppm as well as other 
small peaks in the aromatic region are due to impurities. The other peaks from 1 - 3.5 
represent absorbances from methyl and C-H hydrogens present in both compounds.
(b)
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Figure 3.19. A comparison of the 400 MHz spectra of B4100, (a) before, and, (b) after, 
silica purification. Impurities in B4100 are indicated by small baseline peaks especially 
evident at 2.9 ppm and the poor resolution of the peak shapes. These peaks are absent and 
the peaks better resolved in the purified form of B4100.
PPM
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Figure 3.20.(i). IR spectra of, (a) clofazimine (p), and, (b) clofazimine (s), prepared in
KBr discs, in the range 4,500 - 400 cm'1. (See text for identification of the significant
bands).
(b)
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Figure 3.20.(ii). IR spectra of, (a) B4090, and, (b) B4100 prepared in KBr discs, in the
range 4,500 - 400 cm'1. (See text for identification of the significant bands).
(a)
(b)
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Figure 3.20.(iii). IR spectra of, (a) B4154, and, (b) B4103, prepared in KBr discs, in the
range 3,700 - 400 cm'1. (See text for identification of the significant bands).
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Figure 3.20.(iv). IR spectra of, (a) B3954, and, (b) B3955 prepared in KBr discs, in the
range 3,700 - 400 cm'1. (See text for identification o f  the significant bands).
(b)
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band is even more intense in the amino acid substituted compounds due to the absorption of the 
amine stretches present. The NH2 group also causes the strong band around 1550 cm'1 evident 
in the two examples. Small peaks due to aromatic C-H stretches are evident around 3060 cm'1 
in all spectra. CH3 and CH2 vibrations are also evident in the peaks from 2970 - 2870 cm'1. 
Aromatic ring stretches, C=C, cause the most noticeable bands from 1600-1450 cm'1 except in 
the amino acid substituted analogues where the NH2 absorbance and amide carbonyl C=0 
absorbance at 1620 cm"1 cause them to be partially obscured. The distinctive spectrum of B4103 
is due to the CF3 stretch at 1320 cm'1 with C-F stretches causing strong absorbances at 1150 - 
1050 cm'1. A strong band at 1090 cm'1 is seen on all the mono-chlorinated derivatives due to 
the C-Cl stretch whilst the dichloro analogues (B4100 and B4154) have bands at 1030 and 1120 
cm'1. C-H stretches in the phenazine ring give rise to several bands in the region 900-680 cm'1.
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DISCUSSION
The method described extracts any of the tested phenazines into dichloromethane (DCM) 
by mixing with sodium hydroxide. Under strongly alkaline conditions basic compounds such 
as phenazines become less polar, increasing their hydrophobic affinity. Due to the inherent 
polarity of the lone pair of electrons in the nitrogen molecule, many rimino-phenazines are not 
fully soluble in completely non-polar organic solvents , such as hexane, and organic solvents 
with a partial polar character such as chloroform and DCM are ideal organic extractants. DCM 
is particularly useful due to its volatility and low boiling point (40 °C) which make evaporation 
for reconstitution into HPLC solvents particularly easy and rapid.
Tissue samples must be homogenised first to disaggregate the structural components of 
tissue and allow complete equilibration of phenazines between the biological matrix containing 
them. Serum samples only need to be mixed with the extraction mixture since clofazimine exists 
in serum as part of a liquid phase mixed lipid micelle ((i-lipoprotein) (Conalty and Jina, 1971). 
Complete equilibration after mixing is further assured by placing the extraction mixture in a 
sonicating bath, which has the effect of emulsifying the organic phase into the aqueous phase 
promoting rapid equilibration. The two phases are clarified and separated from each other by 
centrifugation, which draws the heavier DCM phase to the bottom of the mixing tube and 
precipitates heavy biological particles as a ring at the aqueous interface. Removing only part 
of the organic phase reduces contamination by the aqueous phase which could cause problems 
for later HPLC analysis.
3.15.1. Fat and faecal extraction
Extraction of phenazines from fat deposits poses difficulties for a simple organic 
extraction since lipids also tend to co-extract with the clofazimine into the organic phase. 
Although these interfering compounds are soluble in the THF used to reconstitute samples for 
HPLC analysis, they have a very high affinity for the stationary phase of the HPLC column. 
They produce interfering peaks and ultimately a net change in the physicochemical-properties 
of the stationary phase, which is difficult to remove. This problem is largely overcome by 
heating the extracted phenazine with alcoholic sodium hydroxide converting the fats present to 
water soluble soaps which are removed by washing the organic phase with water.
3.15. SIMPLE EXTRACTION OF PHENAZINES USING DCM
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Extraction of faecal samples also causes problems due to the presence of interfering 
compounds. After extraction of blank faecal samples, the organic layer has a pale yellow-green 
colour and these compounds produce peaks which co-elute in the time range of many of the 
phenazines with HPLC, reducing their limit of accurate quantification. The colour and spectrum 
of these interfering substances combined with their origin indicates that they are most likely a 
mixture of faecal porphyrins (breakdown products of heme) with bile salts also possibly being 
present. The net effect of these interfering compounds is to reduce the limit of quantification 
of faecal phenazine levels to approximately 100 ng/g of dry faeces. Although this interference 
from compounds in the faeces could not be overcome, phenazines levels above this limit of 
detection could be accurately measured in these samples.
3.15.2. Advantages/disadvantages of the DCM extraction system
Extraction with DCM is superior to previous extraction systems because :- it can be used 
to extract rimino-phenazines stably from all biological samples, its simplicity, allowing large 
volumes of samples to be extracted, its compatibility with a range of downstream analytical 
methods, especially HPLC, and flexibly, allowing extraction of a large variety of rimino- 
phenazines. The most significant drawback of alkaline DCM extraction is the utilisation of a 
chlorinated organic solvent whose use is regulated under the Montreal Agreement on chlorinated 
chemicals and the ozone layer.
3.16. DEVELOPMENT OF HPLC METHOD FOR RIMINO-PHENAZINES
Initially it was decided that a reversed-phase HPLC method would be the most suitable 
for accurately and sensitively measuring the diverse range of rimino-phenazines used in this 
project. Simple spectrophotometric methods are less sensitive, with associated problems due to 
co-extracting impurities. Gas chromatography (GC) is a more sensitive method for compound 
measurement, but, rimino-phenazines have boiling points above 200 °C and often decompose at 
around this temperature making them unsuitable for analysis by GC.
The highly hydrophobic nature of rimino-phenazines gives them a particularly high 
affinity for the RP stationary matrix and at neutral or alkaline pH this affinity is high enough 
to preclude analysis with conventional HPLC solvents due to the time necessary for elution. As 
the pH of the mobile phase decreases, the phenazine molecule becomes more charged reducing 
affinity for the stationary phase. Three organic modifiers are most appropriate for RP HPLC, 
methanol, acetonitrile and THF, in order of increasing organic solvability. Conventional RP
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columns are limited to mobile phases with a pH of greater than 2 units and generally operated 
above a pH of 2.5 due to the acid lability of the silanol-C18 bond. In practice, THF is the most 
suitable organic modifier for rimino-phenazine analysis, because of these practical limitations, 
and the need for a relatively high water content to carry the pH modifier.
3.17. HPLC CONDITIONS FOR ANALYSIS OF RIMINO-PHENAZINES
An optimal HPLC method should give a reproducible sharp peak for the analyte resolved 
from interfering peaks in as short a time as possible. Method development initially began based 
on a 40:60 THF - 0.5 % (v/v) acetic acid mobile phase as described by Gidoh and Tsutsumi, 
(1981) using a pBondapak C18 column. This system gave broad peaks for clofazimine with very 
long and variable retention times and was, therefore, unsuitable for analysis.
Although the stationary phase in an RP column is generally regarded as being wholly 
hydrophobic, the synthetic methods used to derivatise and render the silica hydrophobic with 
long carbon chains never fully derivatise all the free silanol groups. As a result, a certain 
portion of the column possesses free silanol groups and the column is said to be incompletely 
end-capped. Under acidic conditions, the free silanol groups become negatively charged and can 
cause a separate form of interaction with suitable polar molecular species. Chromatography of 
hydrophobic compounds displaying basic characteristic can be problematic because these 
compounds become positively charged in acidic pH and are attracted both to the hydrophobic 
and free silanol groups. Therefore the interaction of the basic hydrophobic compound becomes 
dependent on equilibrium with the hydrophobic and charged species. The net result is poorly 
resolved chromatographic peaks with variable retention time. This phenomena was thought to 
be one of the contributing factors to the initially poor chromatography of rimino-phenazines.
One solution to this problem is to include a hydrophobic ion-pairing reagent in the 
mobile phase. 1-Hexane sulfonic acid was chosen as ion-pairing agent since the 6 carbon chain 
gives it a strongly hydrophobic character giving strong affinity for hydrophobic compounds, 
whilst the sulfonic acid moiety is sufficiently charged in any RP HPLC mobile phase to be 
useful. Hexane sulfonic acid also has no significant absorbance at 285 nm and so does not 
interfere with phenazine measurement at this wavelength. It is thought that negatively charged 
sulfonic acid groups can charge couple with the positive groups induced in the phenazine 
compound by the pH of its environment. The hydrophobic part of the molecule is attracted both 
to the hydrophobic phenazine and the hydrophobic stationary phase. Whether the hexane 
sulfonic acid initially adsorbs onto the stationary phase producing an adsorbed ion-exchange
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stationary phase, or ion pairs to the charged analyte in the mobile phase which then interacts as 
a neutral species is uncertain (Bidlingmeyer, 1992), but the net result is that interaction with the 
free silanol groups is prevented. Addition of 2.5 mM hexane sulfonic acid markedly reduced 
the peak width and reduced retention time (rj), but the rt still remained variable over the course 
of several sample injections.
As outlined in section 3.13.3., the continuing variance in rt was ultimately traced to the 
evaporation of THF from the open mobile phase reservoir. Due its volatility, THF was 
constantly evaporating and thus reducing the hydrophobicity of the mobile phase over tíme. This 
problem was overcome by sealing the column eluent into the mobile phase reservoir bottle. 
Once the headspace in the bottle was saturated with THF, the constitution, and therefore, the 
properties, of the mobile phase remained constant, eliminitating the variability in rt.
Using the modem computer controlled HPLC system with autosampler produced by 
Beckman also meant that once calibrated, the machine could automatically analyse and measure 
up to 96 samples. By using a photo-diode array (PDA) detector instead of a single wavelength 
U.V. detector, this system could also be used to visualise the elution spectra of the rimino- 
phenazines.
3.17.1. Internal standards in the HPLC analysis of phenazines
The retention time of each phenazine is individual due to differences in the side chain. 
The combination of the extraction and HPLC methods allowed the complete extraction of 
phenazines over a broad concentration range and the use of certain phenazines as internal 
standards (I.S.) for the analysis of other members of the group.
The use of an I.S. is important in the quantification of these agents because the volatile 
nature of the organic extractants used can cause variability due variable evaporation between 
samples and difficulties with accurate measurement of the small volumes of solvents used. 
Expression of the chromatographic results as the peak height ratio (PHR) of analyte to I.S. 
controls for these extraction and sampling errors. Any inaccuracy will affect both phenazines 
present by the same factor, with the overall ratio of one to the other remaining constant for a 
given concentration.
108
3.17.2. M ethods o f im proving HPLC lim its o f  quantification
The dilution factor associated with sampling 1.1 ml from the 2 ml of extracting DCM 
and loading 20 pi from the 60 pi reconstituted means that only 18.3 % of the phenazine present 
is being used for measurement. This was used for convenience and to allow complete 
automation of the HPLC analysis process. However, if greater sensitivity were required, removal 
of almost all the extraction DCM together with injection of all the reconstituted sample could 
bring the limit of quantification down to approximately 2 ng/ml. The sensitivity could be further 
improved by using larger sample volumes.
3.17.3. Accuracy and precision of the HPLC method
The low % RSD for inter- and intra- day analysis show the power of this method for 
measuring a broad range of rimino-phenazine concentrations. In combination with the full 
recovery of phenazines from a variety of biological samples, this method is the most suitable yet 
developed for a complete analysis of different synthetic phenazines in a variety of matrices.
3.17.4. Suitability of HPLC analysis with other anti-leprosy drugs
The results outlined in section 3.13.7. indicate that neither dapsone nor rifampicin 
interfere directly with the HPLC analysis of clofazimine. Unfortunately, the retention time of 
rifampicin could interfere with the B4100 I.S. that was used in project for clofazimine analysis, 
since it possesses a strong UV absorbance and has a similar retention time. However, this 
problem could be overcome by using the agent B3954 as an I.S. because it has a longer retention 
time than these three compounds. The method could be readily used for the analysis of 
clofazimine levels in subjects, receiving concurrent anti-leprosy therapies, with this modification.
3.18. CHEMICAL ANALYSIS OF PHENAZINES
Analysis of the phenazines used in this programme by TLC and HPLC indicated that all 
the phenazines tested, except the Ciba-Geigy sample, contained impurities. TLC gave a quick 
visual estimate of the proportional level of impurity present. The similarity of absorbance 
among the impurities meant that HPLC could be used to quantify the purity of each compound. 
These results indicate that trials of some of these phenazines would necessitate the purification 
of the agents, since impurities could potentially produce side effect or reduce the efficacy of the 
drug.
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HPLC is not suitable as a method for this purification due to column saturation even at 
proportionately low concentrations. This is probably due to the type of interaction between the 
phenazines and the stationary phase of the column. However, these compounds could be 
purified using silica chromatography. A silica column is capable of purifying much larger 
amounts of phenazine. Although alumina chromatography was also capable of purifying B4100, 
this method was more laborious than using a silica column. The purification of these 
compounds could be assessed by TLC, HPLC and NMR. Besides verifying the success of the 
purification methods, NMR is useful in confirming the chemical structure of phenazine 
compounds. IR spectroscopy is also useful in confirming the chemical structure of the 
compounds tested, especially because it is a quick and simple technique, but is unsuitable in this 
case for investigation of purity.
3.19. SUMMARY
A simple liquid-liquid extraction system was developed which could quantitatively and 
stably extract all the rimino-phenazines tested from a variety of biological matrices. Coupled 
to this extraction system, a sensitive, accurate and precise reversed phase HPLC method was 
developed and validated for the analysis of these agents. The purity of these agents was also 
investigated using a number of chemical techniques, and a procedure developed for purifying 
these compounds.
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CHAPTER 4
PRODUCTIO N AND CHARACTERISATIO N OF ANTISERA  
TO RIM INO-PHENAZINES
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4.1. INTRODUCTION
This chapter describes the production of polyclonal antisera to rimino-phenazines. This 
antiserum was produced in rabbits, using drug-protein conjugates, and used to develop antibody 
based assays. The production and characterisation of the conjugates and the resultant antisera 
are described.
4.2. ANTIBODY PRODUCTION
4.2.1. Properties of antibodies
Antibodies are large molecular weight proteins produced by the plasma cells of the 
immune system and their principal function is the recognition and targeting of immune effector 
responses, to control perceived threats to the organism. Five major groups of antibody, IgA, 
IgD, IgE, IgG and IgM, have been described in most mammals (including man), each with 
slightly different characteristics and function. IgG immunoglobulin is widely distributed 
throughout the whole body and is normally the main class of antibody of interest in immune- 
based assays. As shown in Figure 4.1, it consists of two heavy and two light globular 
polypeptide chains linked together by disulfide bonds. Although in reality the resultant three 
dimensional structure is complex, it is commonly simplified to the Y-shaped structure shown in 
this figure. The heavy and light chains have respective molecular weights of 50 KDa and 25 
KDa. The heavy chains are linked to each other by inter-chain disulfide bonds in the hinge 
region, and covalently bound to the each light chain by a single disulfide bond. Functionally 
two major element are evident, the recognition site [F(ab)] present on both arms, and, the 
effector binding [Fc] region (Roitt, 1980; Tijssen, 1985; Seabrook and Atkinson, 1991). These 
parts of the basic antibody structure are illustrated in Figure 4.1
The primary function of the IgG molecule is the recognition of foreign substances 
(antigens) present in the body and the targeting of cellular and physiochemical arms of the 
immune system to attempt to destroy these compounds. Substances recognised as foreign 
include the external components of microorganisms visible to the immune system, foreign 
secretions of these organisms and biomolecules adulterated by (bio-)chemical action. The 
specificity of recognition of IgG molecules is produced on each arm by the interaction of 
variable regions in the heavy and light chain. The combination of the two variable regions with 
each other produces a distinctive three dimensional antigen binding domain (idiotype). The
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Figure 4.1. A diagrammatic representation of the principle structural elements in an IgG 
molecule. Each molecular unit consists of two identical heavy and light polypeptide chains 
linked together by disulfide bonds. The F(ab) portion comprises a light chain and the 
complimentary part of the heavy chain, and contains the antigen binding domain. The F(c) 
region constitutes the remaining parts of the two heavy chains, and is responsible for 
binding other effector elements of the immune system.
Fab
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idiotype is capable of specific and high affinity binding to selective antigenic elements 
(determinants), also known as epitopes, by a combination of an adaptive flexible 3-D structure 
corresponding to the antigenic determinant and possession of regions capable of complementary 
non-covalent bonding to that epitope. The idiotype of a given antibody molecule is fixed but 
tremendous variability is possible among all of the antibodies produced by different cells due 
to hypcrvariabile recombination of the genetic sequences responsible for the amino acid 
sequences in the idiotype of the heavy and light chain (Seabrook and Atkinson, 1991). This 
variability in recognition allows a high degree of selectivity in binding and is capable of 
differentiating between individual atoms in a particular compound (Landsteiner, 1947) up to 
different macromolecular structures of the same biomolecule. In antibodies, nature has provided 
an extremely precise and accurate method of selectively recognising particular agents, and we 
can manipulate this selectivity for the identification and measurement of substances of interest.
4.2.2. Use of antibodies for selective measurement
The selectivity of an antibody makes it potentially very useful for the identification and 
measurement of small amounts of biological agents. However, two difficulties must first be 
overcome to allow antibodies to be useful in an assay. Firstly, there is a need to produce an 
antibody against the substance in question of sufficient selectivity and in suitable volume for the 
requirements of the assay programme. Secondly, a sensitive format for measuring the specific 
interaction of the antibody with the analyte of interest must also be developed.
4.23. General antibody production methods
Three main options are available for the production of antibodies. These are polyclonal 
antibody production in animals, monoclonal antibody production in cultured cells and production 
of antibodies by recombinant genetic methods in eukaryotic and prokaryotic cells. The 
subsequent paragraphs will focus mainly on polyclonal methods, since these are most relevant 
to the work contained in this chapter.
4 .2 .3 a .P o ly c lo n a l a n tib o d y  p ro d u c tio n
When exposed to a perceived threat from a foreign substance two main avenues of attack 
are available to the body. If the substance has a low molecular weight, the body will generally 
try to convert and/or remove the substance by a complex series of physiochemical reactions 
which collectively form the metabolic and elimination systems of the body (Hum and Chantler,
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1980). For larger molecular weight compounds, generally above 10 KDa, and cells or viruses, 
the immune system will try to target and destroy the substance or invader with a variety of toxic 
agents and enzymes. Polyclonal antibody production involves turning the immune system 
against the antigen in question.
The antigen must, therefore, be injected into the body of a suitable animal in a 
formulation capable of eliciting an immune response. Antibodies are present in all mammals, 
so potentially any mammal can be used as an antibody producer, but in practice the commonly 
used animals are rabbits, goats, sheep and donkeys. The choice of animal is generally dependent 
on the volume of antibody required and a knowledge of the species antigenicity of the antigen 
(Catty and Raykundalia, 1988).
The antigen of interest is generally injected sub-cutaneously with an adjuvant to boost 
the immune response. For a novel antigen the immune system initially produces IgM and less 
specific antibodies. With repeated immunisation the response becomes primarily IgG and 
specificity and affinity of the antibody increases (Burrin and Newman, 1991). A process of 
selection and stimulation of antibody-producing B cells to multiply (clonal expansion) gradually 
selects the most effective antibody and concentrates on its production with levels of lower 
affinity antibodies declining (Tijssen, 1985). Since only larger molecular weight compounds, 
generally in excess of 10 KDa, are antigenic, the immune system will generally target many 
different epitopes of the antigen and the stereochemical complexity of an individual epitope may 
be such that several different high affinity antibody fits are produced. Therefore, the antiserum 
will contain IgG produced from the clonal expansion of several different cells and is said to be 
polyclonal.
4.2.3b. Monoclonal and recombinant genetic production of antibodies
The polyclonal nature of animal produced sera may be problematic especially where a 
single defined interaction of antibody and antigen are required. This difficulty can be overcome 
by artificially mass producing cells from an original cell producing the required (monoclonal) 
antibody. This is generally accomplished using B cells harvested from an immunised mouse. 
These cells are rendered immortal by fusion with an immortal mouse myeloma cell line and the 
hybrid stably producing the required antibody is selected and continuously grown in culture 
(Kohler and Milstein, 1976). Although this technique is well established, difficulties in 
production are still common and production costs are high (Tijssen, 1985).
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Developments in manipulation of genetic information (DNA and RNA) have allowed the 
identification, selection and expression of the basic DNA sequence responsible for an antibody 
molecule. Incorporation of this information into prokaryotic and eukaryotic cells has allowed 
the engineering and production of antibodies and antibody fragments (Borrebaeck, 1992). This 
revolutionary advance allows many of the traditional problems of antibody production, such as 
species differences, purity and volume, to be overcome allowing developments in antibody-based 
measurement and antibody-based disease treatment (Seabrook and Atkinson, 1991).
4.2.4. Production of antibodies against low molecular weight compounds.
Despite the molecular level of sensitivity demonstrable by the immune system, only 
compounds of higher molecular weight are inherently antigenic and smaller compounds do not 
elicit an immune response on their own. However, this can be overcome by chemically linking 
the agent of interest to a suitable carrier so that the resultant total molecular weight is above the 
antigenic weight threshold. This process is responsible for the drug hypersensitivity reactions 
which can sometimes accompany treatment with drugs, which are either directly reactive, or, are 
rendered reactive, towards larger molecules in the body. Allergy to penicillin is an example of 
such a response. (Tijssen, 1985). Molecules which can be recognised by the immune response, 
but are too small to be antigenic on their own are termed haptens. Generally molecules of 
interest must be chemically linked to the carrier in a defined manner to ensure an adequate 
antibody response.
4.2.4a. Choice of carrier
Although any large molecular weight molecule antigenic to the animal could be 
employed as a carrier for use in immunisations, one of five types of protein are conventionally 
used. This is principally due to cost and reactivity considerations (Tijssen, 1985). Synthetic 
polypeptides such as poly L-lysine have been used since they are cheap and readily reactive, 
although their poor antigenicity limits their application (Erhlanger, 1980). Fibrinogen has also 
been used especially where its high carbohydrate content (3 %) can be advantageous for the 
chemistry of carrier coupling (Findlay, 1987). Foreign albumins such as bovine serum albumin 
(BSA) are available in large quantities, are well characterised and generally produce soluble 
conjugates (Erhlanger, 1980) although cross reactivity among albumins can present problems in 
particular applications. Thyroglobulin is a large molecular weight protein which is particularly 
suitable for immunisation due to its limited solubility, especially after conjugation, which is 
desirable for an immunogenic carrier. The final common carrier protein is keyhole limpet
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When choosing the optimum carrier some factors are particularly important. The cost 
of the carrier should not be prohibitive for the amount of carrier necessary. The selected carrier 
should be inherently foreign to the organism, or the response will be small if any (Campbell, 
1984; Burrin and Newman, 1991); a more insoluble conjugate is preferable, since it will remain 
at the site of immunisation boosting the local response. The carrier should possess suitable 
reactive groups to allow chemical linkage with the molecule of interest.
4.2.4b. Chemical linkage o f hapten to the carrier protein
The chemical linkage of the compound to the carrier is also critical. The constituent 
amino acids of the carrier protein provide many reactive groups in the form of amino and 
carboxyl groups, although the structural arrangement of the whole protein can obscure a 
percentage of these available groups (Tijssen, 1985). Thiol groups present in sulphur-containing 
amino acids can also provide suitable reactive sites although their relative content is limited in 
most proteins.
Generally, the most critical determinant in the choice of conjugation linkage is the 
chemical nature of the molecule . The chemical method of linkage chosen should not affect the 
structure of the molecule or group of interest on the molecule, structurally, chemically or 
sterically. A single reaction site should be available so as not to elicit the production of 
antibodies to different antigens. The result of the chemical reaction should be a stable 
homogenous product and for an optimal response the chemical reaction should orientate the 
molecule with a suitable epitope to the exterior as far removed from the carrier as possible and 
with an optimal density of hapten on the carrier(Landsteiner, 1947; Burrin and Newman, 1991). 
Some chemical manipulation and derivatisation of the hapten molecule may also be necessary 
to introduce a reactive group in a suitable location, or, to protect potentially reactive components. 
Heterobifunctional chemistries, where the reaction can only link a group on the hapten to the 
carrier, produce much more efficient conjugates since hapten-hapten and carrier-carrier bonds 
are minimised.
Prevalent reaction chemistries include :- EDC-NHS coupling of amino to carboxyl 
groups, diisocyanate coupling to amine groups, peroxidation (particularly for sugar groups), diazo
haemocyanin (KLH), a large oxygen transport protein in the keyhole limpet (a mollusc): In
addition to a high antigenicity, KLH possesses inherent adjuvant properties boosting the overall
immune response (Homquist and Lycke 1993; Burrin and Newman, 1991).
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coupling of amines to aromatic groups and aldehyde conversion to a schiff base (Erhlariger, 
1980).
When introduced into an animal the immune system begins to process the injected 
antigen, by digestion by antigen presenting cells which break up the conjugate and express 
distinct epitopes to the immune system as part of a complex with M H C  II proteins. With a 
typical hyperimmunisation schedule, a suitable level (titre) of antibody should be produced after 
approximately 3 months (Burrin and Newman, 1991).
4.2.5. Purification of serum
Once a suitable titre of antibody is generated in an animal, the crude antibody can be 
obtained by collection of the serum. Generally, the antibody is further purified from this serum, 
since the heterogenous nature of serum can cause problems in many assay systems. Many 
different purification schemes have been developed to cope with the different purity 
characteristics necessary for particular applications. A  common initial clean up procedure for 
neat antiserum is to precipitate the Ig G  present by salting-out with ammonium sulfate, leaving 
contaminating proteins such as albumin in the supernatant (Tijssen, 1985). Further purification 
may be necessary since the purified IgG , resulting from non-specific purification methods, such 
as salting-out, will contain a mix of antibodies some directed against irrelevant epitopes. This 
is particularly true for antisera directed against haptens, where the majority of the specific IgG  
produced is directed against epitopes on the carrier. Even when antisera is produced against 
large molecular weight proteins, only approximately 20 %  of the antibody harvested will be 
directed against the protein (Catty, 1988). Isolation of the selective antibody of interest is 
accomplished using an immunosorbent.
4.2.5a. Immunosorbent purification
An immunosorbent is a matrix containing the epitope of interest. Common matrices 
include stable sugar polymers such as agarose, dextrose or cellulose, glass beads, or, highly 
cross-linked acrylamide (Tijssen, 1985; Dean et al., 1985). The choice of matrix is important 
for the separation and is usually a balance, of low antibody binding, optimal flow characteristics, 
physical and chemical stability for the binding and elution conditions, and ease of hapten 
coupling (Hebell, 1992; Dean et al., 1985). These matrices can often be purchased in an 
activated form which will chemically bind to the hapten when it is added. A  stable surface of 
hapten bound to matrix is then produced. When impure immunoglobulin is added to a column
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of the matrix, the anti-hapten antibody binds to the bound hapten and the remaining IgG  is in 
free solution. This free antibody fraction can be eluted by buffer flowing through and specific 
antibody remains bound to the column.
The specific antibody of interest is eluted by changing the buffer conditions to inhibit 
hapten-antibody interaction. Such changes include high salt low pH buffers, such as glycine pH
2.5, or reducing buffers, 6 M  guanidium hydrochloride, for example, which change the tertiary 
protein structure of the antibody and reduce the non-covalent hapten-antibody interaction. These 
conditions are potentially harmful to the antibody and once eluted it must be returned to 
physiological conditions as soon as possible to minimise the damage caused. In spite of the 
harsh conditions used, highest affinity antibodies can often remain bound to the immunosorbent 
and cannot be eluted.
4.2.6. M easurement of antibody-hapten interaction
4.2.6a. ELISA
M any antibody based formats are available to quantify the antibody-hapten interaction. 
One of the most prevalently used is the Enzyme-Linked ImmunoSorbent Assay (EL ISA ), based 
on 96 well plastic plates. M any different arrangements of this format are possible but the 
principle can be illustrated by a description of a direct E L IS A  similar to that which was used 
in the project to verify the presence of anti-phenazine antibodies.
Figure 4.2 shows a diagrammatic representation of this form of E L ISA . The E L IS A  
plate consists o f clear polystyrene plastic which is treated with gamma radiation to increase its 
stickiness towards proteins. In  step 1, the antigen of interest, in this case a hapten linked to a 
protein, sticks to the activated surface. Non-covalent interactions, of the hydrophobic type are 
the main interactions responsible for this adherence (Tijssen, 1985; Parsons, 1981). Loosely 
bound protein is removed by washing, usually with a detergent, and what remains is firmly, 
though not chemically, bound to the plastic surface. In step 2 a solution of B S A  protein is 
added to block the plate, that is, to occupy any of the plastic surface which is free and could 
potentially bind the antibodies added in later steps. The excess protein is removed by a further 
series of detergent washes, leaving a completely blocked surface. In step 3, test rabbit antibody 
is added to the plate and allowed to react with the hapten. I f  the antibody has a high affinity 
for the hapten, it binds to it, and the unbound fraction is removed by washing. In step 4, a 
second antibody is used to detect and quantify the binding of the test rabbit antibody. This
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Figure 4.2. The principle steps in a direct ELISA to demonstrate the production of anti- 
hapten antibodies. The details of each step arc described in the text.
Step 1. Hapten immobilised Step 2. Remaining sites on
through carrier plate blocked with BSA.
Step 3. Test rabbit antibody 
added.
Step 5. HRP present converts 
OPD to coloured product.
Coloured
* W  '  ^  *
Step 4. HRP-labelled 
anti-rabbit antibody added.
A  A.
KEY
Hapten conjugate
BSA molecules
À Rabbit antibody
HRP-labeUod 
anli-rabbit antibody
A
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second antibody consists of an antibody directed against rabbit IgG  which has an enzyme, horse 
radish peroxidase (HRP), chemically linked to it. This labelled antibody binds to the bound test 
rabbit IgG  and any excess is removed by washing. In step 5, a solution of o-phenylenediamine, 
a substrate of HRP, is added to the wells and is converted into a coloured product by the action 
of the enzyme. The amount of colour produced is quantified by a plate reader which measures 
the absorbance of each well at a specified wavelength. The absorbance produced is proportional 
to the amount of H R P  present which is in turn proportional to the amount of rabbit IgG  bound. 
In order to determine suitable levels of antibody to be used, since the E L IS A  plate surface is 
saturable, a number of dilutions of rabbit IgG  are made. A  comparison of the minimum 
dilutions of rabbit IgG  from different sources, or, from the same source on different occasions, 
can then be made by comparing the minimum dilution of these different samples which gives 
a response above background.
The immobilisation of molecules of small molecular weight on to the E L IS A  plate can 
be problematic. The large molecular size of proteins provides many opportunities for non- 
covalent bonding to the plate, resulting in a stable adherence of these substances. Smaller 
haptens do not possess sufficient numbers of binding groups and tend to be easily removed from 
the plastic (Tijssen, 1985). One method to overcome this difficulty is to produce a protein 
conjugate of the hapten. The hapten is then bound to the plate through the protein. This 
conjugate must be prepared with a different protein, to that used for immunisation, and 
preferably with a different chemistry, to prevent cross-reaction of the rabbit antibody fraction 
directed against the immunogen carrier with the carrier used to coat the plate (Briand et al., 
1985).
Recent developments in E L IS A  plate technology have produced surfaces with reactive 
groups which can covalently bind small molecular weight compounds. Such plates include the 
N U N C  Covalink plate with an amino group on the surface of the plastic which can be rendered 
reactive by chemical treatment (Yonezawa et al., 1993; Rasmussen, 1990). The amine binding 
plate produced by Costar has a succinylated plastic surface rendering it directly reactive towards 
amino groups. Such plates make the measurement of small molecular weight compounds easier, 
since there is no need for the production of a second conjugate, and generally increase accuracy, 
precision and sensitivity of the immunoassay (S0nderg&rd-Andersen et al., 1990). Direct 
coupling to the E L IS A  plate has also been shown to advantageous for larger antigens, increasing 
the stability of the attachment with associated increases in sensitivity and reproducibility (Wood 
and Gadow, 1983; Rubin et al., 1980).
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Constant developments are being made in technologies for measuring antigen-antibody 
interactions. A  recendy developed system for quantification of these interactions in real-time 
is the BIAcore, produced by Pharmacia.
4.2.6b. BIAcore " analysis
The BIAcore is a machine which measures the interaction of molecules based on the 
principle of surface plasmon resonance, and is particularly applicable to studies of antigen- 
antibody interaction (Jonsson and Malmqvist, 1992; Fagerstam et al., 1992). The principle of 
the system is illustrated in Figure 4.3. It consists of a glass chip coupled, to an optical interface 
on one side, and small flow channels on the other . The interface is comprised of a prism which 
is coupled to the glass slide. Monochromatic light, incident from the L E D  source, enters one 
side of the prism at an angle less than the critical angle of refraction and is therefore reflected 
back out, to be detected by a series of photodiode detectors. Although the light is totally 
internally reflected, an electromagnetic component of that light, called the evanescent wave, 
penetrates approximately one wavelength into the medium on the flow side of the chip. Coating 
of this side of the chip with a thin gold surface causes a resonant interaction of the 
electromagnetic wave with the electrons of the gold, producing a reflectance minimum in the 
reflected light. This phenomena is termed surface plasmon resonance (SPR). A  view of the 
reflectance intensity versus the incident angle shows a dip in intensity at a characteristic angle, 
as shown in the figure. The angle at which the SP R  dip appears is very sensitive to changes in 
the net refractive index beside the gold surface, which is in turn changed by variation in the 
mass present on this side. A  thin matrix of carboxylated dextran is bonded to the gold film to 
allow the covalent linkage of molecules to the chip. Any changes in the mass present in this 
matrix produce a shift in the dip angle, and it is these changes in angle which are converted to 
response units by a computer coupled to the detector array. The carboxymethyl dextran chains 
provide a convenient matrix for the immobilisation of biomolecules, such as antigens, and the 
non-covalent interaction of antibodies with these increases the net local mass producing a change 
in the signal.
This system is very powerful for the characterisation of biomolecular interactions, 
particularly those o f an antigen-antibody nature, and allows the visualisation of these interactions 
in real time. In this project the system was used merely to indicate the specific binding of a 
purified antibody to a phenazine antigen, but other routine applications which have been 
validated include, kinetics of antibody-antigen interaction, epitope analysis and concentration 
measurement (Fagerstam et al., 1992; Pellequer and Regenmortel 1993).
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Figure 4J. The optical configuration of the BIAcore. Monochromatic light produced by 
the L E D  is refracted in a prism and the reflected light monitored by a detector array. 
Changes in mass on the chip surface cause a shift in the reflection angle due to SPR. In 
4.3 B the change in this angle is evaluated by the computer system to produce a 
sensogram.
A. BIAcore optical configuration
Flow channel
B. BIAcore signal evaluation
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4.3. PRODUCTION OF PHENAZINE CONJUGATES
Phenazine compounds are difficult to conjugate to proteins due to their aqueous 
insolubility and lack of suitable reactive groups. To overcome these problems reactions of 
rimino-phenazines containing amino acid substituted side chains with proteins were investigated. 
The two compounds chosen, B3955 and B3976, contain the amino acids glycine and 
phenylalanine, respectively, substituted into the rimino-piperidine group of B3640 through their 
carboxyl group. This provides a free amino group for reaction with the carrier protein and an 
increase in aqueous solubility.
Initially two conjugates were prepared, by reacting thyroglobulin (T H Y R ) and bovine 
serum albumin (B SA ) with B3976 using glutaraldehyde. This was performed in conjunction 
with Ms. Patricia McCormack, D.C.U.. A  third conjugate of B3955 linked to K L H  by an ED C -  
N H S  reaction was also prepared for immunising the rabbits when anti-phenazine titre started to 
fall. After reaction the conjugates were dialysed to remove unreacted starting compounds and 
it was necessary to characterise these conjugates to verify the success of the reaction.
4.3.1. Phenazine conjugate characterisation
Characterisation of drug-protein conjugates requires determination of the number of drug 
molecules incorporated. With many molecules, such as peptides, this estimation is difficult since 
there are no clear physicochemical differences between the carrier and the bound hapten. The 
visible absorbance of phenazines makes characterisation relatively straightforward since this is 
not present in the carrier or linker molecules. Several methods of characterisation are available 
and those used were sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
TLC , H PLC , P D A -H P L C  and size exclusion chromatography (SEC). It was noted with the 
glutaraldehyde conjugates that they became insoluble after freeze drying. Conjugate 
characterisation was performed on samples after dialysis.
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4.4.1. S D S -P A G E  analysis of conjugates
The gel used did not distinguish any molecular weight difference between the B SA  
conjugates, BSA-glutaraldehyde control, B S A  and a characterised BSA-7-hydroxy-coumarin 
conjugate sample provided by Dr. Denise Egan, D.C.U. Red bands of low molecular weight 
corresponding to phenazine were evident at the bottom of lanes from phenazine conjugates. 
Samples were also prepared in sample buffer without boiling, and electrophoresed, to investigate 
if  the boiling caused this apparent instability. No difference was noted between boiled and un­
boiled samples.
The results from the electrophoresis were therefore ambiguous since they failed to 
indicate any evidence o f conjugation in these conjugates but also were unable to show 
conjugation in a characterised conjugate.
4.4.2. T L C  analysis of conjugates
In a solvent system consisting of 80:20 (v/v) methanol/water, B3976 separated clearly 
from the protein which remained at the origin. With the B S A  and T H Y R  conjugates two red 
spots were visible. One migrated the same distance as the drug alone, while the other remained 
at the origin. The presence of the proteins with this band at the origin was confirmed by 
staining with iodine vapour. With controls o f B S A  and unreacted drug no B3976 spot was seen 
at the origin.
4.4.3. H P L C  analysis of conjugates
Conjugate samples were analysed by H P L C  using a size exclusion column as described 
in section 2.14.3. of the methods chapter. This type of column separates proteins on the basis 
of their molecular weight by a size dependent interaction with pores in the column particles.
Under the conditions used, the peaks produced by B S A  and a control of B S A  treated 
only with glutaraldehyde gave very similar peak shapes with the same retention time of 16
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minutes. Conjugation with B3976 produced a chromatogram with this B S A  peak and an 
additional peak at 14 mins (Figure 4.4.(i)). A s  Figures 4.4.(i) and (ii) show, the shape and 
relative height of the peak at 14 mins. was altered by varying the reaction conditions. The 
shorter retention time of this peak indicates that it was produced by a group of high molecular 
weight reaction products representing various intermolecular crosslinking of BSA . The strong 
absorbance of B3976 at the monitoring wavelength (280 nm) is responsible for the difference 
in the relative peak height of these higher molecular weight products.
B y  monitoring the column eluent with a photodiode array detector, instead of a 
conventional single wavelength detector, the complete spectrum of these peaks can be monitored. 
Figures 4.5.(i) and (ii) show the typical contour plot of the absorbance intensity versus 
wavelength and time for B S A  and T H Y R , respectively, treated with glutaraldehyde showing 
strong U.V. absorbance for each protein. The production of a conjugate for both proteins is 
evident in Figures 4.6.(i) and (ii), by the coelution of B3976 with the protein, indicated by the 
visible absorbance. The shorter retention times of the conjugate contours also indicate that high 
molecular weight products have resulted from the conjugation reactions. An example of the 
photodiode spectrum at discrete times in the chromatogram is shown in Figure 4.7.
4.4.4. SEC analysis of conjugates.
To estimate the average molecular ratios o f drug bound to protein, conjugates were 
analysed by SEC. W ith the gels used, the conjugates are eluted in the void volume of the 
column while unbound phenazine elutes much later. B y  monitoring the absorbance of the eluted 
fractions at 488 nm the mass of bound phenazine was calculated with appropriate standards. The 
protein content of each fraction was measured using the B C A  assay. Table 4.1 shows the 
average molar ratio o f drug bound to protein. A s this table shows, alteration of the 
glutaraldehyde reaction conditions has a significant effect on the ratio of drug bound. A  two 
step reaction produces a higher relative ratio of drug bound than a one step reaction. The effect 
of variations in reaction conditions were not investigated with the K L H  conjugate.
4.5. METHODS TO MONITOR PRODUCTION OF ANTI-PHENAZINE ANTIBODY
The insoluble T H Y R  conjugate was chosen to immunise two rabbits as described in 
section 2.16.1. o f the method section. To monitor the production of antibodies in these animals, 
ELlSA -based  assays were developed. A  form of direct assay was initially developed to measure 
antibody production. The B S A  conjugate became insoluble when freeze dried and, hence, was
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Figure 4.4.(i) The H P L C  chromatograms o f (A ) BSA-glutaraldehyde control and (B)
BSA-B3976 conjugate. The proteins were analysed on a Protein Pak S W  300 column, 
with a mobile phase of 0.1 M  phosphate buffer, pH  7.0, monitoring at 280 nm with a flow 
rate of 0.5 ml/min. The B S A  control, with 0.1 %  (v/v) glutaraldehyde, gives a single peak 
with the same retention time as B S A  alone (16 mins.) The production of a higher 
molecular weight conjugate is indicated in (B ) by a peak at 14 mins.
Time (Mins.)
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Figure 4.4.(ii) H P L C  chromatograms of BSA -B3976 conjugates produced under different
reaction conditions. The proteins were analysed on a Protein Pak S W  300 column, with 
a mobile phase of 0.1 M  phosphate buffer, pH 7.0, monitoring at 280 nm with a flow rate 
of 0.5 ml/min. The chromatogram in (a) shows the conjugate produced by a one step 
reaction using 0.07 %  (v/v) glutaraldehyde, while (b) shows the conjugate resulting from 
a two step reaction. The different reaction conditions produce differences in the height and 
shape of the conjugate peak, indicating a combination of different ratios o f higher 
molecular weight proteins, and, different drug conjugation ratios.
Time (mins.)
128
Figure 4_5.(I) A  photodiode H P L C  chromatogram showing the spectral contour pattern 
of the control BSA-glutaraldehyde reaction. The proteins were analysed on a Protein Pak 
S W  300 column, with a mobile phase of 0.1 M  phosphate buffer, pH 7.0, monitoring from 
250 to 550 nm with a P D A  detector, at a flow rate of 0.5 ml/min. The B S A  protein has 
a strong U.V. absorbance.
!
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Figure 4 J .(ii) A  photodiode H P L C  chromatogram showing the spectral contour pattern 
of the control THYR-glutaraldehyde reaction. The proteins were analysed on a Protein 
Pak S W  300 column, with a mobile phase of 0.1 M  phosphate buffer, pH 7.0, monitoring 
from 250 to 550 nm with a P D A  detector, at a flow rate of 0.5 ml/min. The T H Y R  
protein has a strong U.V. absorbance with a shorter retention time than B S A  due to its 
higher molecular weight.
O
1 0
Time (mins.)
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Figure 4.6.(i) A  photodiode H P L C  chromatogram showing the spectral contour pattern 
of BSA-B3976 conjugate. The proteins were analysed on a Protein Pak SW  300 column, 
with a mobile phase of 0.1 M  phosphate buffer, pH 7.0, monitoring from 250 to 550 nm 
with a P D A  detector, at a flow rate of 0.5 ml/min. The B S A  protein has a strong U.V. 
absorbance, with a broad retention time due to glutaraldehyde-induced polymerisation of 
the protein. The presence o f a visible absorbance (around 500 nm), eluting at the same 
time as the protein, indicates the chemical linkage of B3976 to the protein.
Time (mins.)
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Figure 4.6.(ii) A  photodiode H P L C  chromatogram showing the spectral contour pattern 
of a TH YR-B3976 conjugate. The proteins were analysed on a Protein Pak S W  300 
column, with a mobile phase of 0.1 M  phosphate buffer, pH  7.0, monitoring from 250 to 
550 run with a P D A  detector, at a flow rate of 0.5 ml/min. The T H Y R  protein has a 
strong U.V. absorbance, but a visible absorbance (around 500 nm), indicating the chemical 
linkage of B3976 to the protein, is also present.
s
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Figure 4.7. Photodiode spectra from the H P L C  photodiode chromatogram of the T H Y R -  
B3976 conjugate shown in figure 4.6(ii). The proteins were analysed on a Protein Pak SW  
300 column, with a mobile phase of 0.1 M  phosphate buffer, pH  7.0, monitoring from 250 
to 550 nm with a P D A  detector, at a flow rate of 0.5 ml/min. A  scan at 8 mins. shows 
the baseline spectrum of the mobile phase before elution of the conjugate. A t 9.9 minutes 
the spectrum shows the strong U.V. absorbance of the protein and B3976 present in the 
conjugate. The presence o f both spectra at the same time confirms the covalent linkage 
of B3976 to the protein. A t 12 mins. the absorbance spectrum is less intense, since there 
is less protein present. However, B3976 and protein are still evident.
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Table 4.1. A  comparison of the drug-protein ratios of BSA , T H Y R  and K L H  conjugates. One 
step reactions produced conjugates with a higher drug to protein ratio than two step reactions. 
As evident with the thyroglobulin results, increasing the concentration of glutaraldehyde or 
B3976 in the reaction also increased the drug to protein ratio.
Protein %
Glutaraldehyde
Reaction drug- 
protein ratio
Conjugate drug- 
protein ratio
BSA 0.07 30 15
0.13 30 20
Two step — 10
THYR 0.08 100 74
0.01 100 89
0.01 150 100
Two step — . . . 49
KLH EDC/NHS 733 990
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unsuitable for immobilisation of B3976. This was overcome by coating the E L IS A  plate With 
B S A  and then conjugating B3976, and in later experiments, B3955, to the protein surface using 
glutaraldehyde.
4.5.1. Optimisation of in situ conjugate method
4.5.1 a.Glutaraldehyde concentration
Various aqueous concentrations of glutaraldehyde, from 50 % (v/v) to 0.5 % (v/v), were 
used to immobilise a concentration of 5 mg/ml B3976 to coated BSA . The titre of antibody 
investigated using serum from each rabbit after 3 immunisations. Controls with no BSA , gave 
a background response. This indicated the necessity for B S A  to mediate the binding of B3976. 
Interestingly, controls with no glutaraldehyde gave a greater response than that seen with high 
concentrations of glutaraldehyde indicating some immobilisation of this agent was occurring 
without conjugation. Figure 4.8 shows the response found with these different concentrations 
of glutaraldehyde. Improved sensitivity was also detected with plates where a two step 
immobilisation was employed, as shown in Figure 4.9. The B S A  coated on the plate was 
activated with glutaraldehyde, washed and drug added instead of reacting B3976 with 
glutaraldehyde and B S A  directly. In  the two step assay, a concentration of 0.1 %  (v/v) 
glutaraldehyde was shown to give the highest response. Using the micro B S A  assay, the amount 
of B S A  immobilised by a one step and two step glutaraldehyde procedures was assessed. As 
Table 4.2 shows, both methods immobilised a significantly greater amount of protein to the 
wells, than was bound with no glutaraldehyde. Further assays showed that the optimal 
concentration of glutaraldehyde was 0.1 %  (v/v) in the activation stage and immobilisation with 
glutaraldehyde in 0.1 M  P B S  gave a superior response than glutaraldehyde in water. However, 
a significant antibody response was seen with controls where no drug was immobilised. This 
indicated that a part of the antisera was binding to the glutaraldehyde surface. In addition, 
washing the immobilised drug initially with solutions containing the detergent, Tween 20, was 
necessary for reproducible responses with all assay formats.
4.5.1b. Phenazine concentration
Using the direct two step method, the effect of varying the concentration of B3976 and 
B3955 was investigated. With this assay, immobilisation with a concentration of 0.5 mg/ml of 
B3976 was shown to give the highest response with various antibody dilutions (Figure 4.10). 
However, comparison between responses seen with various dilutions of B3955and B3976 showed
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Figure 4.8. A  plot of the absorbance obtained following antibody binding, as a function 
of glutaraldehyde concentration used in a single step immobilisation of B3976 and 
quantified by direct E L IS A . A  concentration of 0.5 %  (v/v) glutaraldehyde gave the 
highest response of the concentrations used in this experiment.
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Figure 4.9. A  plot o f the absorbance obtained following antibody binding, as a function 
of glutaraldehyde concentration in one step and two step immobilisations of B3976 and 
quantified by direct E L IS A .  The two step assay gave a superior response with a lower 
relative background response compared to the one step format. For the two step assay a 
concentration of 0.1 %  (v/v) gave the highest response of the concentrations used in this 
experiment.
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Table 4.2. A  comparison of the amount of B S A  bound to the wells of an E L IS A  plate after 
washing. Increasing volume of B S A  from 25 to 50 pi doubles the amount of protein present. 
Addition of 0.1 %  (v/v) glutaraldehyde also further increases the amount of B S A  bound.
Sample M ass of B S A  
immobilised 
(ug)
RSD
(% )
50 pi 2 %  (v/v) B S A  in P B S 0.46 17.5
25 pi 2 %  (v/v) B S A  in P B S 0.20 15.7
25 pi 0.1 % (v/v) glutaraldehyde 
+ 25 pi 2 %  (v/v) B S A  in P B S
0.85 10.7
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Figure 4.10. A  plot o f the absorbance obtained following antibody binding, as a function 
of B3976 concentration in a two step immobilisation and quantified by direct E L ISA . A  
concentration of 0.5 mg/ml B3976 gave the highest response of the concentrations used 
in this experiment. Concentrations above this maximum cause a reduction in the response 
seen. The mean values of duplicate results are shown.
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139
that higher absorbances were seen with B3955, with an optimal response in the range 0.2 : 0.5 
mg/ml (Figure 4.11). During experiments to try to block the immobilisation of these phenazines 
by adding dilutions of lysine, it was noticed that certain concentrations of lysine actually 
augmented the response seen with a direct E L ISA . The expected response was that lysine would 
reduce the antibody binding in a concentration dependent manner, by reducing the amount of 
hapten bound through competition. A s Figure 4.12 shows, addition of 25 pi of 0.1 mg/ml lysine 
to 25 ul of the drug concentration was optimal for this response.
4.5.1c. Effect o f pH on direct glutaraldehyde based assays assay
The effect of pH of the coated BSA , anti-phenazine sera and HRP-labelled antibody was 
investigated. A s Table 4.3 shows, there was little difference between the results at different pH. 
However, coating with B S A  at pH 7.4 and both antibodies at pH 7.4 gave the highest overall 
response.
4.5.Id. Competitive assays
A s mentioned in section 4.5.1a., a significant antibody response to glutaraldehyde was 
evident in control wells with glutaraldehyde alone. To ensure that the results seen were a 
measure of specific interaction of antibody and phenazine, competitive E L IS A s  were developed 
against B3976 and B3955. An  inversely proportional response to the drug concentration was 
detected with both B3976 and B3955 at a concentration of 0.5 - 0.002 mg/ml. A s shown in 
Figure 4.13, a log plot indicated each agent gave a linear response from 0.5 - 0.02 mg/ml. 
Various attempts to produce a competitive assay with phenazines in methanol or aqueous 
dilutions of T H F  or D M F  proved to be unsuccessful.
To further verify that the antisera reacted with phenazines, B3955 was coupled to B S A  
on the surface of an E L IS A  plate using ED C /N H S. Using a concentration of 0.1 mg/ml B3955 
in the conjugation procedure, a surface was produced which was successful both as a direct, 
Figure 4.14, and competitive E L ISA , Figure 4.15, although, the response seen was quite small.
4.5.2. Change in  a n tibod y  t it re  over tim e
The E D C /N H S  based conjugation system was used in an assay format, as described in 
the previous section, to follow the specific anti-phenazine titre of antibody as the glutaraldehyde 
immunisations progressed. A s shown with the response of the male rabbit in
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Figure 4.11. A  plot of the absorbance obtained following antibody binding, as a function
of B3955 and B3976 concentrations immobilised by the two step method and quantified 
by direct E L ISA . A  concentration of 0.5 mg/ml was optimal for both agents, but a greater 
response was seen with B3955. The mean values of duplicate results for the two 
phenazines are shown.
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Figure 4.12. A  plot of the absorbance obtained following antibody binding, as a function 
of lysine concentration in competition with 0.5 mg/ml of B3955 and B3976, used in a two 
step immobilisation of each phenazine and quantified by direct E L ISA . A  concentration 
of 100 ug/ml lysine gave the highest response in this experiment, with both agents. The 
mean values of duplicate results for the two phenazines are shown.
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Table 4.3. A  comparison of the antibody responses seen with the coating protein, rabbit anti- 
phenazine antibody, and anti-rabbit antibody at pH 7.4 or 9.6. The amount of variation is small, 
but the largest response is seen with all proteins in a pH 7.4 environment. The mean of 
duplicates results is shown.
Base pH 7.4 9.6
Rabbit Ab. 
pH
7.4 9.6 7.4 9.6
a-rabb it Ab. 
pH
7.4 9.6 7.4 9.6 7.4 9.6 7.4 9.6
Absorbance of 
1/1000 rabbit 
diln. at 492 
nm  (A.U.)
0.312 0.283 0.287 0.285 0.293 0.261 0.268 0.255
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Figure 4.13. A  plot of the absorbance obtained following antibody binding, as a function 
of B3976 and B3955 concentration, used in a competitive E L ISA . A  concentration
dependent response was seen from 0.5 - 0.002 mg/ml with a linear response from 0.5 - 
0.02 mg/ml for both agents. The mean values of duplicate results for the two phenazines 
are shown.
Abs. 
492 nm 
(A.U.)
Log phenazine concentration 
(mg/ml log units)
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Figure 4.14. A plot of the absorbance obtained following antibody binding, as a function
of B3955 concentration used in a single step immobilisation using E D C  and quantified by 
direct E L IS A . A  concentration of 0.1 mg/ml B3955 gave the highest response of the 
concentrations used in this experiment. The mean values of duplicate results are shown.
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Figure 4.16, this response peaked after seven immunisations. The background response in 
glutaraldehyde increased over the same length of time, indicating that the relative response of 
the antisera had increased against glutaraldehyde to the detriment of the anti-phenazine response. 
The rabbits were switched to an immunisation with the K L H  conjugate produced with 
ED C/N H S.
4.5.3. O ther ELISA plate formats
In an effort to improve the response of the antibody in an assay system, and to further 
verify its affinity for phenazine agents, other plate formats were investigated. These were 
formats involving direct coupling o f phenazines to derivatised plate surfaces (Covalink and 
Amine binding) and non-covalent attachment to silica-coated plates.
4.5.3a. Assays using covalink ELISA plate
This plate contains a secondary amine grafted onto the polystyrene surface (Yonezawa 
et al., 1993; Rasmussen, 1990). Coupling of B3976 with the homobifunctional reagent, B S 3, was 
investigated. A s  shown in Figure 4.17, a concentration of 0.02 mg/ml of B3976 was found to 
give the greatest response in a direct assay.
4.5.3b. Assays using silica coated, plate
The wells in this plate are coated with silica which creates a polar surface of large area 
for adsorption of polar molecules, with a very large surface area (Frey et al., 1993). A s shown 
in Figure 4.18, concentrations of B3976 and especially B3955 could be detected in a direct 
format. However, visually the amount of silica immobilised appeared to be very variable 
between wells producing a poor reproducibility. Competitive formats failed to show a 
reproducible response and no concentration dependent response was seen with the other 
organically soluble rimino-phenazines.
4.5.3c.Assays using amine binding plate
These plates have a N-oxysuccinimide surface to immobilise compounds possessing a 
free amine group. Direct immobilisation of various concentrations of B3955 and B3976 showed 
that a higher response was with B3955 (Figure 4.19). Optimal responses were seen across a 
broad immobilisation concentration range from 0.01 - 0.2 mg/ml of these phenazines and
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Figure 4.16. A plot o f the absorbance obtained following antibody binding, as a function 
of the number of immunisations. A 1/2500 dilution of antisera collected from the male 
rabbit after successive glutaraldehyde conjugate immunisations was used in each case. 
These results were performed by a direct ELISA, using an EDC immobilised B3955 
surface. The antibody response was seen to vary with successive immunisations, and peak 
after seven immunisations.
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Figure 4.17. A  plot of the absorbance obtained following antibody binding, as a function 
of B3955 concentration used in immobilisation to a Covalink E L IS A  plate and quantified 
by direct E L IS A .  A  concentration of 0.02 mg/ml B3955 gave the optimal response for this 
format of plate.
Abs.
492 nm
0 .02 .05 .25 .5 1
B3955 concentration 
(mg/ml)
149
Figure 4.18. A  plot of the absorbance obtained following antibody binding, as a function
of B3955 and B3976 concentration used in a direct E L IS A  using silica immobilisation. 
A  concentration of 0.5 mg/ml of each agent produced a maximal response for each agent, 
with the highest response seen with B3955. The mean values of duplicate results for the 
two phenazines arc shown.
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Figure 4.19. A  plot of the absorbance obtained following antibody binding, as a function 
of B3955 and B3976 concentration used in an amine binding plate and quantified by direct 
E L ISA . Optimal responses were seen across a broad concentration range of 0.01 -0.2 
mg/ml for each agent, with B3955 giving a higher level of binding. The mean values of 
duplicate results for the two phenazines are shown.
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151
concentrations in excess of these values had a reduced response for both agents. These plates 
also successfully coupled another amine-containing analogue, B3832. This analogue was made 
soluble in water by making aqueous dilutions from a stock concentration in D M F. However 
plates coated with either B3955 or B3832 by this method gave irreproducible results in a 
competitive format.
4.6. PURIFICATION OF ANTI-PHENAZINE ANTIBODY
After four immunisations with the K L H  conjugate the anti-serum was purified and 
characterised using SE C -H P L C  and BIAcore methods.
4.6.1. Production of a phenazine immunoaffinity column
An Emphase activated support medium was chosen as the matrix for the immunoaffinity 
column. This matrix consists of beads of a methylenebisacrylamide/azlactone copolymer. When 
water is added, the azlactone ring is hydrolysed and rendered reactive to nucleophiles, such as 
amine groups.
Initially attempts were made to couple aqueous B3955 to this support. However, when 
washed with either 1.5 M  lysine or 0.01 M  PBS, pH  7.4, the red colour was seen to elute from 
the column, until very little remained. Further chemical coupling of B3955 to this column was 
attempted using E D C  and, subsequently, glutaraldehyde. In each case the colour remained even 
with PBS, but addition of the elution buffer (0.1 M  glycine pH 2.5) leached the remaining colour 
from the column.
A  more complex immobilisation scheme was developed using the high affinity 
interaction of biotin and avidin. Using the method described in section 2.17.1. an organically 
soluble amine containing rimino-phenazine, B3832, was coupled through a linker molecule to 
biotin. Avidin was stably coupled to the Emphase matrix and the biotin-B3832 conjugate added. 
After elution of the unbound B3832, a stable phenazine immunoaffinity column was produced.
4.6.1a. Coupling of Biotin to B3832
As described in section 2.17.1. of the methods, as excess of B3832 was mixed with 
biotin amidocaproate-N-hydroxysuccinide in an alkaline mix of D M F. A  difference in the rf
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value of the major spot, before and after N H S  reaction, on T L C  plates using different solvent 
mixes suggested that a product had formed in the reaction. However, the difficulty in visualising 
the conversion of the biotin substituent with D.A.C.A. made this result ambiguous. Using H PLC  
a reaction product was seen. A s Figure 4.20 shows, chromatographic analysis indicated that this 
compound was impure, producing 5 peaks. When reacted with the NHS-biotin compound a peak 
was produced at 3.8 mins. A s shown in Figure 4.21, the presence of this peak is associated with 
a decrease in the size of peaks at 4.6 and 5.7 minutes, while the size of the peak at 3.05 mins. 
remains the same in both chromatograms. Integration of the area of all the peaks showed that 
there was an 18 %  decrease in the relative area of the 4.6 and 5.7 min. peaks, with a 20 % 
increase in the peak area from 3.5 to 4.2 minutes. This indicates that the peak at 3.8 mins. 
represents the reaction of the two compounds with retention times of 4.6 and 5.7 mins. Spectral 
investigation of this peak also indicated that this reaction was with a side-chain substituent of 
a phenazine, since the chromatogram of the 3.8 min. peak exactly matched those at 4.6 and 5.7 
mins. Comparison of chromatograms produced by treating B3832, NHS-biotin compound and 
the B3832-biotin conjugate with D A C A , showed a peak at 1.9 mins due to this agent but failed 
to show any other reaction of the product at 3.8 mins.
4.6.1b. Immobilisation of avidin to emphase column
A  B C A  assay of the 15 ml of supernatant from the avidin immobilisation did not show 
any protein present indicating that most of the protein had bound. After addition of the B3832- 
biotin reaction mix the column was washed with D M F, P B S  and glycine pH 2.5 until no more 
colour eluted. The red colour of the column remained throughout the purification of the 
antibody, indicating that no B3832 was leaching from the column.
4.6.2. Purification of antibody
The initial 7 ml of serum had a total protein content of 545 mg. After centrifugation 
through the 100 K D a  molecular weight cut-off membrane, 443 mg of high molecular weight 
protein remained. This was loaded onto the column and eluted with glycine ,pH 2.5. 0.99 mg 
of purified IgG  protein was eluted.
Analysing the eluted enriched fraction by H P L C  showed a single peak with the same 
retention time as a purified rabbit Ig G  sample, 10.6 mins, as shown in Figure 4.22.
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Figure 4JO. The H P L C  chromatogram of B3832. The sample was prepared and analysed 
as described in section 2.10 of the methods. The presence of five major peaks indicates 
that this compound is not pure. Based on the reaction o f this mixture with the biotin-NHS 
ester (figure 4.21), B3832 is most likely the peak at 4.6 or 5.7 minutes.
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Figure 4.21. An overlaid comparison of the H P L C  chromatograms of B3832 before and 
after reaction with the biotin-NHS ester. When reacted with this ester, a new peak at 3.8 
mins. is produced. The area of this peak matches the reduction in the area of the peaks 
at 4.6 and 5.7 mins. suggesting that the compounds represented by these peaks react with 
the biotin ester.
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Figure 4.22. A comparison of the HPLC chromatograms of the purified rabbit anti- 
phenazine antibody and a control purified antibody. The samples were analysed as 
described in section 2.14.3. of the methods. This indicates that both proteins are of the 
same molecular weight.
Control rabbit IgG 
Purified
Time (mins.)
156
The purified antibody could detect concentrations of B3955, B3976 and B3832 front 0.2 
to 0.02 mg/ml immobilised by direct amine binding plate E L IS A  down to a dilution of 1 in
20,000 (Figure 4.23).
4.6.3. Biacore analysis
Initially, using a concentration of B3955 at 1 mg/ml 11,000 response units (RU) of 
B3955 were immobilised to the chip surface. Although this gave a 1500 R U  response for the 
purified antibody, a large response of 330 R U  was also seen with a control of another purified 
rabbit IgG. When the immobilising concentration of B3955 was brought down to 10 jag/ml a 
response of 2000 R U  was seen. A s Figure 4.24 shows, the immobilised B3955 bound 68 R U  
of control antibody, however, most of this was quickly eluted without a wash step. A  
subsequent addition o f purified antibody gave a response of 606 RU, of which, even after 12 
hours of continuous wash, 543 R U  remained. Attempts at eluting this antibody with 0.05 M  H Q  
and 0.1 M  glycine pH 2.5 were unsuccessful and three washes with 20 % (v/v) acetonitrile in 
0.01 M  NaO H  removed 184 R U  of antibody. A s a control, the other purified rabbit antibody 
was also immobilised to a chip surface and anti-phenazine antibody added. A  small non-specific 
response was seen despite the immobilisation of a large mass of this control antibody. This 
indicates the selectivity of the antibody for the phenazine matrix alone.
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Figure 4.23 A  plot of the absorbance obtained following antibody binding, as a function 
of different dilutions o f the purified antibody, for an immobilising concentration of 0.5 
mg/ml B3955, B3976 and B3832 used in a direct amine binding plate E L ISA . The 
maximum dilution of antibody to give a response was 1/20,000 of the stock antibody 
solution.
Abs. 
492 nm
Antibody dilution
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Figure 4.24. The B IAcore sensogram produced by the addition a control and, later, anti- 
phenazine antibody to a sensor chip surface immobilised with B3955 . The immobilisation 
method and analysis conditions are described in section 2.5.3 of the method chapter. The 
initial response was set as baseline. Addition of 20 ul of 0.2 mg/ml of the control 
antibody produced a response of 68 R U  which went down to 15 R U  after only 120 
seconds. Addition of the same amount o f anti-phenazine antibody produced a response 
o f 606 RU. This response remained high even overnight and ultimately could not be 
brought back to baseline.
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DISCUSSION
4.7. P R O D U C T IO N  A N D  C H A R A C T E R IS A T IO N  O F  G L U T A R A L D E H Y D E
C O N J U G A T E S
Ii is a general axiom of immunology that for a compound to be antigenic, it must have 
a molecular weight in excess of 40 KDa. Smaller compounds, such as peptides, may be weakly 
immunogenic down to a molccular weight of 2 K D A , but often produce low affinity antibodies 
(Catty, 1988; Catty and Raykundalia, 1988; Burrin and Newman, 1991; Hum and Chantler, 
1980). Therefore, it was necessary to produce a conjugate of a suitable phenazine with a protein 
before an anti-phenazine antibody could be raised.
The production of a phenazine protein conjugate was made possible by the synthesis of 
rimino-phenazines which are water-soluble with a reactive group which does not interfere with 
the phenazine ring. Compounds such as B3955 and B3976 are piperidyl-substituted rimino- 
phenazines which have been covalently linked to amino acids via their carboxyl groups. In one 
step, this produces a riminophenazine which is water soluble, allowing reaction with proteins. 
These phenazines also possess an amine group which is readily reactive towards proteins via a 
number of well described chemistries.
Thyroglobulin was chosen as a suitable protein carrier for the immunogen because of 
its availability, large size, abundance of reactive groups and limited solubility when conjugated. 
B S A  was chosen as a screening conjugate carrier because of its cheap cost and availability, and 
general high solubility. Initially, a glutaraldehyde-based conjugation was chosen since it is 
routinely used for hapten-carrier linkage and reacts readily with many haptens and proteins.
Test mixes of glutaraldehyde with B3976 and B S A  gave a protein which remained red 
coloured even after dialysis. This suggested that a conjugation reaction could take place using 
glutaraldehyde and aqueous B3976. This was important because the phenylalanine substitution 
in this compound increases its solubility in water, it rapidly precipitates in neutral or alkaline 
aqueous buffers. Alkaline reaction conditions are generally necessary for many of the common 
conjugation conditions.
In solution, glutaraldehyde exists as a mixture of monomer and polymers of various 
lengths which are in a complex equilibrium. At pH  3, low temperature and high concentration 
the monomeric and low number polymer forms predominate. A s the pH and temperature
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increase, and the glutaraldehyde concentration decreases, the equilibrium is driven to longer 
stable polymers until precipitation occurs. Glutaraldehyde reacts with free amino groups, 
especially the £-amino group of lysine (Peters and Richards, 1977; Habeeb and Hiramoto, 1968). 
In the simple one step reaction, glutaraldehyde will therefore produce four main types of reaction 
with a drug-protein mixture. These are an intra-molecular crosslinking of lysine residues within 
the protein, inter-molecular linking of protein molecules to each other, linking of drug molecules 
to each other, and finally, linking drug molecules to the protein. Drug-protein conjugation is the 
desired reaction and therefore, the other reactions are inefficient and wasteful of reagents. In 
our research, this inefficiency was not critical, since enough B3976 was available. However, the 
need to conjugate limited amounts of expensive drugs or peptides can preclude using this 
method. The polymerisation of glutaraldehyde has the added advantage of introducing a linker 
between the drug and carrier which is very advantageous, both for a strong selective immune 
response, and for antibody screening (Exley et al., 1971; Lindner et al., 1972).
Conjugation via a two step reaction was investigated as a more efficient alternative and 
also because it has been shown that these type of conjugates are superior as immunogens (Zegers 
et al., 1990). Dialysis of the protein against glutaraldehyde introduces a reactive surface which 
can bind the free drug, with remaining reactive groups capped with the more reactive free lysine. 
Characterisation of both conjugates by S E C  indicated that the one step reaction bound a higher 
molar ratio of drug than the two step reaction. Although a high ratio of drug to protein is 
desirable for an efficient immunogen, total drug binding of available residues may not be 
optimal. Erhlanger, (1980) and Landsteiner, (1947) have suggested that conjugation of 10 drug 
molecules to B S A  was best. Thyroglobulin and B S A  contain 177 and 55 lysine residues, 
respectively and, of these, approximately 90 and 19 are accessible on the external surface of the 
protein (Schipper et al., 1991). The conjugation ratio results indicate, that the one step method 
can bind drug to all the available lysine residues, and also, to other residues in the protein, 
especially with higher concentrations o f glutaraldehyde and B3976. The two step reaction 
conjugates a smaller ratio of drug molecules indicating that only the available lysine residues are 
reacted.
When freeze dried, the conjugates became insoluble. The production of insoluble 
conjugates with glutaraldehyde is common, especially when it is present in higher relative 
concentrations (Avrameas and Temynck, 1969). This is desirable for immunising conjugates 
since it localises the immunogen, boosting the A P C  response and concentrating other immune 
cells and mediators in the site of injection. However, this insolubility prevented the prepared 
B S A  conjugate being used to screen antibodies in E L IS A . The insolubility was probably due
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to a combination of increased activation of residual free glutaraldehyde, and conversion of longer 
polymers present, to monomers, by the low temperature, and increased concentration as water 
was removed. The insolubility of the B S A  conjugate could have been overcome by not freeze 
drying it; however, it was noticed that some of the conjugate precipitated when stored, and it 
was decided to produce the conjugate in situ with each E L IS A  plate.
High concentrations of glutaraldehyde in the one step immobilisation produced lower 
responses. This may indicate either excess cross-linking of the BSA , reducing the available 
residues for drug conjugation, or, binding of too much drug to the B S A  surface. Other authors 
have also found that a concentration of 0.2 %  (v/v) glutaraldehyde was optimal for conjugation 
reactions (Avrameas and Temynck, 1969; Avrameas, 1969). The importance of an optimal drug 
density in the screening E L IS A  was seen by the increased response seen with the inclusion of 
lysine in the E L IS A  formats.
4.8. G L U T A R A L D E H Y D E  IM M O B IL IS A T IO N  O F  P H E N A Z IN E S  O N  E L IS A
P L A T E S
Assessment of the amount of B S A  bound with different immobilisation reactions showed 
that glutaraldehyde had a significant effect on the immobilisation of the protein. The 
augmentation in binding results from increasing the net molecular mass of BSA , through cross- 
linking, and also through, poorly characterised, covalent linkage of the polyglutaraldehyde with 
the plastic surface (Tijssen, 1985; Stanislawski et al., 1980; Barret, 1977; Dobbins-Place and 
Schroeder, 1982). Although this had a minor effect in the assays described, this is very 
significant for assays involving proteins, especially those of relatively low molecular weight 
(Klasen et al., 1982; Suter, 1982; Wood and Gadow, 1983).
The polymeric nature of glutaraldehyde, and its inherent foreignness, caused problems 
in the antibody production. A ll glutaraldehyde-based E L IS A s  had a high background due to the 
presence of an anti-glutaraldehyde component in the antisera. The development of an anti-linker 
response is common and has been noted by other workers using glutaraldehyde conjugates 
(Briand et al., 1985). Although this response was difficult to quantify, since an anti- 
glutaraldehyde format was not developed, the constant increase in the response to the B SA -  
glutaraldehyde wells, and the reduction in the drug titre over time indicated that the anti- 
glutaraldehyde response was predominating at the expense of the anti-B3976 response. This was 
overcome by switching to another immunising conjugate.
162
4.9. PRODUCTION AND CHARACTERISATION OF EDC/NHS-KLH CONJUGATE
Keyhole limpet haemocyanin (K L H ) is the oxygen transport protein in the keyhole 
limpet mollusc. It is one of the largest known protein molecules, with a molecular weight up 
to nine million Daltons (Bannister, 1981). K L H  has some inherent advantages as an 
immunogen. Its large size provides a very large area and variety of conjugation sites, and makes 
it very antigenic. It is phylogenically very distant from mammalian proteins, again making it 
very antigenic, but also ensuring that it does not crossreact with sera against mammalian proteins 
(Burrin and Newman, 1991). It was decided to use a K L H  conjugate with another amino acid- 
substituted phenazine, B3955, to provide sera which could be purified and characterised. 
Coupling with E D C /N H S  was chosen since this is very different to the glutaraldehyde reaction 
and successful conjugates with other organically soluble drugs had been described in the 
literature (Grothaus et al., 1993).
Characterisation of this E D C  conjugate by S E C  indicated that the approximate molar 
ratio of drug bound was 990. The exact ratio of binding is impossible to calculate because of 
the multi-subunit nature of K LH , but these calculations are based on an average molecular 
weight of 5 M D a  assumed since the molecular weight range quoted by the supplier was 3 - 7.5 
M D a. At first glance this ratio appears very large, but it is of similar proportion to the ratios 
quoted for T H Y R  and B SA . E D C  catalyses the formation of an amide bond between carboxylic 
acids and amines on its own. However, it has been reported that the addition of N H S  improves 
yield by reducing hydrolysis of the O-acylurea intermediate (Staros et al., 1986). The 
heterobifunctionality of this reaction provides a degree of selectivity, since B3955 only possesses 
a free amino group which must couple to a carboxyl group through ED C . This conjugate 
remained partially soluble even when freeze-dried, unlike the glutaraldehyde reaction.
4.10. C H A R A C T E R IS A T IO N  M E T H O D S
4.10.1 Analysis of conjugates by S D S -P A G E
The form of S D S -P A G E  used in this project proved to be unsuitable for the analysis of 
conjugates. The presence of a red band at the bottom of the gel, coupled with the lack of a red 
colouration associated with the protein band, which had the same migration distance as 
unmodified protein, initially suggested that the conjugation had been unsuccessful or unstable. 
Analysis of the conjugate by other methods indicated that a significant portion of B3976 
remained non-covalently attached to the conjugate even after dialysis. The red band was
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therefore due to unbound drug. The lack of red colouration in the protein band was probably 
due to too little being present to see the colouration. The lack of difference in migration time 
was due to the properties of the gel and similar problems have been reported by others (Briand 
et al„ 1985). An electrophoresis method for the analysis of conjugates was subsequently 
published by Kamps-Holtzapple et al., (1993).
4.10.2. Analysis of conjugates by TLC
Proteins, such as B S A  and T H Y R , are not usually analysed by T L C  methods because 
the large number of polar groups they possess prevent them from migrating in T L C  solvents. 
However, in the case of the phenazine conjugates produced, the free phenazine should be mobile 
on the silica plate, while any conjugated agent should remain with the protein. This system is 
therefore suitable as a qualitative method for assessment of conjugation.
The results indicated that a conjugate had been produced and also showed that simple 
spectrophotometric measurements of the dialysed conjugate would be useless for determination 
of the conjugation ratio, since, a large mass of unreacted drug remained bound to the protein
even after dialysis.
4.10.3. Analysis of conjugates by HPLC
The conjugate samples were analysed by H P L C  using a column which separates 
principally on the basis of molecular weight. The eluent was monitored at 280 nm since both 
drug and protein have a strong absorbance at this wavelength. Unfortunately, this precluded 
selective identification of the B3976 bound to protein, but did demonstrate the production of 
higher molecular weight conjugates by the presence of peaks with shorter retention times. 
Monitoring the eluent at 476 nm did not give any additional information. However, using a 
photodiode array detector the absorbance of the eluent could be monitored at all wavelengths 
simultaneously. A s  expected, T H Y R  and B S A  controls, which had been reacted with 
glutaraldehyde, give strong U.V. absorption on their own. However, with the conjugate samples, 
the association of the visible absorbance spectrum of B3976 with the protein absorbance clearly 
indicates direct linkage of the drug to protein. Controls of glutaraldehyde-treated protein are 
important in the P D A  verification of such conjugates since, under certain circumstances, 
glutaraldehyde can produce coloured products when reacted with amino-acids (Peters and 
Richards, 1977). Although knowledge of the extinction coefficient of B3976 would allow the 
measurement o f the amount of drug present at any given time, the strong U.V. absorbance of
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this agent prevents estimation of the mass of associated protein present.
4.10.4. Analysis of conjugates by SEC
Separation of free drug from the conjugates produced by S E C  allowed estimation of the 
amount of drug present. Coupling this measurement with protein determination of the same 
fractions by B.C.A. allowed a direct estimation of the ratio of each present. With KLH, the 
estimation has large associated errors due to variability in molecular weight of the units of 
protein present. A ll the estimations merely represent an average ratio of drug bound to protein, 
since no effort was made to separate the conjugate on the basis of molecular weight. The results 
also clearly show that the larger proteins bind a higher ratio of drug molecules due to the 
presence of more reactive groups per unit molecule.
4.11. CONJUGATE IMMUNISATION
No effort was made to purify the conjugates further since the reactive compounds had 
been inactivated and rimino-phenazines are not inherently toxic (see section 5.22.). A s expected, 
the rabbit had started to produce an antibody after the third immunisation. Interestingly, the titre 
of the antibody neither increased consistently nor remained constant over time suggesting that 
the amount of antibody produced over a given period of time is affected by many variables. 
Possibly important factors include general state of health, of the animal, the presence of 
infections and changes in the sub-class of antibody being produced (Tijssen, 1985). Ultimately 
the anti-glutaraldehyde response was seen to predominate and a phenazine conjugate with K L H  
was used to produce sufficient anti-phenazine sera for purification and characterisation.
4.12. ELISA ASSAYS
4.12.1. Direct assay response
Initially, a direct assay was used to show that both rabbits produced a specific antibody 
response against B3976. However, BSA-glutaraldehyde control wells gave high responses. 
Therefore, it was necessary to investigate and verify antibody production by other methods, since 
the response seen could have been an artifact of glutaraldehyde binding. Modification of the 
method of immobilising B3976 using a two step procedure produced a significantly better 
response with lower relative background absorbances. Measurements of the ratio of drug-protein 
binding in the conjugates, suggests this may be due to the binding of B3976 to the exterior
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surface of the protein matrix, in the two step method, where it is more accessible to antibody 
binding (Zegers et al., 1990).
4.12.2. Competitive assay response
The production of an anti-phenazine antibody was proved using the competitive assay 
and assays not involving glutaraldehyde immobilisation of phenazincs. In the competitive assay, 
the only variable is the amount of free phenazine, and if higher concentrations of free phenazine 
reduce the response seen, then an anti-phenazine antibody must be present. This is further 
supported by eliminating glutaraldehyde completely from the assay and using other methods of 
immobilisation. The establishment of a proportional response, between the amount of 
immobilised phenazine and the resultant amount of antibody binding, confirms the presence of 
an anti-phenazine antibody.
The results of the competitive assay indicate that the antibody produced had a poor 
affinity. The linear range of the assay (0.02 - 0.6 mg/ml) is both broad and insensitive. Higher 
affinity antibodies detect low concentrations of analyte, generally, in a narrow range, due to the 
strong association and low dissociation constants of antibody-analyte interaction.
4.12.3. Variation in antibody affinity for phenazines
B3976 and B3955 differ only in the amino acid substitution present. However, a greater 
antibody response was seen in all the direct assays formats with B3955, even though the 
antibody was raised against a B3976 conjugate. Both agents had a maximal response using 
similar reaction concentrations, which indicates that similar levels of drug are being immobilised 
in each case. The difference must therefore reflect a variation in the affinity of the antibody for 
the two agents. The glycine substituent in B3955 increases its aqueous solubility and, therefore, 
increases access to water soluble substances, including antibodies, when immobilised. Better 
molecular access would give the antibody a superior affinity for B3955, despite the identical 
nature of the epitope for B3955 and B3976.
4.12.4. Effect of spacial factors in response
Comparison of the responses seen with the immobilisation of B3976 and B3955 showed 
that both had an optimal reaction concentration of approximately 0.5 mg/ml. When lower 
concentrations of these phenazines were used, smaller responses were seen, indicating that the
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level of drug immobilised was dependent on the amount available. Concentrations in excess of 
the 0.5 mg/ml value caused a reduction in the response seen. Results from the conjugation 
reactions suggest that excess free phenazine does not inhibit the binding of these agents to the 
protein. Therefore the reduction in response must represent a situation where excess phenazine 
immobilised inhibits the antibody-hapten interaction. Similar results were also noted with direct 
ED C , Covalink and amine-binding plate assays, and have been noted by other authors using 
different antigens on several plate formats (Frey et al„ 1993).
These results might be explained by three non-mutually exclusive possibilities. The first 
possibility is that an optimal spacing of phenazine molecules exists on the immobilised protein 
surface. A  surface where the phenazine molecules are immobilised using concentrations of agent 
above 0.5 mg/ml in the reaction mixture produces a surface where there is little free space 
between each drug molecule. This could sterically hinder complete binding of the antibody 
present which would then be easily eluted in subsequent washing steps (Jefferis and Deverill, 
1991; Stenberg and Nygren, 1988). This suggestion is supported by the increase in antibody 
binding seen when particular concentrations of lysine were included to compete with drug 
binding. This form of steric hinderance has been described for other immobilised haptens 
(Butler, 1980; Rotmans and Scheven 1984; Yonezawa et al., 1993).
Secondly, saturation of the protein surface with phenazine might produce a "sticky" 
surface, where drug molecules stuck to each other and blocking proteins adhered non- 
specifically, preventing access to the antibody molecules. Evidence for this conclusion comes 
from the BIAcore, where excess immobilisation caused a large amount of binding from a control 
antibody. At lower immobilisation concentrations, less anti-phenazine antibody was seen to 
bind, but non-specific binding of the control antibody was almost eliminated. Although amino 
acid substitution renders B3976 and B3955 water soluble, these molecules are still very 
hydrophobic, and, in an aqueous environment, will tend to stick together and to other 
hydrophobic compounds, such as hydrophobic residues in proteins. Coupled with their polar 
characteristics, this makes these agents very sticky towards proteins.
The final possibility is that higher concentrations of free phenazine cause non-covalent 
adherence of these agents to the protein and plastic surfaces present. During the assay, antibody 
binds to this free component, but the washing steps overcome the non-covalent binding of the 
drug, and so the associated antibody is also lost during the washing steps. Evidence suggesting 
this possibility is shown in control wells where B S A  and phenazine, but no glutaraldehyde were 
included. These wells were seen to bind antibody. The need for an initial wash with a Tween
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solution which would remove much of this non-covalently bound fraction also supports this 
possibility. This necessity for a Tween wash in hapten-immobilised plates has been noted by 
other authors (Yonezawa et al., 1993; S0nderg&rd-Andersen et al., 1990).
4.12.5. Responses to other phenazines
The failure to develop a concentration dependent response to the other phenazines in 
either a competitive format or with silica coated plates, is probably due to the aqueous 
insolubility of these compounds. When dissolved in methanol, these organically soluble 
compounds can be immobilised onto a silica surface. However their insolubility prevents 
interaction with the antibody in an aqueous environment. These substances can be introduced 
into an aqueous environment by initial solubilisation in D M F . This creates a D M F  solvent 
sphere around the molecules which is further solvated by water molecules. However, this 
solvent sphere is relatively impenetrable to the, water solvated, antibody molecules, preventing 
antibody binding. Immunoassays have been developed against relatively aqueously insoluble 
compounds such as taxol using up to 20 % (v/v) methanol in antibody solutions (Grothaus et 
al., 1993), but 20 % (v/v) methanol would not solubilise the organically soluble compounds 
investigated in this project. The difficulty in using stronger water soluble organic solvents is 
illustrated for example by the use of 20 %  (v/v) dioxane in immunoaffinity elution buffers, 
where the solvent inhibits the antigen-antibody interaction, causing elution of the antibody from 
the column. The importance of the aqueous solubility o f these compounds is further illustrated 
by the increased antibody affinity towards B3955 instead of B3976, which was discussed above.
4.13. A N T IB O D Y  P U R IF IC A T IO N
Conventionally, initial antibody purification is performed by salting out the antibody 
present using ammonium sulfate. However, this procedure is time consuming and can lead to 
significant losses of antibody. It was decided to investigate a more rapid clean-up approach, 
using ultrafiltration. This process separates the proteins present on the basis of molecular 
weight. Protein greater than the 100 K D a  molecular cut-off are retained inside the membrane 
solvent reservoir. Smaller molecular weight substances and solvent pass through the pores under 
the influence of centrifugal forces. This both concentrates the high molecular weight fraction 
present, and, by washing through with buffer, removes contaminating proteins and small 
molecular weight compounds. Ig G  antibodies have a molecular weight of approximately 160 
K D a  and are therefore concentrated in the process. Unfortunately, other high molecular weight 
substances are also present, particularly lipoproteins. Methods are available to remove these
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substances (Tijssen and Kurstak, 1974; Tijssen, 1985), since they can interfere in certain 
immunoassays, but it was decided to try to immunoaffinity purify the antibody without removing 
these contaminants. Immunoaffinity purification is necessary since the majority of the antibodies 
present are directed against other substances, including the carrier protein.
4.13.1. Use of the Emphase matrix
The Emphase matrix was chosen as a suitable immunoaffinity support for several 
reasons. The polymeric beads of polyacrylamide provide a very rigid support, allowing 
resistance to high pressures and flow rates. This means that large volumes of antibody can be 
purified quickly. This matrix is relatively resistant to harsh aqueous conditions and to organic 
solvents, important since immobilisation ultimately necessitated using organic solvents. The 
matrix is also very hydrophilic, reducing non-specific protein adsorption and helping to maintain 
hydrophobic compounds in solution phase (Hermanson et al., 1992). With the first attempt at 
production the immobilisation probably failed since the coupling could not be carried out in a 
high salt, high pH buffer. Incorporation of a suitable organic solvent might be a feasible 
alternative for this type of immobilisation. However, the failure of this reaction was not evident 
until high salt/low pH  buffers were used, which overcame the non-covalent interactions of B3955 
with the column.
4.13.2. Coupling using avidin/biotin
It was decided to utilise the extremely high affinity of the avidin-biotin reaction to 
immobilise B3955. Avidin is a tetramer of a 15 K D a  sub-unit protein possessing a single high 
affinity binding site for the vitamin, biotin. The affinity of this interaction is so strong that the 
association and dissociation constants are impossible to accurately measure, but dissociation 
constants of approximately 1015 M  have been calculated (Bayer and Wilchek, 1990). The 
binding is also insensitive to changes in pH, salt, addition of chaotrophic agents, or organic 
solvents (Bayer and Wilchek, 1990). This interaction can, therefore, bridge the difficulties of 
interactions in a mixed aqueous-organic system. The biotin caproate is particularly useful in this 
case. Biotin is water soluble and binds to a site inside the avidin molecule (Bayer and Wilchek, 
1990). Addition of a N H S  ester to the molecule renders it reactive towards nucleophiles, 
especially amino groups. The ester and the caproate linker make the whole molecule organically 
soluble, and the linker also overcomes the potential steric problems of the biotin-avidin 
interaction (Tijssen, 1985). The success of biotinylation reactions is generally monitored by 
TLC, but this did not provide a clear picture in this case. However, the polar nature of this
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biotin analogue made the biotin-derivatised phenazine more polar allowing the reaction to be 
monitored by the phenazine H P L C  method. The azlactone group coupled the avidin to the 
matrix and addition of the reaction immobilised the biotinyl-phenazine derivative. Successful 
production of an affinity matrix was indicated by the absence of colour elution even in high salt, 
low pH buffer.
The matrix was blocked with B S A  since the immobilised phenazine could be anticipated 
to have a high non-specific affinity for proteins. The high molecular weight serum fraction was 
added to the column and non-specific proteins were eluted with PBS. The specific antibody 
present was then eluted using glycine, pH  2.5, with 10 % (v/v) dioxane. Glycine and tris buffers 
and the dioxane present with the antibody were removed using the ultrafiltration membranes and 
several washes. Comparison of the H P L C  chromatographic profiles of this antibody with 
another purified antibody, indicated that this method produced IgG  of similar purity. The 
activity of this antibody was demonstrated by direct E L IS A  and BIAcore analysis.
4.14. U S E F U L N E S S  O F  A N T IB O D Y
The failure of the antibody to recognise the organically soluble phenazine, limits its use 
and application, since all therapeutically useful rimino-phenazines to date are exclusively 
organically soluble. In addition, as shown in chapter five, these organically soluble compounds 
do not exist in a free form in the blood or tissue, so an additional extraction method would also 
have to be used to measure these compounds, even if  a suitable antibody measurement format, 
such as the silica coated plates, were developed. However, the work outline in this chapter is 
illustrative of the methods of producing antibodies against hydrophobic compounds and the 
difficulties involved. The antibody produced might also be suitable for the measurement of other 
naturally occurring phenazines such as those produced by several microorganisms, although this 
possibility was not investigated.
4.15. S U M M A R Y
Several conjugates of proteins with amino acid substituted rimino phenazines were 
produced using different methods. The conjugates were characterised and the approximate ratio 
of drug bound calculated. Two of these conjugates were used to develop an antibody in rabbits. 
This antibody was used in a number o f plate formats and successfully recognised the more 
soluble rimino-phenazines B3955, B3976 and B3832, but could not bind organically soluble 
phenazine compounds. An immunoaffinity column was produced which utilised the strong
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affinity of biotin for avidin to immobilise biotinylatcd B3955 to an avidin column. The antibody 
was purified using this column and characterised by H P LC  and BIAcore studies.
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CHAPTER 5
INVESTIGATIONS OF THE PHARMACOLOGY OF SELECTED
RIMINO-PHENAZINES
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5.1. INTRODUCTION
This chapter describes some investigations into the absorption, distribution, elimination 
and toxicity of a series of rimino-phenazine compounds. These agents were administered to 
animals and the drug levels in tissue, blood and faeces quantified. With selected agents, a 
preliminary investigation of their potential toxicity was made. The potential anti-malarial 
activity of two of these agents was also explored.
5.2. DISPOSITION ON PHENAZINE AGENTS
A ll the phenazines used in this project were initially supplied in the form of crystal 
powders. When synthesised, the conventional method of purification is recrystallisation, which 
involves reducing the organic solubility of the product liquor, until the phenazine precipitates. 
Less organically soluble impurites remain in solution, and the two are then readily separated by 
filtration. Crystallisation of these agents also renders these compounds stable in storage. When 
given to a subject in this form, the crystals must first dissolve to give the free drug, before 
absorption can occur. Larger crystals are more resistant to the solvation conditions in the gut, 
so overall absorption will be reduced or take longer. With the initial human trials of clofazimine 
only approximately 10 - 20 % o f the administered dose was absorbed, but using a finer 
micronised crystal form the absoiption was significantly increased (Barry et al., 1959 and 1960; 
Barry, 1969; Vischer, 1969; Yawalker and Vischer, 1979).
The intrinsic chemical properties of phenazines, such as their lipophillicity and pKa, are 
also important for absorption and distribution. A  tentative structure activity relationship has been 
established for many of the pharmacodynamic properties of phenazines including activity against 
different bacteria and cancer cells, and, stimulation of phospholipase A 2 (Barry, 1969; Barry et 
al., 1970; Franzblau and O ’Sullivan, 1988; Franzblau et al., 1989; O ’Sullivan et al., 1992; Van 
Landingham et al., 1993; Zeis et al., 1987 and 1990; Savage etal., 1989). However, the optimal 
compounds may be therapeutically inactive due to sub-optimal pharmacokinetics.
5.3. PHARMACOLOGICAL PROFILE AND DRUG DISPOSITION
Before any drug can produce its desired action, it must first pass through several 
processes, all of which will have an effect on its final pharmacogical profile. A  general scheme 
for the profile of an orally administered drug, such as clofazimine, is outlined in Figure 5.1.
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Figure 5.1. A  flow diagram of the process which contribute to the pharmacoological 
profile of an orally administered drug. This process is normally divided into three phases. 
The pharmaceutical phase describes the processes taking place from the administration of 
an agent to release of the substance into the body fluids. The pharmacokinetic phase 
describes what the body does to the drug and the resultant effect on the body is 
encompassed in the pharmacodynamic phase.
Formulated dose of drag
Admini Oration
Disintegration/dissolution to 
suitable physicochemical form
Ffaammceimtical
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The various processes involved are divided into three phases. In the pharmaceutical phase; the 
formulation of an agent is changed, from the stable production form, in which it is given, to the 
form by which it is absorbed. The pharmacokinetic phase encompasses the subsequent steps of 
absorption, distribution, metabolism and excretion. The pharmaceutical and kinetic phases 
describe what happens to a drug. This is also termed the drug disposition. The pharmacological 
effect, or what the drug does to the body, is evident in the pharmacodynamic phase, where an 
agents interacts with a specific system to produce the complete, therapeutic and toxic, effect 
seen. This effect is, therefore, a product of the interaction of all elements of each phase, and 
any variation in one may ultimately lead to a change in the whole pharmacological profile of 
the agent (Bowman and Rand, 1980; Taylor and Kennewell, 1993). The profile of a 
pharmaceutical agent is strictly unique to an individual, since it represents a product of 
biochemical variation. However, the physico-chemical properties of the drug are usually the 
most significant factor, allowing generalisations to be made about the profile of an agent in the 
population as a whole. Subsequent sections describe some of the elements important to the 
pharmacology o f phenazines.
5.3.1. Im portant pharm aceutical phase considerations
Administration of drugs via the oral route is the most common and popular method of 
giving medications (Taylor and Kennewell, 1993). This popularity is due to ease and 
convenience of administration, both from a doctor and patient perspective, and the lack of pain 
or discomfort, commonly associated with other routes. Effective treatment of the particular 
condition for which the medication is given is dependent on the disintegration of the dose, 
stability in the gastro-intestinal tract (G IT), absorption into the systemic circulation and delivery 
to the site of action. Other factors which are particularly important include the variance in the 
physicochemical environment with different regions o f the G IT , for example the acidity of the 
stomach, and the localisation of specific processes, such as fat absorption, to particular regions.
5.3.2. Pharmacokinetic phase
5.3.2a. Physicochemical factors affecting absorption
The principle barrier to the initial absorption of orally delivered drugs are the membranes 
of the cells lining the gut. Drugs can pass through this membrane by diffusion or by utilising 
a specific carrier transport mechanism (Bowman and Rand, 1980). Absorption via a carrier- 
mediated process is unusual, since these systems are very specific for natural compounds and
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few drugs meet the structural requirements. Aqueous diffusion is generally limited to small 
water soluble compounds, such as ethanol. The most important absorption process for drugs is 
lipid diffusion. A s a hurdle to absorption, the cell membranes behave like a lipid barrier. The 
most important parameter governing this diffusion is the permeability constant, which is closely 
related to the lipid/water partition coefficient of a drug. The lipid solubility of an agent is 
dependent on its degree of ionisation, which changes according to the pH environment of the 
drug (Foster, 1991). A  low pH  will tend to protonate acidic drugs, such as salicylates, which 
reduces ionisation and increases absorption (Bowman and Rand, 1980). Therefore, the greatest 
absorption per unit area for these compounds is in the stomach, where the environment is acidic. 
More alkaline agents need an alkaline environment to be un-ionised and are generally better 
absorbed in the near neutral environment of the small intestine. A s the organic solubility of the 
agent increases, this behaviour tends to deviate from these rules (Taylor and Kennewell, 1993). 
Strongly hydrophobic agents may tend to remain in the cell membrane, due to their affinity for 
this environment, and these compounds will also have limited solubility. Phenazines, especially 
clofazimine, are examples of such agents (Morrison and Marley, 1976(a,b)).
Most orally administered drugs are given in a solid state, as particles of some form. The 
most common types of particles are crystals of the particular agent, since these are generally 
stable and easy to produce. The particle size of a substance has a significant effect on 
absorption by the oral route. Reduction of particle size gives a larger surface area to volume 
ratio, which decreases the time necessary for equilibration to a saturated free concentration. In 
general, reduced particle size is also associated with a more rapid and complete drug absorption 
(Foster, 1991).
5.3.2b. Absorption of hydrophobic compounds
The first major region of absorption of any orally administered drug is the stomach. The 
stomach is a large muscular bag which is designed to begin the process of digestion by secreting 
lytic enzymes, secreting acid and thorough mixing (Bowman and Rand, 1980). The mixing 
process increases absorption by augmenting dissolution. However, the low pH environment 
present generally limits drug absorption to soluble acidic compounds, since these compounds 
become un-ionised, as outlined above. The gastric contents then empty into small intestine. 
This region is physiologically highly adapted for absorption of nutritional compounds. The most 
significant adaptation is the very high surface area of this region, produced by finger-like 
projections called villi, which allows the absorption of compounds which would otherwise be 
unfavourable in this environment (Taylor and Kennewell, 1993). The small intestine secretes
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many emulsifying agents, amongst many other substances, to allow the absorption of fats and 
fat soluble compounds, and is therefore the principal site of absorption of strongly hydrophobic 
drugs (Bowman and Rand, 1980). The most important of these emulsifiers are bile acids and 
salts secreted into intestine by the liver, via the gall bladder and bile duct. The bile acids are 
oxidation products of cholesterol and the salts are produced by conjugation with taurine or 
glycine. These compounds possess hydrophobic and hydrophilic groups and form micelles with 
lipid soluble compounds which solvate these compounds in an aqueous environment. In so 
doing, the overall fat solubility is augmented and these substances dissolve even in the presence 
of a largely aqueous environment (Bowman and Rand, 1980). The micelles are then brought 
through the epithelial lining of the intestinal wall by a combination of fusion with the cellular 
membrane and pinocytosis by these cells. The lymphatic and blood systems drain this part of 
the G IT. The lymphatic system carries mixed micells of fats and lipoproteins, termed 
chylomicra, away to be distributed to the body. However, with a few very rare exceptions, most 
drugs enter the blood stream which then flows directly to the liver (Bowman and Rand, 1980). 
This is the principle metabolic organ of the body, where hydrophobic compounds are usually 
made more polar, by a series of enzymes including the cytochrome P450 family, to allow their 
removal in an aqueous environment.
The presence of food in the G IT  stimulates the physical and biochemical mechanisms 
involved in the absorption o f nutrients. This includes the movements of the intestine, and the 
many substances needed for nutrient absorption, both of which are important for drug absorption. 
The presence of fats, in particular, in food stimulates release of bile and provides a large volume 
for the solubilisation of hydrophobic drugs (Bowman and Rand, 1980). A ll these factors 
normally significantly increase the absorption of fat soluble drugs.
5.3.2c. Lymphatic absorption
Absorbed compounds with a molecular weight in excess of 10 K D a  have a higher 
affinity for the lymphatic system and will preferentially enter the circulation via this route 
(Muranishi, 1991). The blood system has a 500 fold greater flow than the lymphatic system, 
and it has been calculated that selective entry of a low molecular weight drug into the lymphatic 
system necessitates that the drug has a partition coefficient into chylomicron lipid of at least
50,000 (Charman and Stella, 1986; Tucker, 1993). Despite this fact, examples of selective 
lymphatic absorption of strongly hydrophobic compounds exist, and, it has been suggested that 
drug delivery vehicles, such as oleic acid, can increase the partition of certain pharmaceuticals 
into the lymphatic system (Muranishi, 1991).
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5.3.3. Measurement of drug absorption
Despite the large surface area and specialist transport processes present for absorption 
of substances from the G IT, the amount of a particular dose absorbed may be less than 100 % 
of the administered amount. This incomplete absorption is particularly common with drugs that 
are not easily absorbed and/or which are relatively insoluble in the G IT, due to physicochemical 
or formulation properties. With compounds that are rapidly eliminated after absorption, an 
accurate estimate of the amount of absorption can be made by measuring the blood level, or the 
eliminated dose present in the urine. Alternatively, measurement of the fraction of the dose 
present in the faeces gives a measure of absorption. Measurement of faecal drug levels by 
conventional methods can often be difficult due the presence of a heterogenous mixture of 
interfering substances. A  convenient way to measure drug absorption can be to include a small 
amount of radiolabelled compound in the dose. The amount eliminated can therefore be assessed 
by measuring the radioactivity of the faecal samples (Reynell and Spray, 1956).
With compounds that are absorbed and then rapidly eliminated into the faeces, 
measurement of the unabsorbed percentage of drug is more complex, since the amount of drug 
present in the faeces represents the unabsorbed fraction plus an amount eliminated from the 
body. This problem was overcome in this project using a dietary marker, chromium oxide. This 
substance is not absorbed by the G IT  (Davignon et al., 1968; Hildebrant and Marlett, 1990; 
Czubayko et a l,  1991; Sauer et al., 1991). When administered with a drug, the chromium 
travels through the G IT  and its presence in the faeces represents the transit time from mouth to 
anus. Any drug appearing in the faeces with the chromium represents the unabsorbed fraction. 
Any drug found in the faeces after the chromium has been eliminated represents the fraction of 
drug that has been absorbed and then eliminated into the faeces, for example, by the bilary 
excretion route. Chromium is also useful in these experiments because rats and mice are 
coprophagous, that is, they eat some of their own faecal pellets (Kraus, 1980). Any drug present 
in the faeces could therefore be reabsorbed. Recycling of faecal contents will show up as a 
reemergence of chromium.
5.3.4. Distribution of hydrophobic compounds
After absorption, any drug must be transported by the blood system to its site of action. 
For hydrophilic compounds this transport may be in the form of free drug in the plasma. 
However, many drugs are bound to other blood constituents, especially serum albumin, which 
has both low and high affinity sites for acidic, basic and hydrophobic compounds. When this
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binding is of high affinity, the drug is essentially unavailable for activity, since only the 'free 
form can interact with the appropriate receptor or system, and this fraction represents an inactive 
drug depot. A  significant consequence of protein binding is that the apparent plasma solubility 
of the drug is increased (Bowman and Rand, 1980).
In very rare cases, it has been suggested that lipoproteins especially (3-lipoprotein may 
act as a carrier for hydrophobic drugs (Conalty and Jina, 1971; Ichihashi et al., 1992). 13- 
lipoprotein, also known as low density lipoprotein (LDL), is a large colloidal mixture of an 
apolipoprotein, triglycerides, free fatty acids, phosphatides and cholesterol. This mixture makes 
the L D L  complex very hydrophobic while remaining in solution in the plasma. This property 
is vital since the principle function of L D L  is the transport of cholesterol to various cells in the 
body (Cullis and Hope, 1985). Although all cells in the body have a requirement for cholesterol, 
since it is a vital structural component of the cell membrane, four major groups of cells have 
particular affinities for L D L . These are the adipose, liver, reticuloendothelial and certain tumour 
cells (Cullis and Hope,1985, Vitols, 1991).
The adipose cells act as fat storage depots for the body, storing lipids which act as fuel, 
structural components, and chemical precursors for the rest o f the body. The lipid deposited in 
adipose cells constitutes approximately 15 - 20 % of the average body weight, and can absorb 
large amounts of fat soluble drugs (Bowman and Rand, 1980). The equilibration of blood levels 
of hydrophobic compounds with adipose tissue is slow, due to low blood flow of this region of 
the body, and drugs binding to these cells are turned over very slowly (Bowman and Rand, 
1980). Liver cells have a high turnover of cholesterol, principally as a precursor for many 
steroid based hormones and bile compounds (Bowman and Rand, 1980). Reticuloendothelial 
cells have a high uptake of lipoproteins possibly to control cholesterol and lipoprotein levels and 
deposition in the body (Fielding and Fielding, 1985). The high uptake of L D L  by tumour cells 
is thought to be principally due to the requirements of cellular kinetics and proliferation 
(Samadi-Baboli et al., 1989). Although L D L  is not a significant carrier for many drugs, even 
hydrophobic agents, techniques have been developed to incorporate chemotherapeutic agents into 
L D L  and synthetic congers (Iwanik et al., 1984; Samadi-Baboli et al., 1989; Filipowska et al., 
1992). The selective uptake by tumour and reticuloendothelial cells has been shown to improve 
the therapeutic profile of these agents in cancer treatment and the chemotherapy of selected 
diseases (Iwanik et al., 1984; Chaudhuri et al., 1989; Samadi-Baboli et al., 1989; Filipowska et 
al., 1992).
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5.4. NO VEL M ETH ODS O F DRUG TAR G ETIN G  AND DELIVERY
Drug-based therapies have been developed for many diseases and afflictions, and have 
undoubtedly had a dramatic effect of the general standard of health of man and animal kind. 
However, even with modem sophisticated pharmaceutical technology many diseases remain 
poorly treated. In many instances, very active agents exist for clinical or radical cures of these 
afflictions, but poor pharmacological profiles limit or prevent their general use. The long list 
of limitations includes:- formulation difficulties, including instability of the active compound in 
storage or administration; poor absorption, often due to the inherent biological barriers we 
possess; inappropriate distribution, to the wrong body systems, or, in too low a concentration to 
the correct target receptor; unwanted metabolism to less desirable compounds, prematurely 
stopping the clinical effect, or producing undesirable consequences; and, too rapid excretion and 
elimination. However, advances are being made which may allow improved or broader activity 
of existing drugs, or, the use of compounds that have been useless up to now, due to some of 
the reasons outlined above.
These new developments include;- new forms of administration, including transdermal 
delivery (Taylor and Kennewell, 1991); chemical coupling o f drugs to other compounds to 
change the net physicochemical properties (Bodor and Brewster, 1983), leading to organ-specific 
delivery; incorporation into biopolymers for controlled and selective drug release (Saffran, 1992); 
coupling to receptor specific compounds, especially antibodies, for cell specific drug delivery 
(Engert and Thorpe, 1992); incorporation into lipid vehicles, including liposomes, to change drug 
pharmacokinetic and pharmacodynamic properties (Cullis and Hope, 1985); and incorporation 
into macromolecular complexes, such as cyclodextrins, to change the net physicochemical 
properties of a drug (Szejtli, 1988). The production and properties of drug-cyclodextrin 
complexes is discussed below since such complexes were made with clofazimine in this project 
in an attempt to improve the pharmacokinetics of this drug.
5.4.1. Cyclodextrins and their applications in pharmaceuticals
Cyclodextrins are cyclic oligomers o f glucose produced by the action of the enzyme 
cyclodextrin transglycosylase, an amylase, on starch. Three types of cyclodextrin are used in 
pharmaceutical preparations, a-cyclodextrin, which has six glucose units, P-cyclodextrin (P-CD) 
has seven and y-cyclodextrin, eight (Bender and Komiyama, 1978; Szejtli, 1988). The linkage 
of each glucose unit in cyclodextrins produces a structure with a cone-like shape as shown in 
Figure 5.2. The narrow end of the cone contains the glucose primary hydroxyl groups while the
180
Figure 5.2. The chemical structures of the three principal naturally occuring cyclodextrins. 
a-cyclodextrin consists o f a ring of 6 glucose units, (3-cyclodextrin, seven units, and y- 
cyclodextrin, eight units. In each case a cone shaped structure is produced. The inside 
of the cone is apolar and relatively hydrophobic due to the ether linkages and the carbon 
backbone. As a consequence of the confirmation o f the glucose units, all secondary 
hydroxyl groups are found on one edge of the cone, and all primary hydroxyls on the 
other.
«CD PCD yCD
69 nm
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wide end contains the secondary hydroxyl functionalities. Skeletal carbons and ether oxygen 
groups make the interior of the molecule hydrophobic, while the outside remains relatively water 
soluble. The net result is a cone shaped molecule with a hydrophobic microenvironment in the 
core, which can accommodate hydrophobic molecules, while the whole molecule is water soluble 
(Szejtli, 1988).
Cyclodextrins are useful in pharmaceutical technology because small organic molecules, 
or organic groups of larger molecules can form an inclusion complex by reversibly inserting into 
the core of the cyclodextrin (Duchene, 1988). Once complexed, the compound takes on the bulk 
properties of the cyclodextrin, including, especially, the high aqueous solubility (Weiszfeiler et 
al., 1988). In addition to increasing drug solubility, cyclodextrin complexation also has 
applications in increasing drug stability, camouflaging undesirable compound tastes and 
odours, increasing oral bioavailability, reducing direct drug-associated tissue damage, converting 
liquid drugs to crystalline form and allowing new methods of drug administration (Duchene, 
1988; Nagai, 1987; Szejtli, 1988). Cyclodextrins are non-toxic by the oral route, and parenteral 
toxicity is only associated with high doses of poorly soluble derivatives (Szejtli, 1988; Gerloczy 
et al., 1994).
Although these compounds are relatively soluble in aqueous media, the secondary 
hydroxyl groups can interact with each other, via hydrogen bonds, to stabilise the crystal lattice, 
reducing the potential solubility, especially of (3-CD, in water. This problem is overcome by 
chemically modifying to produce hydroxyalkyl derivatives (Muller et al., 1988; Brewster et al., 
1989). These reactions produce cyclodextrins, such as hydroxypropyl-(3-cyclodextrin (HPCD). 
These compounds are very water soluble (>100 % w/v) while maintaining, and in some cases, 
augmenting, the complexation properties of cyclodextrins. The high solubility and lack of 
toxicity, makes HPCD very useful as a vehicle for the parenteral delivery of poorly soluble 
pharmaceuticals. Parenteral delivery can produce high plasma drug levels while circumventing 
problems of stability, absorption and/or rapid metabolism (Brewster et al., 1989). The 
complexed agents still maintain their full potency, since, the complex dissociates to deliver the 
active agent.
5.5. MONITORING OF TOXICITY
An unfortunate consequence o f therapy with all drugs are the associated toxic side 
effects. With some drugs, those with a high therapeutic index, the dose at which toxic 
complications outweigh the therapeutic effect is very high. Unfortunately with some compounds,
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there is little selectivity, and a serious degree of toxicity is inherent with the dosage necessary 
for clinical effect. Toxicity has many different degrees of severity and can be very varied 
among individual patients due to the inherent biochemical variation we all possess (Timbrell, 
1982). Before any new agent can be released into the patient population, it must first be tested 
in a variety of systems with increasing complexity and similarity to the human system. Data 
from these experiments will normally yield sufficient information on the type and complexity 
of toxicity likely to be experienced in vivo. A typical regime after demonstration of efficacy in 
a disease model would include cell culture and isolated tissue studies, followed by acute, sub- 
chronic and chronic testing of high doses in mice, rats and/or other suitable small mammals. 
Assuming that a compound passes these tests, higher animals will be involved, and ultimately 
toxicity will be assessed in human volunteers. Even with such rigorous assessment, the full 
toxicological picture will only emerge after many years of widespread use (Foster, 1991).
5.5.1. Toxicity testing
Two forms of toxicity are often evident, a dose-responsive and a non-dose-related 
reaction. The non-dose related response is usually idiosyncratic and associated with a low dose 
administration to selected individuals. Examples in this class include drug allergies and 
carcinogen-induced cancers. This form of response can be very difficult to anticipate from non­
human experiments and only appears with a statistically sufficient population. The more usual 
forms of toxicity are dose related. In these cases, the toxic response can be directly related to 
the concentration of drug present at one time or over a cumulative time period (Timbrell, 1982). 
Usually a particular cellular system is the target, and this system is the first to show symptoms 
of a toxic effect. This form of toxicity is generally simpler to work with and model, and often 
empirical estimations can be made on a theoretical basis. Examples of this form of toxicity 
include organ specific toxicities such as hepatotoxicity or nephrotoxicity, or, cell specific 
toxicities such as haemolysis or neurotoxicity. Overt toxicity is generally easy to recognise and 
quantify, and has been used in the past for comparison of toxicity between compounds. The 
most infamous of these procedures has been LD50 estimations of toxicity (Briggs and Oehme, 
1980). The LD50 is the dose o f agent required to kill 50 % of test subjects. This value gives 
crude acute data on the inherent lethality of a particular agent, but gives little insight on the 
likely consequences o f chronic low dose administration. From academic and ethical 
considerations this form of assessment has been largely superseded by a more mechanistic 
approach giving more relevant information on the consequences of conventional doses.
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5.5.2. Toxicity assessm ent
Any system in the body can potentially be a target for the toxic effects of an agent. To 
measure and describe of any form of toxicity necessitates the demonstration of a statistically 
significant difference in a particular system after drug exposure. The choice of marker selected 
to quantify the toxic effect is critical. It should be sensitive and accurate to the level of damage, 
without interference, convenient to measure and should also be species relevant. The principal 
form of toxicity measured include haematological toxicity, hepatotoxicity and nephrotoxicity but 
other forms such as reproductive toxicity, teratogenicity and mutagenicity will also have to be 
investigated for any new pharmaceutical agent.
The blood system, liver and kidneys are most likely to demonstrate the toxic potential 
of an agent since many drugs are concentrated or react with systems in these environments. The 
damage produced by a toxic insult can take many specific forms, but certain markers can be 
chosen to quantify both broad and specific types of damage (Boyd, 1962; Clampitt and Hart, 
1978). A common and sensitive indicator of damage is increased cellular permeability to 
macromolecules (Boyd, 1983). Certain enzymes are only found in background levels outside 
particular cells (Balazs et al., 1961). Using selective assays for the measurement of these 
enzymes allows the demonstration and measurement of selective toxicity in a cell. Other 
common markers include changes (increases or decreases) in the numbers and morphology or 
form of cell types. This is a common adaptive response to toxic attack and cells may also stop 
normal growth patterns and/or die. Cells may produce or secrete abnormal macromolecules due 
to interference in key production or transport systems, or loss of cellular control mechanisms.
Damage to the kidney is usually reflected by changes in the type and relative 
concentration of certain compounds present. Under normal conditions, the glomerulus only 
allows low molecular weight compounds to filter through to the urine and the presence of large 
substances such as enzymes and especially haemoglobin can be an indicator of kidney damage. 
Therefore, urinary monitoring is a sensitive indicator of nephrotoxicity, and o f the general state 
of the whole body.
More subtle changes can often be seen by monitoring toxic effects on higher level 
functions. Although an animal cannot directly say that it is feeling unwell, changes in 
established behavioural patterns including food and water intake, pasificity or agressivness and, 
especially, activity can indicate unwanted general effects. All of these markers can be changed 
by other factors, such as age, and it is therefore important to have appropriate controls.
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5.5.3. Urinary N M R profiles as a toxicity indicator
A recent method of demonstrating and quantifying toxicity, especially nephro- and 
hepatotoxicity is the use of NMR to identify changes in a number of cell-system-specific urinary 
compounds and metabolites (Sanins et al., 1990; Murgatroyd et al., 1992). The principles and 
practice of NMR are outlined in section 3.11.1. NMR has traditionally been used in chemical 
analysis with deuterated solvents. Analysis of compounds in non-deuterated solvents is now 
possible with Fourier transform data manipulation, more powerful magnets and radiofrequency 
oscillators, and, special saturation methods (Nicholson and Wilson, 1991). The method used in 
this project reduced the contaminating water signal by reconstitution in deuterated water (D20 )  
and presaturating the residual water signal. Saturation of the water signal is accomplished by 
irradiating the sample with a high intensity radio field at the exact frequency of absorbance of 
water at the same time as the varying radio frequency is applied. The water absorbance becomes 
saturated and can be filtered out of the complete signal. This gives a profile showing the NMR 
absorbance of all the components present at a concentration of greater than approximately 10 
mM (Sanins et al., 1992).
5.5.3a. The principle o f urinary NMR analysis
The principle of this system is outlined in Figure 5.3. Specific cells in the kidney 
nephron are responsible for the absorption or secretion of selected compounds in the urine. For 
many of these compounds, the transport process involved are active and energy requiring. Any 
damage to these cells can cause the disruption of these process (Gartland et al., 1989). For 
example hippurate is actively secreted into normal urine. Damage to kidney cells interrupts this 
secretion and the hippurate signal disappears from the urinary profile. Many different 
compounds are processed in this way by the different cell types present. The result of a toxic 
insult will be a "fingerprint" since increases and decreases in the levels of certain compounds 
are associated with specific cell types (Sanins et al., 1992; Holmes et al., 1992). The level of 
toxic damage can be quantified, both by the relative intensity of the change in the compound 
signal and by the identification of the damaged systems, since certain systems are more sensitive 
to toxic disruption (Gartland et al., 1990).
5.5.4. Advantages o f NMR analysis
NMR analysis is as sensitive as other modem methods of toxicity assessment but has 
several advantages over existing techniques. From the point o f view of the subject the method
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Figure 5.3. A diagrammatic representation o f the principle of the NMR analysis of urine.
(A) Blood is filtered through the glomerulus which acts as a molecular sieve, only 
allowing smaller molecular weight compounds through. The cells of the nephron absorb 
certain compounds while others are actively secreted into the glomerular filtrate, which 
then becomes urine. Analysis by NMR shows peaks due to compounds present in 
relatively high concentration, while absorbed compounds hardly figure in the spectrum.
(B) Any damage to these cells affects these absorption and secretion processes, changing 
the relative concentration of the compounds, and producing a different and characteristic 
spectral profile.
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is non-invasive and needs no clinical procedures, such as dye injection, to obtain a result. NMR 
analysis is very rapid and needs a minimum o f sample preparation. Other methods of sample 
treatment, such as adjusting the pH to 3.5 and adding urea, minimise the sample preparation 
necessary (Murgatroyd et al., 1992). A very large variety of organic molecules can be measured 
at the same time, from a small sample, without a bias towards, for example, chromogenic 
compounds or a particular chemical class of compound. This also means that unexpected results 
will be picked up without a battery of unnecessary tests. Other methods, such as HPLC, can be 
readily coupled for more specific and sensitive analyses. Other liquid biological samples, such 
as plasma, cerebrospinal fluid and bile can also be analysed (Wevers et al., 1994; Wilson et al., 
1989). This method is very suited to simultaneous investigations of metabolism and toxicity, 
since many drug metabolites are found in the urine in concentrations well above the sensitivity 
threshold for analysis (Nicholson and Wilson, 1989; Kriat et al., 1991; Lommen and Groot, 
1993).
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RESULTS
The established model for measuring the pharmacokinetics of phenazines was oral 
gavage of a drug solution into the stomach of a mouse, generally for a period of 21 days. 
Initially, groups o f mice were gavaged by this method for 21 days with the different phenazines 
tested. The tissue levels of each agent are shown in Figures 5.4.(i) - (v). B663 levels were 
measurable in all tissues, with the highest levels in the fat. High levels were also evident in the 
kidney, liver, lung, and spleen. The lowest level of B663 were found in muscle tissue. With 
the B749 group high drug levels were also seen in the kidney, liver, lung and spleen tissue, but 
notably, the fat concentration was very low. The animals in the B3954 group showed very low 
levels of this agent, with the only significant levels being found in the kidney, liver and spleen. 
Comparison with the B663 and B749 drug levels shows that proportionally very little drug was 
present in the tissue. The highest tissue levels of phenazine were associated with the B4090 
group. The levels o f phenazine in this group were several times those found in the B663 kidney, 
liver and spleen. However, the level of B4090 found in the fat was proportionately very low. 
High levels of phenazine were also found with B4100 in kidney, liver, lung and spleen, with low 
levels o f drug in the fat tissue. Although these drug levels were greater than those seen in B663, 
B749 and B3954 tissue samples, the amount present in all tissues was less than that seen B4090. 
Interestingly, levels o f phenazine were found in the cerebral tissue of all animals except those 
of the B3954 group. Table 5.1. shows the values measured.
Autopsy of these animals, showed that the B663-treated group was significantly 
discoloured. The skin, particularly around the ears and paws of the animals, was orange 
coloured. All fatty tissue and mesentery were very orange coloured and the intestine was a deep 
orange-red colour. The liver and spleen were also lighter in colour than normal with an orange 
tinge. The orange colouration of body fat was also evident in an animal which died after only 
4 days of treatment. The fat o f the B749 dosed animals had a similar colour to normal. The 
fatty mesenteric tissue around the liver, spleen and intestine had a pink-red discolouration and 
the intestine was red coloured. The colour of the B3954-treated animals was the same as a 
normal mouse. The intestine o f the B4090 mice was wine coloured, and the fat had a slight 
orange tinge. The fat o f the B 4100 mice was also slightly orange coloured with a strong pink 
colour to the intestine.
5.6. M O USE EXPERIM ENTS
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Fig u re  5 .4 .(i). The tissue levels in mice following administration of 20 mg/kg/day of 
B663 by gavage for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The concentration of B663 for each tissue is the mean of the 
values measured in three animals.
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Figure 5.4.(ii). The tissue levels in mice following administration of 20 mg/kg/day of 
B749 by gavage for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The concentration of B749 for each tissue is the mean of the 
values measured in three animals.
Graph of tissue B749 
concentration in mice
,D.
Drug conc. 
in tissue
« g / g
■ Drug conc. +/■ S
Tissue
190
Figure 5.4.(iii). The tissue levels in mice following administration of 20 mg/kg/day of 
B3954 by gavage for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The concentration of B3954 for each tissue is the mean of the 
values measured in three animals.
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Figure 5.4.(iv). The tissue levels in mice following administration o f 20 mg/kg/day of 
B4090 by gavage for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The concentration of B4090 for each tissue is the mean of the 
values measured in three animals.
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Figure 5.4.(v). The tissue levels in mice following administration of 20 mg/kg/day of 
B4100 by gavage for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The concentration of B4100 for each tissue is the mean of the 
values measured in three animals.
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Table 5.1. The concentration of phenazines in the cerebral tissue of mice. The animals had 
received a dose of 20 mg/kg of B663, B749, B3954, B4090 or B4100 for 21 days by oral 
gavage. In each case the number of animals assayed was 3.
Drug Mean cerebral 
concentration (pg/g)
Standard deviation (pg/g)
B663 4.47 1.22
B749 1.16 1.64
B3954 *
•
B4090 0.72 0.02
B4100 1.89 0.30
* Below limit of detection
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Samples from mice receiving B663 as part of an investigation of therapeutic efficacy 
against Mycobacterium, avium by Dr. Ji in the Faculte de Medecine, Pitie-Salpetriere, Paris, were 
also investigated (Figure 5.5). Despite receiving an oral dose of 20 mg/kg of B663 six times 
a week for 12 weeks, a comparison of the tissue levels shows that they are less than those seen 
in the B663 group from the phenazine study (Figure 5.4.(i).). Variability in B663 tissue levels 
between animals is also evident in these results.
To investigate if these agents could be administered in another way, B663 was 
incorporated into mouse food and given to the animals at the same dose for the same period of 
time, 21 days. As shown in Figure 5.6, administration of the drug in food gave superior tissue 
drug levels.
5.7. TREATMENT OF MALARIA-INFECTED MICE
To investigate if any of these agents had any anti-malarial activity, groups of mice were 
dosed with phenazines for two weeks and then inoculated with Plasmodium bergheii. The 
control and the three phenazine-treated groups o f mice all became ill on the sixth day and had 
to be sacrificed. This indicated that an approximate dosage of 20 mg/kg of B663, B4090 or 
B4100, had no effect anti-malarial effect in this model. The sulfasalazine group remained clear 
of infection until the drug was removed, when they too became susceptible and had to be killed.
5.8. RAT EXPERIMENTS
To investigate if the higher drug levels of the tetramethylpiperidine-substituted 
phenazines was due to superior absorption o f these agents, it was decided undertake a more 
sophisticated experimental investigation. Administration of phenazine agents to rats in specially 
built cages also allowed a more complete investigation of their pharmacokinetics and potential 
toxicity.
5.8.1. Tissue distribution of B663, B4090 and B4100
Figures 5.7.(i) - (iii) show the tissue distribution of these agents. As expected, B663 
gave high tissue levels with the highest concentration associated with the fatty tissue. Autopsy 
of these animals showed that all tissues had an orange colouration, especially the fat which was 
intensely orange. This colour was evident on the ears and paws of the animals, and a red
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Figure 5.5. The levels of B663 in mice following administration by oral gavage of 
20mg/kg/day of B663 six days a week for 12 weeks. The animals were receiving B663 
as part of a drug testing programme by Dr. Ji, in the Faculte de Medecine, Pitie- 
Salpctricrc, Paris. The levels of clofazimine arc less than those seen in figure 5.4.(i). due 
to a different gavage formulation. The results are the mean of two analyses. The bar 
represents the standard deviation o f each duplicate.
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Figure 5.6. A comparison of the tissue levels of B663 in mice following, (A) a dose of 
20 mg/day of B663 in food for 21 days, and (B) administration o f 20 mg/kg/day of B663 
by gavage also for 21 days. The drug concentrations were measured using the HPLC 
quantification method. The levels of B663 in each tissue are higher in the group receiving 
the drug by food. Each tissue concentration is the mean of the values measured in three 
animals.
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Figure 5.7.(i). The tissue levels in rats following administration of B663 in the diet at a 
concentration of 0.035 %  (w/w) for 20 days of a 26 day study. The drug concentrations 
were measured using the HPLC quantification method. The concentration of B663 for 
each tissue is the mean o f the values measured in three animals.
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Figure 5.7.(ii). The tissue levels in rats following administration o f  B4090 in the diet at 
a concentration o f 0.035 % (w/w) for 20 days o f  a 26 day study. The drug concentrations 
were measured using the HPLC quantification method. The concentration o f B4090 for 
each tissue is the mean o f the values measured in three animals.
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Figure 5.7.(iii). The tissue levels in rats following administration of B4100 in the diet at 
a concentration o f 0.035 % (w/w) for 20 days o f a 26 day study. The drug concentrations 
were measured using the HPLC quantification method. The concentration of B4100 for 
each tissue is the mean o f the values measured in three animals.
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colouration was also seen in patches of their fur. Very high drug levels were seen in the liver, 
lung and spleen tissues of the B4090 group. Despite this, very little drug was found in the fatty 
tissue. The intestinal tissue of these animals was strongly red-purple coloured and the fat had 
a very slight pink tint. High spleen, liver and lung drug levels were also seen in the B4100 
animals, but as with the mice, the B4100 tissue drug levels were less than those of the B4090 
group. These animals had a red coloured intestine and the fatty tissue was slightly orange 
coloured. As with the mice, levels of phenazine were also measurable in cerebral tissue (Table
5.2.). Measurement o f the serum levels of these agents showed that B663 gave the highest blood 
concentration (Table 5.3.). Serum levels o f B4090 were also measurable. However, the levels 
of B4100 were very low and near the limit of detection for the HPLC method. Serum samples 
were also subject to ultrafiltration through a 3 KDa molecular weight cut-off membrane. Drug 
could only be measured in the high molecular weight reteníate o f these samples, indicating near 
complete plasma protein-binding of the drugs.
5.8.2. Absorption of B663, B4090 and B4100
Measurement of the amount of drug present in the faeces following a single oral dose 
of agent gave a measure o f the amount o f drug eliminated. To allow for the possibility that a 
certain fraction of the faecal phenazine might be produced by elimination of some of the 
absorbed dose, a non-absorbable dietary marker, chromium oxide, was included in the initial 
drug dose. Any drug present at the same time as the chromium, therefore, represents non­
absorbed drug.
Figures 5.8.(i) - (iv) show the egestion profiles o f phenazine and chromium in the four 
groups. Analysis of the chromium results shows that the typical transit time for these animals 
was 24 hours. The profiles are also similar for the control and phenazine-treated groups. 
Recycling of the egested chromium is evident from the undulation of the faecal chromium levels 
after the main dose has been eliminated. The cumulative amount of drug produced when near 
100 % of the chromium had appeared in the faeces was taken as the non-absorbed drug fraction. 
This was taken from the initial dose and expressed as a percentage to give the absorption values 
quoted in Table 5.4. These results show that most of the B663 administered by this route was 
absorbed. More B4100 remained unabsorbed, but interestingly, nearly half of the administered 
dose of B4090 was not absorbed. This is particularly surprising since this compound gave by 
far the highest overall tissue drug levels.
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Table 5.2. The concentration of phenazines in the cerebral tissue of rats. The animals had been 
fed with food containing 0.035 % (w/w) B663, B4090 or B4100 for 20 out of 26 days. In each 
case the number of animals assayed was 3.
Drug Mean cerebral 
concentration Cjng/g)
Standard deviation (jig/g)
B663 0.38 0.13
B4090 0.39 0.05
B4100 0.21 0.03
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Table 5.3. The concentration o f phenazines in the serum of rats. The animals had been fed 
with food containing 0.035 % (w/w) B663, B4090 or B4100 for 20 out of 26 days. In each case 
the number of animals assayed was 3.
Drug Mean serum concentration 
(fig/ml)
Standard deviation 
(fig/ml)
B663 0.78 0.27
B4090 0.21 0.01
B4100 0.003 0.001
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Figure 5.8.(i). The profile o f the dietary marker, chromium, egestion in faeces following 
administration of a single dose of 0.6 %  (w/w) chromium in food to a group of control rats 
receiving no phenazine. The chromium content of the faeces was measured by the 
spectrophotometric method. Most o f the chromium appears after 24 hours, indicating that 
this is the dietary transit time in these animals. Chromium continues to be egested due to 
the coprophagous nature o f these rodents.
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Figure 5.8.(ii). The profile of chromium egestion in faeces superimposed on the egestion 
of B663 following administration o f a single dose o f 0.6 %  (w/w) chromium and 0.035 %  
(w/w) B663 in food to a group of rats. The chromium content o f the faeces was measured 
by the spectrophotometric method and the amount of phenazine present quantified by the 
HPLC method. The B663 profile can be seen to follow that of chromium.
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Figure 5.8.(iii). The profile of chromium egestion in faeces superimposed on the egestion 
of B4090 following administration of a single dose of 0.6 % (w/w) chromium and 0.035 
%  (w/w) B4090 in food to a group of rats. The chromium content of the faeces was 
measured by the spectrophotometric method and the amount of phenazine present 
quantified by the HPLC method. A second hump is evident at 49 hours due to 
coprophagia.
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Figure 5.8.(iv). The profile o f chromium egestion in faeces superimposed on the egestion 
of B4100 following administration of a single dose o f 0.6 %  (w/w) chromium and 0.035 
% (w/w) B4100 in food to a group of rats. The chromium content of the faeces was 
measured by the spectrophotometric method and the amount of phenazine present 
quantified by the HPLC method.
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Table 5.4. The egested and absorbed percentage of B663, B4090 or B4100 in rats. The animal 
drug groups were given a single dose of food containing 0.035 %  (w/w) phenazine and 0.6 % 
(w/w) chromium oxide. Chromium was used as a control to monitor transit of the drugged food. 
The amount of phenazine and chromium egested in the pooled faeces was measured and the 
amount of phenazine recovered expressed as a percentage of the original dose. The remaining 
dose was the absorbed percentage.
Drug % Egested %  Absorbed
B663 14 86
B4090 49 51
B4100 25 75
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5.8.3. B4100 and B4090 toxicity m easurem ent
Potential toxicity o f these compounds was assessed by measuring several different 
indicator parameters and comparing these values with the B663 and control groups. The 
parameters measured were behavioural and feeding characteristics, blood enzymes and cell 
numbers, animal weights over the experiment and post mortem tissue weights, and urinary 
markers of toxicity. The urine was analysed by NMR (and these results are reported in section
5.9.1.) and using combination test strips sensitive to pH, glucose, ascorbic acid, ketones, nitrite, 
protein, bilirubin, urobilinogen and blood. None of the values for these parameters were 
different between the groups or changed over the course of the experiment. No changes were 
noted in pecking order, activity, cleaning and condition or aggressiveness in the groups over 
time. No differences in water intake was noted between the groups although general water 
intake did vary due to variations in environmental conditions. Feeding characteristics varied 
between the groups as shown in Figure 5.9.(i). The average daily consumption of treated or 
drugged food was seen to decrease slightly over the course of the experiment. This difference 
increased from the B663 to B4090 to B4100 group. Comparison with the change in the amount 
of non-treated food in Figure 5.9.(ii) shows that there was a corresponding increase in the 
amount of this food eaten. This also had a corresponding effect on the weight gain of these 
animals over the course of the experiment (Table 5.5.). Post mortem tissue weights were very 
similar among all the groups of animals.
The change in aspartate aminotransferase (AST), alanine amino transferase (ALT) and 
sorbitol dehydrogenase (SDH) blood enzymes was measured over the course of the experiment. 
AST levels increased in all groups over the course of the experiment, but ALT and SDH were 
similar between groups before and after the experiment. Blood samples were also analysed by 
Dr. Hugh Larkin in the Veterinary school o f University College Dublin for the following 
parameters before and after the experiment:- packed cell volume (PCV), haemoglobin 
concentration (Hb), red blood cell count (RBC), mean corpuscular haemoglobin concentration 
(MCHC), mean corpuscular volume (MCV), total white blood cell count (WBC), neutrophils, 
eosinophils, lymphocytes, monocytes and protein content. Table 5.6.(i). - (iv). shows all the 
results obtained. The only apparent difference seen was with the neutrophil count of the B4090 
and B4100 groups.
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Figure 5.9.(i). The average daily intake of drugged food for the control, B663, B4090 and 
B4100 treatment groups of raLs. In all groups the intake of treated food decreased over 
time. However, this effect was more noticeable in the B663, and especially, the B4090 
and B4100 groups.
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Figure 5.9.(ii). The average daily intake o f normal animal food for the control, B663, 
B4090 and B4100 treatment groups of rats. In the control group the consumption hardly 
varied. However, in the phcnazine groups the consumption increased over time 
particularly with B4090 and B4100 animals whose intake of drugged food was lowest, as 
shown in figure 5.9.(i).
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Table 5.5. The percentage change in weight of each animal in the different phenazine treatment 
groups after 26 days of the treatment schedule.
Animal Initial weight (g) Change in weight %
(final wt. - initial wt.) 100 
initial wt
Control 1 257.1 9.5
Control 2 288 5.4
Control 3 264.9 4.9
B663 1 257.5 7.5
B663 2 252 4.9
B663 3 250 2.7
B4090 1 257.5 0.9
B 40902 248.3 -5.0
B 4 0 9 0 3 250.8 6.6
B4100 1 257.2 2.6
B 41002 230.1 -0.6
B 4 1 0 0 3 229.6 0.9
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Table 5.6.(i). The values of the various haematological parameters before and after the feeding
experiment for the control rat group. In each case the number of animals assayed was 3.
Drug Control
Parameter Before S.D. After S.D. Units
AST 36.5 2.7 353.9 66.0 U/L
ALT 101.4 24.2 62.2 5.2 U/L
SDH 4.76 1.4 5.5 3.1 mU
PCV 0.4 0.0 0.5 0.0 L/L
Hb 134.0 3.0 150.0 8.7 g/L
RBC 8.4 0.4 8.7 0.71 1012/L
MCHC 320.0 10.0 336.0 15.3 g/1
MCV 50.5 0.5 51.3 0.6 fL
WBC 7.4 1.9 5.9 1.5 10%
Neut 1.5 0.2 0.9 0.3 109/L
Eos 0.05 0.05 0.16 0.11 io9/l
Lymph 5.7 1.6 4.8 1.4 io9/l
Mono 0.1 0.1 0.03 0.06 io9/l
Prot 68.0 1.0 65.0 5.0 g/L
213
Table 5.6.(ii). The values of the various haematological parameters before and after the feeding
experiment for the B663 rat group. In each case the number of animals assayed was 3.
Drug B663
Parameter Before S.D. After S.D. Units
AST 68.4 33.6 401.6 11.6 U/L
ALT 129.1 22.2 72.0 16.6 U/L
SDH 5.4 3.1 7.9 3.5 mU
PCV 0.4 0.0 0.4 0.0 L/L
Hb 142.3 12.3 144.0 8.2 g/L
RBC 7.7 0.5 7.6 0.3 1012/L
MCHC 356.6 5.7 360.0 0.0 g/1
MCV 50.6 1.2 52.7 2.1 fL
WBC 8.0 2.4 7.6 1.8 10%
Neut 1.8 0.4 1.0 0.3 io7 l
Eos 0.03 0.05 0.07 0.05 io9/l
Lymph 6.2 1.8 6.4 1.4 109/L
Mono 0.03 0.05 0.1 0.1 109/L
Prot 64.3 4.5 65.0 2.0 g/L
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Table 5.6.(iii). The values of the various haematological parameters before and after the feeding 
experiment for the B4090 rat group. In each case the number of animals assayed was 3. An 
increase in the neutrophil count of these animals was noted *.
Drug B4090
Parameter Before S.D. After S.D. Units
AST 35.4 2.4 340.1 81.1 U/L
ALT 84.0 12.5 81.0 10.0 U/L
SDH 5.0 0.8 13.5 4.0 mU
PCV 0.4 0.0 0.4 0.0 L/L
Hb 147.7 3.2 134.0 15.7 g/L
RBC 8.2 0.2 7.2 0.9 1012/L
MCHC 340.0 20 356.7 5.8 g/1
MCV 52.3 1.5 53.3 0.6 fL
WBC 6.1 3.0 9.3 2.2 109/L
Neut 1.2 0.2 4.5* 0.5 109/L
Eos 0.1 0.1 0.1 0.1 109/L
Lymph 4.7 2.9 4.81 2.6 109/L
Mono 0.03 0.05 0.0 0.0 109/L
Prot 71.7 5.9 66.0 3.6 g/L
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Table 5.6.(iv). The values of the various haematological parameters before and after the feeding 
experiment for the B4100 rat group. In each case the number of animals assayed was 3. An 
increase in the neutrophil count of these animals was noted *.
Drug B4100
Parameter Before S.D. After S.D. Units
AST 74.0 67.3 206.8 37.6 U/L
ALT 73.4 22.2 54.1 11.2 U/L
SDH 5.4 2.1 11.0 1.6 mU
PCV 0.4 0.0 0.4 0.0 L/L
Hb 144.7 12.7 132.3 20.3 g/L
RBC 8.3 0.8 7.0 1.0 1012/L
MCHC 333.3 20.8 340.0 20.0 gA
MCV 51.6 4.0 56.0 4.4 fL
WBC 6.3 0.8 11.3 0.6 109/L
Neut 1.3 0.2 4.8* 0.7 io9/l
Eos 0.2 0.2 0.0 0.1 io9/l
Lymph 4.8 0.5 6.1 0.5 io9/l
Mono 0.06 0.05 0.30 0.20 io9/l
Prot 71.3 1.5 68.3 1.5 g/L
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5.8.4. Tissue distribution o f B4103 and B4154
Using the same apparatus and methodologies described for the tetramethylpiperidine 
derivatives, the absorption and tissue distribution of B4103 and B4154 were investigated. Figure
5 .10.(i) - (iii) shows the tissue levels of B663, B4103 and B4154. The drug tissue level profile 
of B663 is very similar in shape and magnitude to the previous experiment, as might be 
expected. B4103 produced higher levels of drug in the spleen, liver and lung, but lower level 
of drug in the fat tissue. The tissue levels of B4154 were low relative to the other two 
compounds, with the highest concentration seen in the fat tissue. The cerebral and serum levels 
of these three compounds are shown in Tables 5.7 and 5.8 respectively. The level of B663 
present in the cerebrum was similar to that found in the TMP distribution study, but the serum 
level was much lower in this experiment. Both B4103 and B4154 gave higher levels in the 
brain than B663. Serum levels of these agents were less than the level seen with B663. 
Autopsy of the B663 group was similar to that described earlier. The fat of B4103 was slightly 
tinted orange and the intestine had a light red colouration. The orange colouration of the B4154 
group was more a little more intense than that in the B4103 group, with a similar level of red 
colouration evident in the intestine.
5.8.5. Absorption of B4103 and B4154
Figures 5.1 l.(i) - (iii) show the absoiption profiles of these compounds. In this 
experiment the transit time was shorter with most of the egested chromium and phenazine agents 
appearing in the faeces after 10 hours. Table 5.9 shows the calculated drug absorption figures 
derived from this data. The percentage absorption of B663 was very similar to that seen in the 
previous experiment. The absorption level o f B4154 was lower than the B663 value but B4103 
gave the highest absoiption of any of the compounds tested in this project.
5.8.6. B4103 and B4154 toxicity measurement
No changes in behaviour or urinary parameters were noted over the course of the 
experiment. These animals had normal eating patterns and weight gains unlike those of the TMP 
study animals. Blood markers of toxicity were not investigated for this group.
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Figure 5.10.(i). The tissue levels in rats following administration o f B663 in the diet at 
a concentration of 0.035 % (w/w) for 20 days o f a 26 day study. These results are part 
of the investigation of tissue levels of B4103 and B4154. The drug concentrations were 
measured using the HPLC quantification method. The concentration of B663 for each 
tissue is the mean of the values measured in three animals.
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Figure 5.10.(ii). The tissue levels in rats following administration of B4103 in the diet 
at a concentration o f 0.035 % (w/w) for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B4103 for each tissue is the mean of the values measured in three animals.
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Figure S-lO.(ili). The tissue levels in rats following administration of B4154 in the diet 
at a concentration o f 0.035 % (w/w) for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B4154 for each tissue is the mean of the values measured in three animals.
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Table 5.7. The concentration o f phenazines in the cerebral tissue of rats. The animals had been 
fed with food containing 0.035 % (w/w) B663, B4103 or B4154 for 20 out o f 26 days. In each 
case the number of animals assayed was 3. Drug levels were measured using the HPLC 
procedure described in the methods chapter.
Drug Mean cerebral 
concentration (pg/g)
Standard deviation (pg/g)
B663 0.47 0.13
B4103 5.54 0.23
B4154 7.70 0.23
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Table 5.8. The concentration of phenazines in the serum of rats. The animals had beeni fed 
with food containing 0.035 % (w/w) B663, B4103 or B4154 for 20 out of 26 days. In each case 
the number of animals assayed was 3. Drug levels were measured using the HPLC procedure 
described in the methods chapter.
Drug Mean serum concentration 
(Ug/ml)
Standard deviation 
(|ig/ml)
B663 0.18 0.08
B4103 0.09 0.02
B4154 0.04 0.01
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Figure 5.11.(i). The profile o f chromium egestion in faeces superimposed on the egestion 
of B663 following administration of a single dose of 0.6 %  (w/w) chromium and 0.035 % 
(w/w) B663 in food to a group of rats as part o f the investigation of B4103 and B4154. 
The chromium content o f the faeces was measured by the spectrophotometric method and 
the amount o f phenazine present quantified by the HPLC method. The B663 profile can 
be seen to follow that o f chromium.
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Figure S .ll.(ii) . The profile of chromium egestion in faeces superimposed on the egestion 
of B4103 following administration of a single dose o f 0.6 % (w/w) chromium and 0.035 
% (w/w) B4103 in food to a group of rats. The chromium content of the faeces was 
measured by the spectrophotometric method and the amount of phenazine present 
quantified by the HPLC method. Unlike the B663 group (figure 5.1.(i)), a large portion 
of the dietary contents were egested after 10 hours.
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Figure 5.11.(iii). The profile of chromium egestion in faeces superimposed on the 
egestion of B4154 following administration of a single dose of 0.6 %  (w/w) chromium and 
0.035 % (w/w) B4154 in food to a group of rats. The chromium content of the faeces was 
measured by the spectrophotometric method and the amount of phenazine present 
quantified by the HPLC method. Unlike the B663 group (figure 5.1 l.(i)), and similar to 
the B4103 group (figure 5.11 .(ii)), a large portion o f the dietary contents were egested after 
10 hours.
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Table 5.9. The egested and absorbed percentage of B663, B4103 or B4154 in rats. The animal 
drug groups were given a single dose of food containing 0.035 % (w/w) phenazine and 0.6 %  
(w/w) chromium oxide. Chromium was used as a control to monitor transit of the drugged food. 
The amount of phenazine and chromium egested in the pooled faeces was measured and the 
amount of phenazine recovered expressed as a percentage of the original dose. The remaining 
dose was the absorbed percentage.
Drug % Egested % Absorbed
B663 17 83
B4103 8 92
B4154 24 76
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5.9. INVESTIG ATIO NS O F T O X IC ITY  U SING  NM R
5.9.1. NMR of rat urines
Urine sample from all of the rat groups were investigated by NMR. Figure 5.12.(i) 
shows a typical urinary profile from a control rat. The important component peaks present are 
indicated in the figure. Figure 5.12.(ii) shows a comparison of the urinary spectrum from a 
control animal with that of a rat exposed to a single small dose of carbon tetrachloride, a known 
toxicant. Changes which are evident include the absence of peaks due to hippurate, urea and 
trimethylamine N-oxide (TMAO), and increases in the peaks produced by glucose, lactate, and 
ethanol. Figure 5.12.(iii) shows a comparison o f the control with the spectra from all the rat 
groups investigated. As this figure shows, the urinary profiles were very similar for all the 
groups tested.
5.9.2. NMR of rabbit urines
To further investigate the potential of this method, urine samples from rabbits were 
analysed. Figure 5.13 shows a comparison of the spectrum from a control healthy rabbit with 
that from an animal that died from what was later shown to be nephropathy. The control 
spectrum shows some species differences from that of the rat equivalent in the levels of 
creatinine, TMAO, taurine, citrate and succinate. The spectrum from the nephropathic rabbit 
shows a decrease in urea, phenylalanine and tyrosine, with increases in lactate, citrate and 
glycine. Post mortem pathological analysis by Dr. Peter Nowlan of the Bioresources unit, 
Trinity College Dublin, had the following results. There were periportal aggregates of 
lymphocytes in the liver, with bands of interstitial fibrosis in the kidney. At a functional level, 
there were adhesions of the glomerular tufts of the Bowman’s capsules and proteinaceous casts 
in the tubule. The chronic interstitial nephritis described, caused an elevated level of urea in the 
blood which made the animal ill. The most likely cause o f this disease was a chronic infection 
with the encephalazooan parasite E. cuniculi although high levels of circulating antibody may 
have contributed to the morbidity.
5.10. DISTRIBUTION OF CLOFAZIMINE-CYCLODEXTRIN COMPLEXES
Figure 5.14.(i). - (vi). shows a comparison of the B663 levels in the clofazimine, 
clofazimine-(3-cyclodextrin and clofazimine-hydroxypropyl-(3-cyclodextrin groups. As expected,
227
Figure 5.12.(i). The urinary NMR spectrum from a control group of rats. The urine 
sample was freeze dried and reconstituted in an equal volume of deuterated water (D20 ), 
with the pH adjusted to 7.0 using HCl/NaOH. The spectrum was analysed using the presat 
water suppression programme on a 400 MHz spectrometer. The significant peaks evident 
are labelled. Trimethylamine N-oxide (TMAO) gives the peak of greatest intensity, a 
complex doublet peak due to partially deuterated water (HOD) is also evident. Urea and 
hippurate are particularly important, from a toxicological perspective, indicating that the 
secretory systems of the kidney are functioning.
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Figure 5.12.(ii). A comparison of the urinary NMR spectrum from a control group of rats 
(spectrum (a)) with that of a rat given a dose o f carbon tetrachloride, a toxicant(spectrum 
(b)). The urine samples were freeze dried and reconstituted in an equal volume of 
deuterated water (D20 ) , with the pH adjusted to 7.0 using HCl/NaOH. The spectra were 
analysed using the presat water suppression programme on a 400 MHz spectrometer. The 
loss of secretory capacity is illustrated by the absence of compounds including hippurate 
and urea. Damage to the absorptive functions and aerobic metabolic pathways is indicated 
by the presence o f glucose, ethanol and lactate.
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Figure 5.12.(iii). A comparison of the urinary NMR spectrum from all the groups of rats 
investigated. The urine samples were freeze dried and reconstituted in an equal volume 
of deuterated water (D20 ) , with the pH adjusted to 7.0 using HCl/NaOH. The spectra 
were analysed using the presat water suppression programme on a 400 MHz spectrometer. 
The similarity of the spectra indicates that there is no evidence of a significant toxic effect 
with these compounds after 26 days of treatment.
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Figure 5.13. A comparison of the urinary NMR spectra from a control rabbit and a rabbit 
which later died from nephropathy. The urine samples were freeze dried and reconstituted 
in an equal volume of deuterated water (D20 ), with the pH adjusted to 7.0 using 
HCl/NaOH. The spectra were analysed using the presat water suppression programme on 
a 400 MHz spectrometer. Some species specific differences are evident when compared 
to the rat spectrum in figure 5.12.(i). The kidney disease in the nephropathic rabbit can 
be seen to affect the secretion of certain amino acids, increasing the levels of glycine 
present, while decreasing the amount o f certain aromatic amino acids seen. Disruption of 
the aerobic metabolic pathway in kidney cells of this animal is also evident with the 
increases seen in certain key metabolic intermediates.
(pp™)
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Figure 5.14.(i). The fat levels of B663 in rats following administration of B663, B663-P- 
cyclodextrin (b-cd), or, B663-hydroxypropyl-(3-cyclodextrin (hyd-b-cd) in the diet at a 
concentration of 0.035 %  (w/w) B663 for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean of the values measured in the three animals in the 
group.
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Figure 5.14.(ii). The spleen levels o f B663 in rats following administration of B663, 
B663-(3-cyclodcxtrin (b-cd), or, B663-hydroxypropyl~p-cyclodextrin (hyd-b-cd) in the diet 
at a concentration of 0.035 % (w/w) B663 for 20 days of a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean o f the values measured in the three animals in the 
group.
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Figure 5.14.(iii). The liver levels o f B663 in rats following administration of B663, B663- 
p-cyclodextrin (b-cd), or, B663-hydroxypropyl-p-cyclodextrin (hyd-b-cd)in the diet at a 
concentration of 0.035 % (w/w) B663 for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean of the values measured in the three animals in the 
group.
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Figure 5.14.(iv). The lung levels of B663 in rats following administration of B663, B663- 
P-cyclodextrin (b-cd), or, B663-hydroxypropyl-p-cyclodextrin (hyd-b-cd) in the diet at a 
concentration o f 0.035 %  (w/w) B663 for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean of the values measured in the three animals in the 
group.
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Figure  5 .14 .(v). The kidney levels o f B663 in rats following administration of B663, 
B663-(3-cyclodextrin (b-cd), or, B663-hydroxypropyl-(3-cyclodextrin (hyd-b-cd) in the diet 
at a concentration of 0.035 %  (w/w) B663 for 20 days of a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean of the values measured in the three animals in the 
group.
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Figure 5.14.(vi). The serum levels of B663 in rats following administration of B663, 
B663-p-cyclodextrin (b-cd), or, B663-hydroxypropyl-|3-cyclodextrin (hyd-b-cd)in the diet 
at a concentration of 0.035 % (w/w) B663 for 20 days o f a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The concentration 
of B663 for each sample is the mean of the values measured in the three animals in the 
group.
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the highest concentration of B663 was found in the tissue fat of the animals. The highest tissue 
levels of B663 were consistently from the hydroxypropyl-P-cyclodextrin group (Figure 
5.14.(vii)). The clofazimine group generally gave the next highest drug levels, compared to the 
lowest levels in the P-cyclodextrin group, although there was very little difference between the 
values measured in the serum and spleen o f these two groups.
5.10.1. GIT levels of clofazimine
Washed tissue samples from sections of the GIT with mesentery removed were also 
analysed for clofazimine levels from an animal in the clofazimine control group. As shown in 
Figure 5.15., the highest drug concentration was found in the ileum, with the lowest 
concentration in the fundus of the stomach.
5.11. ABSORPTION OF CLOFAZIMINE IN CYCLODEXTRIN COMPLEXES
Table 5.10 shows the egestion and absorption results from this experiment. The 
clofazimine group gave the lowest percentage absorption of the groups. This value is lower than 
had been seen with other clofazimine absorption groups. The clofazimine used in the 
cyclodextrin complexes and in the control was from the same batch, but this batch was different 
from that used in all the other experiments. The percentage absorption was highest in this study 
with the hydroxypropyl complex with the P-cyclodextrin giving a similar %  absorption value to 
clofazimine on its own. Toxicity o f the complexes was not investigated since there is an 
extensive literature on the toxicity-free characteristics of orally administered cyclodextrins.
5.12. INTRAVENOUS ADMINISTRATION OF A CLOFAZIMINE-CYCLODEXTRIN
COMPLEX
Experiments with the cyclodextrin complexes showed that the p-cyclodextrin complex 
with clofazimine was not especially water soluble, but the hydroxypropyl complex was very 
water soluble. In sterile physiological saline, a proportionally large amount of cyclodextrin was 
dissolved as indicated by an intense red colouration. Not all the added complex would dissolve 
in water, so in the first experiment an excess of the complex was mixed with saline and the 
undissolved fraction removed. A 1 ml sample of the injected filtrate contained 267.5 ug of 
clofazimine so the total dose received on this occasion was 1.337 mg (approximately 5 % of the 
amount of clofazimine present in the suspension). Analysis o f the blood samples over 48 hrs
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Figure 5.14.(vii). The tissue levels of B663 in rats following administration o f B663, 
B663-(3-cyclodextrin (b-cd), or, B663-hydroxypropyl-(i-cyclodextrin (hyd-b-cd) in the diet 
at a concentration of 0.035 % (w/w) B663 for 20 days of a 26 day study. The drug 
concentrations were measured using the HPLC quantification method. The results show 
that the hydroxypropyl cyclodextrin complex consistently gave the highest tissue levels of 
B663. The concentration of B663 for each sample is the average of the values measured 
in the three animals in the group.
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IFigure 5.15. The levels of B663 in different regions o f the GIT from a rat which had 
been receiving B663 in the diet at a concentration of 0.035 % (w/w) for 20 days of a 26 
day study. The drug concentrations were measured using the HPLC quantification method. 
The highest concentration is seen in the ileal tissue suggesting that this is the principal 
region of B663 absorption.
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Table 5.10. The egested and absorbed percentage of B663 from B663, B663-(3-cyclodextrin (p- 
CD-B663) or B663-hydroxypropyl-P-cyclodextrin (Hyd-(3-CD-B663) dosed food in rats. The 
animal drug groups were given a single dose of food containing 0.035 %  (w/w) phenazine and 
0.6 %  (w/w) chromium oxide. Chromium was used as a control to monitor transit of the 
drugged food. The amount of phenazine and chromium egested in the pooled faeces was 
measured and the amount of phenazine recovered expressed as a percentage of the original dose. 
The remaining dose was the absorbed percentage.
Drug group % Egested % Absorbed
B663 31 69
P-CD-B663 28 72
Hyd-p-CD-B663 19 81
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showed that the plasma concentration of clofazimine never went above 50 ng/ml. No untoward 
effects were noted in the animal. To investigate what had happened to the injected dose of 
clofazimine, a large dose of the complex was later administered. Table 5.11. shows the resulting 
levels of clofazimine in the blood and tissue immediately after administration. The results show 
that some of the drug was found in the blood but most of the administered dose had been 
deposited around the body particularly in the spleen, kidney and lung.
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Table 5.11. The concentration of phenazines in the serum and various tissues of a rabbit 
following a I.V. dose a saturated solution of 15 ml of B663-hydroxypropyl-f}-cyclodextrin. Drug 
levels were measured using the H P L C  procedure described in the methods chapter.
Rabbit tissue B663 concentration
Fat 3.7 (pg/g)
Spleen 32.7 (pg/g)
Kidney 26.6 (pg/g)
Lung 50.0 (pg/g)
Liver 19.0 (pg/g)
Serum 0.38 (pg/ml)
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DISCUSSION
The experiments outlined in this chapter are all of a preliminary nature, investigating the 
basic properties of the agents investigated. In each case the number of animals used was very 
small and as a result the data from each experiment cannot be compared by the conventional 
statistical models. With certain results, for example, the increased tissue drug levels associated 
with B4090 administration, a very clear difference is evident. However, with observations such 
as the comparison of tissue levels in the cyclodextrin study, any differences present are clouded 
by the biological variation present. Therefore, the results are largely qualitative in nature, 
indicating trends, rather than quantifying the effect. Multiplication of the experimental design 
would provide a statistical weight to all of the findings of this project.
5.13. P H E N A Z IN E  D IS T R IB U T IO N  S T U D IE S  IN  M IC E
A s  outlined in the introduction of this chapter, the pharmacokinetic and 
pharmacodynamic properties of a drug are of equal importance for the net therapeutic outcome. 
Other authors have investigated the phamacodynamic properties of phenazines in vitro and in 
vivo models o f microbial infection (Grumbach, 1960; Barry, 1969; Barry etal., 1970; Franzblau 
and O ’Sullivan, 1988; Franzblau et al., 1989; O ’Sullivan et al., 1988, 1990 and 1992; Van 
Landingham, et al., 1993; Zeis et al., 1987 and 1990; Savage et al., 1989). However, the most 
active agent in a test tube may be totally ineffective if it cannot get to its site of action. The 
major side effects of phenazines, skin discolouration and crystal deposition (Hastings, 1976; 
Moore, 1983; Jopling, 1976; Desikan etal., 1975; Desikan and Balakrishnan 1976; Mason etal., 
1977 ;Levy and Randall, 1970), are principally the result of kinetic rather than dynamic 
properties of phenazines. The work in this chapter was undertaken to investigate the disposition 
of phenazines, in the hope of finding a phenazine with the optimal kinetic properties. M ice have 
been extensively used for this type of study in the past because they appear to distribute 
phenazines throughout their bodies in a similar way to humans, and they give qualitative data 
quickly and simply (Barry et al., 1960; Conalty and Jackson, 1962; O ’Sullivan et al., 1990). 
The standard method of dosing these agents has been oral gavage, since this delivers a defined 
dose in a controlled fashion.
M ice treated in this way with clofazimine demonstrated the typical distribution profile 
(Barry et al., 1960; Conalty and Jackson, 1962; Stem, 1969; O ’Sullivan et al., 1990). High 
levels were especially evident in the fatty tissue and also in organs with a significant 
reticuloendothelial component. This profile is also seen in man (Desikan and Balakrishnan,
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1976; Mansfield, 1974). The visual observation of high fat levels in a mouse after only four 
days of treatment may have important kinetic implications. This result implies that when given 
over a period of time, clofazimine is rapidly sequestered into the body fat. In  experiments by 
Barry et al„ (1960) where B663 was given to mice and the tissue levels measured over different 
periods of time, drug levels were seen to initially rise in tissues with a high reticuloendothelial 
content. Over several hours the drug levels in these tissues declined but steadily increased in 
fat tissue. A s outlined in the introductory chapter, it is this high fat concentration of clofazimine 
which is largely responsible for the stigmatising orange colouration seen in most cases of 
clofazimine therapy. In  leprosy, the causative organism, Mycobacterium leprae is principally 
found in the cells of the reticuloendothelial system. Therefore, a new therapeutic phenazine 
should ideally produce a high concentration in the reticuloendothelial system, while exhibiting 
low levels in the fatty tissue.
With B749 the tissue profile was different. H igh levels were seen in the kidney, lung, 
spleen and especially the liver, with lower levels evident in the fat tissue. This low fat 
concentration has also been noted in previous experiments (Barry and Conalty, 1965). B749 has 
a tertiary amine substituent which reduces its fat solubility. Reducing this fat solubility allows 
higher concentrations to build up in other tissues due to the high affinity for reticuloendothelial 
cells.
B3954 produced very poor tissue levels in mice. This analogue has a substituted 
piperidine on the rimino-nitrogen, which reduces fat solubility. Unfortunately, due to 
experimental design, this type of experiment give no suggestion as to why the tissue levels seen 
were so low. The most likely possibilities are that the rimino-subsUtuent in this analogue 
reduces its absorption from the G IT , and/or, causes increased excretion from the body.
B4090 gave very high drug levels in the kidney, spleen and, especially, the liver tissue. 
The fat levels of this agent were low, particularly, when compared to the levels in other tissues. 
A  similar profile was seen with B4100, although the overall tissue concentrations produced was 
less. Again, the limitations of this experiment prevented an explanation of the underlying cause 
of this difference.
With the exception of B3954, levels of phenazine were also found in the brain tissue of 
these mice. Only Barry et al., (1960) have previously demonstrated the presence of phenazines 
in brain tissue, although the hydrophobic nature of phenazines should allow transport through 
the blood-brain barrier. Mansfield, (1974) and Desikan and Balakrishnan, (1976) failed to find
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levels of clofazimine in the human brain. However, the level measured in these experiments is 
below their limit of detection. The presence of clofazimine in the brain may explain the 
giddiness side effect of therapy which has been described (Browne and Hogerzeil, 1962; Waters, 
1969).
5.14. IM P L IC A T IO N S  O F  P H E N A Z IN E  L E V E L S  IN  M IC E
These experiments permit the selection of a potentially more active phenazine for further 
testing. The tissue profile of B3954 indicates that it would have little therapeutic use since it 
produces very low drug levels. B749 would be potentially useful since it gives similar tissue 
levels to clofazimine, without the discolouration associated with high fat concentrations or 
crystallising inside cells (Barry and Conalty, 1965). However, the most interesting compounds 
are the tetramethyl (TM P ) compounds B4100 and especially B4090. The low fat levels of 
B4090 combined with its less intense colour (see section 3.13.4) indicates that this compound 
would produce little direct discolouration. However, the secondary darkening often produced 
by clofazimine therapy (Browne, 1965; Pettit, 1967; Levy and Randall, 1970) might still be 
evident. These compounds have been shown to be more active in vitro and do not crystallise 
inside cells (O ’Sullivan et al„ 1992; Van Landingham et al., 1993). This indicates that these 
compounds could be more active against leprosy with less side effects.
5.15. L IM IT A T IO N S  O F  M O U S E  E X P E R IM E N T S  A D M IN IS T E R IN G  P H E N A Z IN E S
B Y  G A V A G E
The underlying reason behind the differences in tissue levels of each agent were unclear, 
so it was decided to investigate absorption and distribution in more detail. The oral gavage of 
mice has certain inherent limitations. The drug can only be given as an aqueous 
solution/suspension. The technique can produce variations from normal drug absorption due to 
the method of dosage, and deaths due to trauma and direct damage are common. Phenazines 
are poorly soluble in the gavage solution and absorption is therefore limited by the crystal size 
of the administered dose. The importance of this insolubility was indicated by the differences 
in the tissue levels between the mice in this experiment and those of Dr. Jis programme. This 
effect has been noted by other authors (Noufflard and Berteaux, 1961). Despite receiving a 
larger dose, the tissue levels were lower due to the lack of detergent in the gavage solution. 
Attempts to further increase the solubility of the gavage solution, by adding ethanol at a final 
concentration of 10 %  (v/v), successfully dissolved more drug but caused dehydration in the 
animals, preventing use. Inclusion of a drug in animal food is a simpler, less stressful method
246
of administration for stable drugs. In the case of clofazimine administration, this system is 
closer to the human method of dosing, since clofazimine is taken after feeding to improve 
absorption. The comparison of animals receiving a similar dose of B663 in food versus those 
receiving B663 by gavage indicates improved drug absorption and this was also noted by Barry 
et al., (1959 and 1960). The increased absorption of clofazimine taken with food, over 
clofazimine has been clearly shown for human subjects (Schaad-Lanyi et al., 1987). In these 
cases, a high fat content in the meal appears to promote absorption. This finding suggests that 
absorption into the lymphatic system is significant in B633 absorption in the human case. 
However, Barry et al., (1960) have shown that the fat content of food has little effect on 
phenazine absorption in mice.
5.16. EXPERIMENTS WITH MALARIA
In  a paper by Sheagren, (1968) it was suggested that clofazimine had a significant anti- 
malarial effect in mouse models of malaria. Since a similar model was available in the school 
it was decided to investigate if this effect could be seen with B663, B4090 or B4100. The 
animals were given two weeks of drug treatment to allow the drug levels to build up in their 
bodies. Unfortunately, no difference was evident in the time before onset of serious morbidity, 
between the negative control and phenazine treatment groups. In the initial paper, it was found 
that a dose of 1.8 m g per mouse was needed to suppress disease progression in 50 % of mice. 
This represents a dose of 6.3 g for an average man which would be expected to cause significant 
side effects if  given for any prolonged period of time. The mice in this programme received 
approximately 0.4 m g of drug (human equivalent 1.4 g) per day, since it was hoped that a lower 
dose given before infection might prove as active with one or more of the phenazines. The lack 
of activity in this experiment indicates that the anti-malarial effect seen is only evident at very 
high doses which could not be administered in human therapy. The difference in findings may 
be due to the fact that phenazines drugs are not usually found in erythrocytes where the malarial 
parasite lives. A s the administered dose increases, perhaps the concentration of clofazimine 
reaches a therapeutic level inside the infected erythrocytes.
5.17. RAT EXPERIMENTS
It was decided to use rats as an experimental model for a number of reasons. 
Physiologically and anatomically they are very similar to mice, but their larger size allows larger 
samples, especially of blood, to be taken without having a detrimental effect on the animal. Rats 
are also a standard species in initial metabolic and toxicological screens, since a vast amount of
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physiological data on them has been produced over many years (Briggs and Oehme, 1980).' A  
special metabolism cage was constructed to give more information on feeding and absorption 
over a prolonged period of time. Conventional metabolism cages are designed for using single 
animals for short periods of time, usually a maximum of a few days (Kraus, 1980; Knight et al„ 
1984). The apparatus outlined in section 2.6.1. permitted convenient measurements of food and 
drug intake, allowing estimation of absorption and feeding patterns over the longer period of 
time needed for sub-chronic investigations. Other investigators have used tissue levels to 
compare the absorption of phenazines (Byrne et al., 1989). However, as the rat absorption 
results have shown tissue levels do not correlate with absorption values.
5.18. DISTRIBUTION OF PHENAZINES IN RATS
Comparison of the individual phenazine levels in rats and mice indicated a similar tissue 
distribution profile in both species. The actual drug concentration was generally higher in the 
rats probably due to superior absorbance associated with drug incorporation into food. B4090 
gave the highest tissue level of any of the agents tested. The profile of tissue levels was similar 
for the three T M P  derivatives tested, B4090, B4100 and B4103, with high levels in the spleen 
liver and lung and very low fat drug concentrations. This provides further evidence of the likely 
therapeutic improvement which would be seen with B4090 treatment instead of clofazimine. 
Within this group the presence of a double chlorination of the anilino and phenyl groups or a 
trifluoro methyl substitution seemed to have little effect on the drug level in the tissues 
measured. The chlorination of the seven position of the phenazine nucleus seems to increase 
tissue levels. Unfortunately, these high tissue levels are associated with low serum drug levels. 
The tissue levels of B4154 were inferior to the T M P  derivatives, and the more lipophilic nature 
of this compound is indicated by proportionally high fats drug levels. However, this compound 
also gave the highest cerebral drug concentration.
5.19. SERUM LEVELS OF PHENAZINES
The phenazines were initially developed as a treatment for tuberculosis. A s outlined in 
section 1.2. of the introduction, many phenazines, especially clofazimine, were very active in 
vitro and in some in vivo models of T.B. In  higher animals and man clofazimine proved to be 
ineffective against common forms of the disease. Clofazimine is active against a number of 
infections caused by mycobacteria, and its lack of efficacy in the treatment of T.B. implies that 
it is not reaching sufficient concentration in the environment of T.B. It has been suggested that, 
unlike the bacteria inhibited by clofazimine, T.B. can exist outside the intracellular environment
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(O ’Sullivan personal communication). An  ancillary aspiration of this project was to find a 
suitable method of increasing the serum levels and serum activity of these compounds to produce 
an effect against T.B. Barry et al., (1959) have also shown an approximate correlation between 
both the plasma and overall body concentration and the mean survival time of T.B. infected 
mice. None of the compounds tested reached serum concentrations as high as clofazimine. The 
low blood levels in B4090 and especially B4100 are possibly the result of a greater affinity for 
tissue components. However, Barry et al.,(1959, 1960 and 1965) noted that less hydrophobic 
phenazines produce lower plasma concentrations, even in portal plasma from the intestine. 
These authors also noted that clofazimine produced very high levels in lymph, especially when 
given in a lipid vehicle, while a less hydrophobic, more polar, compound, B720, produced very 
low lymph levels. This indicates that although high tissue affinity may explain some of the 
variance in kinetic distribution between phenazines, the whole picture is still unclear.
Conalty and Jina, (1971) demonstrated that p-lipoprotein, now known as low density 
lipoprotein (LDL), was the principal carrier of clofazimine in the blood. Transport in rat blood 
was investigated using ultrafiltration membranes with a 3 K D a  molecular weight cut-off. Any 
free phenazine would pass through this membrane since they have a molecular weight below the 
cut-off value. With B663 and the T M P  derivatives B4090 and B4100, drug could only be 
measured in the high molecular weight retentate of the membrane. This indicates that 
phenazines do not exist in a free form in the blood. This finding is also supported by the 
observation that addition o f serum reduces the activity of phenazine compounds under in vitro 
conditions (Barry et al., 1948), indicating that a serum component sequesters free phenazine. 
Clofazimine is transported by L D L  and this would therefore appear to be the most likely carrier 
of phenazines in general. However, other lipoproteins are also present in the blood. The affinity 
of the various lipoproteins varies for specific cell types, and variations in the type carrying a 
specific phenazine could explain some of the differences seen in drug levels associated with 
particular phenazine agents.
5.20. ABSORPTION OF PHENAZINES
It was an unexpected finding that high tissue levels were not the result of better 
absorption. The highest tissue levels were seen with B4090 where only approximately half of 
an administered dose was absorbed. With the other compounds which produced lower tissue 
concentrations of drug, absorption was higher, up to 92 %  in the case o f B4103. Following the 
faecal concentration of phenazine for 105 hours with a non-absorbed control of chromium, 
indicated that there was very little faecal elimination of these compounds after the absorption
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of a single dose. Although the egestion was shorter in the B4103-B4154 experiment, both sets 
of transit times are within reported values (Thompson and Hollis, 1958; Varga, 1976; 
Hildebrandt and Marlett, 1990). The difference in this one experiment is possibly due to some 
form of environmental upset. Possible explanations for the differences in overall tissue levels 
seen include an increased excretion as the concentration of phenazine increases in the body or 
changes in the absorption pattern over the course of the experiment. The strong colouration of 
the intestine evident with these drugs might also suggest that this tissue could act as an 
absorption depot for absorbed drug especially in the case of agents with low affinity for fatty 
tissue. Lower tissue drug levels may be the result of storage in the intestine, although this 
possibility was not investigated. In addition, a lower affinity for fatty tissue would also increase 
the pool of phenazine available to all the other tissues relative to that associated with 
clofazimine.
5.21. SITE OF CLOFAZIMINE ABSORPTION
Measurement of the drug levels in different regions of the G IT  of a clofazimine-treated 
rat showed the highest concentration in the jejunum of the small intestine. This section of the 
G IT  is the principal region of drug absorption, particularly o f hydrophobic compounds (Bivin 
et al., 1979), and the high concentration of clofazimine found here suggests that phenazines are 
mainly taken up in this area. Desikan and Balakrishnan, (1976) have noted very high 
clofazimine levels in small intestinal tissue of human patients which suggests a similar possibility 
in man.. Mansfield et al., (1974) and Yawalker and Vischer, (1979) have shown high levels 
of clofazimine in human bile. Bile is released into the duodenum, proximal to the jejunum, and 
is a major contributor to the absoiption of lipophilic substances. The high biliary concentration 
suggests that clofazimine may engage in entero-hepatic circulation, being absorbed by the 
jejunum and any fraction excreted in the bile, reabsorbed as it passes through the jejunum. This 
possibility could not be easily verified in rats, since they do not possess a gall bladder.
5.22. TOXICITY STUDIES
The general lack of toxic side effects associated with clofazimine therapy is well 
documented (Vischer, 1969; Stenger et a l, 1970; Hastings, 1976; Bulakh, 1983; Peters et a l, 
1983). Any potentially new replacement would have to be as non-toxic, as well as more active, 
to compete. It is, therefore, of little use to develop a new phenazine for treatment without 
having some evidence of its innocuousness. In the experiments described, a dose well in excess 
of that normally administered to a patient was used. The typical dose of clofazimine is 100 mg
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for an adult of average weight, 70 kg. The dose of 20 mg/kg given to these animals therefore 
extrapolates to a human dose of 1400 mg. Such an excess would be expected to magnify the 
symptoms of any inherent toxicity especially if  given over longer period of time. Toxicity 
would be unexpected in phenazines since clofazimine is so non-toxic. However, the first 
phenazine tested in humans, B283, had relatively serious toxic side effects (Lane, 1951; Allday 
and Barnes, 1952). Besides the exceptions noted in the subsequent sections, all parameters 
remained unchanged and within the reported values (Kozma et al., 1972; Ringler and Dabich, 
1979; Loeb and Quimbey, 1989).
5.22.1 Blood indicators of toxicity
A s outlined in section 5.5.2. of this chapter, the kidneys, liver and blood system are the 
most common organs to display toxicity. In the rat, circulating levels of S D H  and A L T  are 
sensitive and specific indicators of hepatotoxicity (Balazs et al., 1961; Ringler and Dabich, 1979; 
Boyd, 1983). I f  any of the agents tested were hepatotoxic, a large increase in the measured 
activity of these enzymes in the blood would be expected (Korsrud et al., 1972). This was not 
seen, indicating no hepatotoxicity. High levels of A S T  are indicative of soft tissue, including 
liver, damage, in this species (Boyd, 1983; Meeks, 1989; Hoffman et al., 1989). The levels of 
this enzyme were found to have increased in all the animals at the end of the experiment. Since 
there was no difference in the magnitude of the increase seen between the food and B663 
control, an age or food related factor is the most likely cause for this elevation (Ringler and 
Dabich, 1979).
The only change noted between the start and end of experiment in the blood cell analysis 
was in the number of neutrophils in the B4090 and B4100 groups. Agents which are selectively 
toxic to the immune system generally reduce the number of these specific cells in the blood. 
Neutrophils are usually increased in inflammatory and infectious states and some form of 
infection in the two groups is a possible explanation of the results seen. Alternatively, these 
T M P  derivatives may in some way selectively stimulate the production of neutrophils. This 
would be advantageous in combatting many microbial diseases.
5.22.2 Behavioural indicators of toxicity
The lack of an effect on the behavioural patterns of the animals in the group suggests 
that the animals do not feel ill when taking any of these agents. Measurement of the cerebral 
concentrations of these drugs indicates that they can cross the blood brain barrier. However, the
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absence of behavioural changes indicates that there is little or no interaction with the 
psychomotor centres in the brain.
5.22.3. Urinary indicators of toxicity
Variations in the constitution of urine are a sensitive indicator of kidney function and 
the general state of health of the body. In this project the urine was monitored by two 
techniques. The test strips provide data of a more qualitative nature on possible toxicity. The 
combination of the strips used allows a basic screen for the detection of diabetes, metabolic 
abnormalities, liver diseases, biliary and hepatic obstruction, haemolytic diseases and bacterial 
infections of the urinary tract (Ragan, 1989). Analysis by this method is imprecise, but is very 
effective as a rapid indicator for guiding more specific and precise tests. The absence of any 
change in any of the groups reinforces the other findings of no overt toxicity of these 
compounds.
5.22.4. Urinary analysis by NMR
N M R  analysis o f urine is a relatively new technique in the arsenal available to study 
toxicity. Again no evidence of toxicity was found in any of the groups tested, but the positive 
control of a carbon tetrachloride-treated animal demonstrates the type of results which could 
have been evident. The system as described here give mainly qualitative results as to the 
presence or absence a toxic effect. For example the absence of hippurate in the urine of the 
positive control urine is indicative o f damage to the specific hippurate transport system found 
in the cells of the proximal tubule of the kidney (Bowman and Rand, 1980). More sophisticated 
analysis allows qualitative and quantitative analysis by characterising the resultant urinary 
fingerprint, as well as measuring the net increase or decrease in specific peaks (Gartland et al., 
1990). The result seen with the rabbit urine demonstrate that this technique is equally useful in 
the testing and diagnosis of pathological conditions especially as an adduct to other methods 
(Nicholson and Wilson, 1991; Anthony et al., 1992; Lundina et al., 1993; Bock, 1994).
5.22.5. Other toxicity tests
Before going on to human trials a larger scale of investigation involving other specific 
toxicity tests would be necessary. The animal results outlined in this chapter only provide a 
general indication of the likely level of toxicity which might be expected. The numbers of 
animals used are too small to give statistical weight or allow a broad generalisation of the
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innocuousness of these compounds. Other forms of toxicity which would have to be investigated 
include mutagenicity, carcinogenicity, teratogenicity and cardiac toxicity.
5.23. CYCLODEXTRIN STUDIES
5.23.1. Effects of cyclodextrins on clofazimine absorption
Cyclodextrin complexes of clofazimine were prepared to study possible methods of 
modifying the absorption and distribution of clofazimine. M any authors have shown that 
cyclodextrin-drug complexes can have a significant effect on the pharmacokinetics of certain 
drugs, especially poorly soluble hydrophobic agents (Levai et al., 1988; Jansen and Hilbers, 
1988). In this study, only the hydroxypropyl-P-cyclodextrin-clofazimine complex appeared to 
increase absorption as compared to an equivalent dose of clofazimine. Unfortunately, these 
results are equivocal since although this cyclodextrin improved absorption relative to clofazimine 
from the same batch, the absorption value is very similar to that seen with B663 in previous 
experiments. The most likely factor to cause the reduced absorption seen with the clofazimine 
group in this experiment was differences in the size or form of the clofazimine crystals from this 
batch. I f  this was the case, then increased absorption seen with hydroxypropyl-cyclodextrin 
complexation represents a meaningful augmentation of clofazimine absorption.
5.23.2. Effect of hydroxypropyl-(3-cyclodextrin on clofazimine distribution
The hydroxypropy-(3-cyclodextrin complex also gave the highest tissue and serum 
concentrations of clofazimine. The animals in this group had a slightly greater food intake per 
unit weight than the other animals in the programme. This resulted in an increased drug intake 
of approximately 10 %  compared with the other groups. While this may have had the effect of 
increasing the tissue concentration of clofazimine, this 10 %  difference does not account for the 
magnitude of the difference in drug concentrations seen with the hydroxypropyl-cyclodextrin 
complex. The increased food intake in this group may reflect the masking of some undesirable 
taste associated with the clofazimine administration, or may be the result of a perceived 
improvement in the food taste for the animals. Masking of bad odours from compounds is a 
common application of cyclodextrin complexation (Szejtli, 1988). These results are consistent 
with the decreased food intake associated with B4090 and B4100 administration in food being 
caused by a drug associated malodour.
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5.23.3. Effect of (3-cyclodextrin on clofazimine distribution
The absorption and tissue levels produced by the (3-cyclodextrin-clofazimine complex 
indicate that this form of dosage has no effect on the pharmacokinetics of clofazimine. With 
the hydroxypropyl complex the incorporation of clofazimine was easy to verify because one 
could see the resultant colouration of an aqueous solution. With the (3-cyclodextrin complex this 
was not evident. The powdered complex appeared to be less soluble than fi-cyclodextrin on its 
own, suggesting that clofazimine had stuck to the outside of the molecule, rather than forming 
an inclusion complex. Alternatively, the dissociation constant of the complex may be so low 
as to prevent the extensive release of clofazimine in the small intestine where it can be absorbed. 
When broken down in the large intestine and colon, the released clofazimine would not be 
readily absorbed since no specific transport mechanisms for hydrophobic agents exist in this area 
of the G IT.
5.23.4. Mechanism of hydroxypopyl-cyclodextrin increase in clofazimine absorption and
distribution
Cyclodextrins are not absorbed from the G IT. The hydroxypropyl-cyclodextrin probably 
increases drug absorption by increasing the aqueous solubility of clofazimine. The complex with 
clofazimine would release single molecules of clofazimine when other parts of the intestinal 
environment have a higher affinity for either the drug or cyclodextrin. These single molecules 
would more readily form the micells with fats and bile compounds necessary for clofazimine 
absorption. The rapid solubilisation of clofazimine from the complex instead of slower crystal 
dissolution is probably responsible for the higher serum concentrations of clofazimine seen. 
Analysis of the solution prepared for rabbit injection suggests that only approximately 5 %  of 
the hydroxypropylcyclodextrin-clofazimine powder was actually a water soluble complex. 
Purified complex from the mixture could therefore be expected to further increase both 
absorption and serum levels of clofazimine. Approximately 70 - 80 %  of an administered 
clofazimine is absorbed in humans. Although hydroxypropyl-cyclodextrin could increase the 
absorbance of clofazimine, it is unlikely that the added cost of production would offset the small 
likely increase in efficacy. Complexation with poorly absorbed phenazines such as B4090 would 
be expected to have a significant effect, reducing the dosage necessary to produce the standard 
effect.
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5.23.5. Distribution of an I.V. Dose of hydroxypropyl-cyciodextrin-ciofazimine complex
Since the hydroxypropyl complex was so water soluble, we attempted to use it to 
produce high blood levels of clofazimine. This would be expected to be beneficial in the 
treatment of acute mycobacterial infections since conventional therapy takes several weeks to 
build up sufficient therapeutic clofazimine levels. The spectrum of clofazimine might also be 
extended to other diseases such as tuberculosis as outlined in section 5.19. Measurement of the 
serum levels resulting from the intra venous injection of the complex were therefore 
disappointing. Although a large dose of clofazimine was injected into the bloodstream, very 
little remained there. To investigate what was happening to the injected dose the experiment 
was repeated several weeks later with a larger dose of the complex. The pattern of drug 
deposition is consistent with precipitation of clofazimine from the complex particularly in the 
capillary beds of the body which have extensive blood flow. No untoward effect was noticed 
in the animal after dosing, but such precipitation could cause clot formation in a human body 
with potentially fatal consequences.
The rapid precipitation of clofazimine from the complex suggests that the dissociation 
of clofazimine from this cyclodextrin is too rapid in the blood. M any other cyclodextrins exist 
(Brewster et al., 1989) and if  a slower dissociating, aqueously soluble, complex could be 
produced it should be possible to produce high plasma levels of clofazimine which could reach 
the site of infection more rapidly and in a higher concentration. The therapeutic potential of 
such a formulation would be much better than currently exists.
5.24. OTHER FORMULATIONS OF CLOFAZIMINE
Other methods of increasing the dissolution of clofazimine have been investigated. 
Krishnan and Abrahams, (1991) have shown an increased dissolution of clofazimine in acidic, 
neutral and alkaline media using a maleic anhydride copolymer. In later experiments this 
formulation was given by gavage to pigs and successfully increased the blood levels of 
clofazimine (Krishnan and Abrahams, 1994). Kailasam et al., (1994), produced an implantable 
form of clofazimine in a polylactic co-glycolic acid polymer. Although, this polymer produced 
measurable levels of clofazimine over time, the level produced was significantly lower than seen 
with oral administration. Liposomal preparation of clofazimine have been made by Mehta et al., 
(1993) and Sritharan, (1993). Sritharan showed that different liposomes could target clofazimine 
to different tissues. In  the paper by Mehta et al., (1993) incorporation, generally, did not lead 
to increased activity against a variety of mycobacteria. However, the potent activity of
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clofazimine against mycobacteria, combined with the possibility of parenteral administration of 
these complexes, suggests that this formulation could extend the therapeutic usefulness of 
clofazimine. Therefore, several drug formulation technologies exist which could have a very 
significant effect on the therapeutic spectrum and efficacy of clofazimine. A  combination of 
these methods with some of the phenazine analogues studied in this project may ultimately prove 
to be supremely effective.
5.25. S U M M A R Y
The basic pharmacokinetics of several different rimino-phenazine drugs were 
investigated. Tetramethylpiperidine derivative gave the highest overall tissue levels, whilst 
giving the lowest fat concentrations, despite a lower percentage of absorption compared to 
clofazimine. Administration of these agents also gave no indications of toxicity in rats. When 
combined with data from in vivo and in vitro investigations of antimicrobial activity, these 
results suggest that these derivatives might be more active with less side effects. Therefore, 
these compounds warrant further evaluation, initially in greater numbers in more sophisticated 
and varied animal models, and, perhaps, ultimately in man.
The cyclodextrin studies suggest that complexes with water-soluble cyclodextrin 
derivatives might increase the oral absorption of clofazimine, and, by extrapolation, other 
phenazines. It may also be possible to produce cyclodextrin complexes with phenazines which 
allow parenteral administration for acute anti-bacterial treatment. These complexes also warrant 
further development and investigation.
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CHAPTER 6
OVERALL CONCLUSIONS
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CONCLUSION
The work presented in this thesis has focused on three areas of rimino-phenazine 
research.
Chapter 3 described development and verification of a new extraction and quantification 
method for rimino-phenazines. A  limited investigation of the purity of these agents was 
undertaken using a variety of chemical techniques and a procedure was developed for purifying 
these drugs. The combination of the new extraction and H P LC  methods is a significant 
improvement on existing procedures allowing the accurate and precise measurement of all of the 
rimino-phenazine compounds tested. Therefore, this system would be suitable for a large scale 
evaluation of the pharmacology of any of these agents, including clofazimine.
Chapter 4 outlined the synthesis of phenazine-protein conjugates, the production of anti- 
phenazine antisera, using two of these conjugates, and the subsequent use and characterisation 
of the resultant antibody. Phenazine-protein conjugates were produced and characterised using 
the amino-acid substituted phenazines B3955 and B3976. These agents were linked to the 
proteins bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin using 
glutaraldehyde and E D C /N H S  as conjugating agents. Antisera was produced in two rabbits. 
This antisera could detect water-soluble phenazines in a variety of ELISA-based formats but 
could not detect the more hydrophobic phenazines. The antisera was also purified and 
characterised using a phenazine affinity column. The lack of sensitivity of the antibody to the 
hydrophobic phenazines limits its use and application, since all of the pharmacologically relevant 
rimino-phenazines are hydrophobic. The methods described are also applicable to the production 
of antibodies to other hydrophobic agents.
In  chapter 5, the basic pharmacokinetics of some selected rimino-phenazines was 
investigated using the methods described in chapter 3. Tetramethylpiperidine-substituted 
phenazines gave the highest tissue levels and also gave proportionately lower drug levels in body 
fat. Investigations of several indicators of toxicity, including the newly developed method of 
urinary N M R  analysis, did not indicate any evidence of toxicity associated with administration 
of these compounds in animals. A  complex of clofazimine with hydroxypropyl-(3-cyclodextrin 
produced a more water soluble formulation which increased the absorption of clofazimine. 
When given intra venously, this complex rapidly precipitated its clofazimine content. Although 
this clofazimine complex was not successful as an I.V. formulation of clofazimine, other 
cyclodextrin formulations might allow clofazimine administration by this route. Combined with
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the increased anti-bacterial activity of these compounds in vitro, the selective effects on drug 
tissue levels outlined suggest that the tctramethylpiperidine-substituted compounds might be 
more active in the treatment o f mycobacterial infections with less side effects, in the case of 
leprosy, many of the current drug treatments have associated therapeutic limitations. These 
include, serious associated toxic effects over the Lime course of the therapy, development of 
resistance by M. leprae to ihe drug, and, inherent difficulties in monitoring their usage in a third 
world situation. Therefore, further testing, ultimately leading to human trials, appears warranted, 
especially in the case of leprosy treatment.
I
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